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Abstract 
The type I transmembrane receptor SORLA (also known as LR11) is a member of 
the mammalian VPS10p-receptor family. The receptor, which is mainly expressed 
in the central nervous system (CNS), is characterized by high structural homology 
to endocytosis- and sorting-receptors. Outside the CNS, expression of SORLA can 
be found in a variety of tissues, including kidney. 
This study analyzes the localization and function of the receptor in the murine 
kidney. While expression of SORLA in the collecting duct has been described 
before before, this work shows that the receptor can also be found in epithelia of 
the thick ascending limb of Henle’s loop (TAL), the distal convoluted tubule and 
the connecting tubule. 
This distinct renal expression pattern suggests a role for SORLA in transepithelial 
transport processes. To determine which processes the receptor might be involved 
in, the kidney function of mice, wich carry a complete deficiency of the Sorla 
gene, was analyzed. These animals show defects in electrolyte handling: they are 
wasting Na+, Cl-, K+, and Ca2+ (under normal conditions and/or after water depri-
vation). The salt loss phenotype is accompanied by decreased mean arterial pres-
sure and heart rate as well as mis-regulated secretion of aldosterone. 
In line with this observation, SORLA is also expressed in the adrenal gland, par-
ticularly in the zona glomerulosa, the place of aldosterone synthesis. Additionally, 
microarray-based gene expression analysis in the adrenal gland revealed signifi-
cant down-regulation of several genes of the epinephrine synthesis pathway in 
mice lacking SORLA. This defect results in lower adrenal levels of the hormone. 
Epinephrine influences kidney function by triggering renin release via the -
adrenergic pathway. A decreased release of epinephrine could therefore explain 
the abnormal arterial pressure in mice with disruption of the Sorla gene. 
However, this mouse model’s renal defects cannot only be explained by adrenal 
malfunction: In the kidney, the lack of SORLA results in differential expression of 
the electrolyte transporter NHE3 and, to a lesser extent, ROMK. Even more strik-
ing is the altered phosphorylation of the two cation-chloride cotransporters NCC 
and NKCC2, as their activity is regulated by phosphorylation. 
The signaling kinase SPAK has been reported to regulate the activity of NKCC2 
and NCC. The transporters’ abnormal phosphorylation coincides with the atypical 
distribution of the kinase in TAL of Sorla(-/-) mice, suggesting a role of the recep-
tor in establishing the localization of SPAK. This hypothesis was further substan-
tiated by the identification of putative SORLA-interacting proteins involved in 
trafficking. 
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Kurzfassung 
Der Typ I Transmembran-Rezeptor SORLA (auch LR11) gehört zur VPS10p-
Rezeptor Familie in Säugern. Der Rezeptor mit starker Homologie zu Endozytose- 
und Sorting-Rezeptoren ist am stärksten im zentralen Nervensystem (CNS) 
exprimiert. Außerhalb des CNS ist SORLA in einer Vielzahl von Geweben zu 
finden, unter anderem in der Niere. 
Diese Arbeit widmet sich der Lokalisation und der Funktion des Rezeptors in der 
murinen Niere. Zusätzlich zur bereits bekannten Expression SORLAs im Sammel-
rohr zeigt diese Arbeit eine auf den dicken aufsteigenden Ast der Henleschen 
Schleife (TAL), den distalen Konvolut und den Verbindungstubulus ausgedehnte 
Expression. 
Das klare distale Expressionsmuster lässt eine Rolle des Rezeptors in 
transepithelialen Transportprozessen vermuten. Um genau festzustellen, welche 
Prozesse von SORLA beeinflusst werden, wurde die Nierenfunktion von Mäusen 
mit einer vollständigen Defizienz des Sorla-Gens (Sorla(-/-)) untersucht. Diese 
Tiere zeigen Defekte in der renalen Elekrolythomöostase: sie verlieren Na+, Cl-, 
K+, und Ca2+ (im Normalzustand und/oder nach Trinkwasserentzug). Eine Ernied-
rigung von Blutdruck und Herzfrequenz sowie eine fehlregulierte Sekretion von 
Aldosteron gehen mit dem Salzverlust-Phänotyp einher. 
Passend zu dieser Beobachtung konnte eine Expression von SORLA in der Ne-
benniere – speziell in der Zona glomerulosa, dem Ort der Aldosteron-Synthese – 
gezeigt werden. Microarray-basierte Genexpressions-Analyse in der Nebenniere 
offenbarte eine signifikant verminderte Expression mehrerer Gene des Adrenalin-
Synthesewegs in Sorla(-/-)-Mäusen. Dieser Defekt resultiert in einer verringerten 
Menge des Hormons in den Nebennieren der Tiere. Adrenalin aktiviert die Frei-
setzung von Renin in der Niere über -Adrenorezeptoren. Eine reduzierte Freiset-
zung von Adrenalin könnte daher den gesenkten Blutdruck in Mäusen mit Sorla 
Gen-Defizienz erklären. 
Dennoch lassen sich die Nierendefekte des Mausmodells nicht ausschließlich 
durch gestörte Nebennierenfunktion erklären. In der Niere bewirkt das Fehlen von 
SORLA eine veränderte Expression der Elektrolyttransporter NHE3 und, in gerin-
gerem Maße, ROMK. Noch stärker sticht die veränderte Phosphorylierung der 
beiden Kation-Chlorid-Cotransporter NCC und NKCC2 hervor, deren Aktivität 
durch Phosphorylierung reguliert wird. 
Es ist bekannt, dass die Signalkinase SPAK die Aktivität von NKCC2 und NCC 
reguliert. Die anormale Phosphorylierung fällt mit einer untypischen Verteilung 
der Kinase im TAL der SORLA-defizienten Mäuse zusammen. Dies deutet auf 
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eine Funktion des Rezeptors beim Trafficking von SPAK hin. Durch die Identifi-
zierung von Transportproteinen als putative Interaktionspartner SORLAs konnte 
diese Hypothese bekräftigt werden. 
Stichworte: SORLA, LR11, Niere, Nebenniere, NKCC2, SPAK 
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1 Introduction
1.1 The VPS10p-receptor gene-family 
Recently, a group of type 1 transmembrane proteins with single transmembrane 
domains and short carboxyl-terminal (c-terminal) cytosolic domains was identi-
fied. Its members are characterized by the presence of a homologous amino-
terminally (n-terminally) located region of about 700 amino acids. This common 
feature – the so-called VPS10p domain, being named after the yeast protein 
VPS10p – endows the gene family with its name: the vacuolar protein sorting 10 
protein-receptor (VPS10p-receptors) family (figure 1). 
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Figure 1: VPS10p-receptor family. Cartoon depicting the domain structure of yeast VPS10p, 
hydra HAB and mammalian members of the VPS10p-receptor family (SORLA, sortilin, SORCS1, 
SORCS2, and SORCS3). In contrast to other members of the family, SORLA and HAB share 
structural elements with members of the LDL-receptor family (YWTD -propeller, EGF-like do-
main, CR-domain repeats and fibronectin type-III domains). 
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1.1.1 Non-mammalian VPS10p domain receptors 
To maintain organelle function in eukaryotic cells, it is important that proteins 
performing those tasks reach their destination organelle. A system playing a major 
function in organelle-targeted protein-distribution is the trans-Golgi network 
(TGN). It directs newly synthesized proteins towards secretory pathways or routes 
them to endosomal, lysosomal or vacuolar compartments (Alberts, et al., 1995). 
By mutational analysis, a number of genes were identified as being essential for 
proper vacuolar function in baker’s yeast (Saccharomyces cerevisiae). Assuming a 
role in protein transport to the vacuole, these genes were designated vacuolar pro-
tein sorting (VPS)-genes. Gene number ten of this group (VPS10; official name: 
PEP1) codes for the protein VPS10p (VPS10 protein, also PEP1p, figure 1) (Mar-
cusson, et al., 1994). 
The 210 kDa type 1 transmembrane receptor VPS10p, which mainly localizes to a 
late Golgi compartment, is the sorting receptor for multiple vacuolar hydrolases. 
This protein has been shown to be involved in sorting of the soluble yeast vacuo-
lar carboxypeptidase Y (CPY) from the late Golgi compartment to the vacuole via 
a prevacuolar endosome-like compartment. To achieve this function, the receptor 
cycles between the late Golgi and prevacuolar endosome-like compartments 
(Cereghino, et al., 1995; Cooper and Stevens, 1996; Marcusson, et al., 1994; Vida, 
et al., 1993). 
This process is similar to the function carried out by cation-independent mannose 
6-phosphate receptors (CI-MPRs) in mammalian cell types. CI-MPRs bind their 
soluble target enzymes in the TGN and shuttle them to endosomal or lysosomal 
compartments using small transport vesicles. To achieve this function, the CI-
MPRs directly or indirectly bind to adaptor proteins, which initiate vesicular bud-
ding by recruiting clathrin and coupling the transport vesicles to the cytoskeleton 
(Bonifacino and Rojas, 2006; Kornfeld, 1992). 
That the VPS10p domain developed early in eukaryotic evolution and also fulfills 
versatile functions on other branches of the evolutionary tree, is reflected in the 
metazoan Chlorohydra viridissima (hydra) by the head activator binding protein 
(HAB), a homologue of the mammalian SORLA (figure 1). In contrast to the 
yeast sorting protein VPS10p, HAB is involved in signaling processes. The 200 
kDa protein was isolated by affinity chromatography for factors that bind the head 
activator peptide of hydra. This neurotrophic peptide stimulates cells to divide. It 
is responsible for the determination and the final differentiation of nerve cells and 
head-specific epithelial cells (Schaller, et al., 1996). As a head activator binding 
receptor, HAB is involved in the head-specific proliferation and determination of 
stem cells in the freshwater polyp (Hampe, et al., 1999). 
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1.1.2 The mammalian VPS10p domain receptors 
Previously, five receptors sharing the VPS10p domain have been identified and 
characterized in humans and mice (figure 1): SORLA (Hermans-Borgmeyer, et al., 
1998; Jacobsen, et al., 1996), sortilin (Navarro, et al., 2001; Petersen, et al., 1997), 
SORCS1 (Hermey, et al., 2003; Hermey, et al., 1999) SORCS2 (Nagase, et al., 
2000; Rezgaoui, et al., 2001) and SORCS3 (Hampe, et al., 2001; Hermey, et al., 
2004; Kikuno, et al., 1999). 
All five receptors possess signals for rapid internalization and intracellular sorting 
in their short carboxyl-terminal cytoplasmic domains (Hermey, et al., 2004). Be-
cause of this fact and because of their homology to the yeast VPS10p, a function 
for the mammalian VPS10p-receptors in trafficking at the TGN has been antici-
pated. 
The most important functions of these receptors are believed to lie in the nervous 
system, since all of them are expressed in the adult nerve cells and are highly 
regulated during embryogenesis (Ben-Ari, 2001; Hermans-Borgmeyer, et al., 
1998; Hermans-Borgmeyer, et al., 1999; Hermey, et al., 2004; Hermey, et al., 
2001; Rezgaoui, et al., 2001). This distinct expression pattern suggests participa-
tion of the different VPS10p-receptors in specific neuronal processes. But further 
expression of VPS10p-receptors in non-neuronal tissue also hints at additional 
functions of these proteins in other organs. 
 
1.1.3 The VPS10p domain 
Before outlining the individual mammalian members of the VPS10p-receptor 
family and their distinctive features, this section deals with the most significant 
feature they have in common: the VPS10p domain. There is only a modest se-
quence similarity between the different VPS10p domains, but they all share com-
mon structural features. 
Sortilin’s VPS10p domain is the best-characterized so far. Its structure was previ-
ously predicted by computational methods (Paiardini and Caputo, 2008). Re-
cently, Quistgaard et al. determined the crystal structure of sortilin in complex 
with its ligand neurotensin (Quistgaard, et al., 2009). 
The mature VPS10p domain can be subdivided into two structurally confined sec-
tions. At the c-terminal side of sortilin’s VPS10p domain, two small (56 and 82 
amino acid residues, respectively) domains constitute the so-called 10CC module 
(depicted as part of the VPS10p domain in figure 1), a motif containing ten con-
served cysteines present in all members of the VPS10p family known so far. In 
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contrast to the rest of the VPS10p domain, the 10CC domain is very similar in all 
the receptors in terms of primary structure and spacing of the ten cysteines. The 
large (531 amino acid residues in sortilin) n-terminal portion of the domain forms 
a ten-bladed -sheet-propeller. To date, the VPS10p domain receptors form the 
only known protein family comprising this structural feature. The tunnel formed 
by the -propeller is on one side partially blocked by interactions with the 10CC 
module. The binding of ligands occurs at the inner rim. Different binding partners 
most probably not only have to compete for their actual binding site, but could 
also be subject to mutual sterical hindrance within the limited tunnel (Quistgaard, 
et al., 2009). 
The complex structural features of the VPS10p domain is further modified by 
several posttranslational processing steps. VPS10p-receptors are translated as so-
called pre-pro-proteins. Being integral transmembrane proteins, they carry an n-
terminal signal peptide (prepeptide) for co-translational translocation into the en-
doplasmic reticulum (ER). A second peptide (44-100 amino acid residues), the 
propeptide, is cleaved off by a furin-like protease activity while the receptors tran-
sit the TGN (Hermey, et al., 2003; Jacobsen, et al., 2001; Munck Petersen, et al., 
1999). The propeptide can have an intrinsic chaperone-like function, facilitating 
correct folding of the VPS10p domain and changing or blocking the receptors 
affinity for premature binding of ligands (Jacobsen, et al., 2001; Munck Petersen, 
et al., 1999; Westergaard, et al., 2004). However, it has been shown for SORCS1 
and SORCS3, that they do not require cleavage of the propeptide for ligand bind-
ing (Hermey, et al., 2003; Westergaard, et al., 2005). 
 
1.1.4 Sortilin 
The structurally simplest mammalian VPS10p-receptor (cf. figure 1) is sortilin. It 
was first characterized after purification by affinity-chromatography against the 
receptor-associated protein RAP, a chaperone binding to receptors of the LDL 
receptor gene family in the endoplasmic reticulum and thereby preventing prema-
ture ligand-binding (Petersen, et al., 1997). In parallel, it was identified as neuro-
trophin receptor (Mazella, et al., 1998; Petersen, et al., 1999) and as a protein 
abundant in the low density microsomal vesicles containing the insulin-responsive 
glucose transporter type 4 (GLUT4) in adipocytes (Morris, et al., 1998). 
Sortilin is expressed in a variety of tissues, notably in brain, spinal cord, muscle, 
testis and kidney. In neuronal tissue, the receptor is found in pyramidal neurons of 
the cerebral cortex and the hippocampus, in cortical glia, in granule cells of the 
dentate gyrus and cerebellar Purkinje cells, in postmitotic retinal ganglion cells 
and in the superior cervical ganglion and dorsal root ganglia (Arnett, et al., 2007; 
Jansen, et al., 2007; Nykjaer, et al., 2004; Sarret, et al., 2003). 
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At a subcellular level, approximately 90% of the receptor molecules can be found 
in the Golgi. Only a minor fraction can be detected at the cell surface at any given 
time (Morris, et al., 1998; Petersen, et al., 1997). Together with the ability to in-
ternalize surface-bound ligands, this finding supports the assumption of sortilin 
being a trafficking receptor. Retrograde transport of sortilin from the late en-
dosome to the TGN is depending on the cytosolic adaptor sortin nexin 1 (Mari, et 
al., 2008). 
1.1.4.1 Structure of Sortilin 
Even though its extracellular domain consists of only one domain (Petersen, et al., 
1997; Quistgaard, et al., 2009), it has been reported, that this domain in sortilin 
can bind multiple ligands including lipoprotein lipase (Nielsen, et al., 1999), pre-
cursor of sphingolipid activator proteins (PSAP) (Hassan, et al., 2004; Lefrancois, 
et al., 2003), sphingomyelinase (Ni and Morales, 2006), neurotensin (Mazella, et 
al., 1998; Petersen, et al., 1999) and precursors of the nerve growth factor 
(proNGF) (Nykjaer, et al., 2004) and the brain-derived growth factor (proBDNF) 
(Chen, et al., 2005; Teng, et al., 2005). 
The carboxyl-terminal region carries a lysosomal sorting motif, the so-called 
acidic-cluster dileucine motif (DxxLL), shared by the mannose-6-phosphate re-
ceptors. This element mediates Golgi-localized -ear-containing Arf-binding pro-
tein (GGA) -dependent intracellular trafficking from the Golgi apparatus to late 
endosomes (Bonifacino and Traub, 2003). In addition, sortilin carries a YSVL-
motif for rapid internalization (Morinville, et al., 2004; Nielsen, et al., 2001; 
Tooze, 2001). 
The functionality of the receptor’s carboxyl-terminal domain as mediator for traf-
ficking has been demonstrated by Nielsen et al. by fusing the cytoplasmic tail of 
sortilin to the luminal domain of the cation-independent mannose 6-phosphate 
receptor (CI-MPR). Expression of this chimeric receptor led to a full rescue of the 
misrouting of lysosomal hydrolases in otherwise CI-MPR-deficient cells (Nielsen, 
et al., 2001). 
1.1.4.2 Function of Sortilin 
1.1.4.2.1 Sortilin and Regulation of Neurotrophin Activity
Even though the percentage of receptor molecules on the cell surface may be 
small, it plays an important role in neurotrophin action. 
Neurotrophins are growth factors regulating neuronal survival, axon and dendrite 
specification, target innervations and synaptogenesis (Chao, 2003). They evolved 
early in the vertebrate lineage from gene duplication events (Hallböök, 1999). 
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Four neurotrophins, all sharing sequential and structural homologies, are ex-
pressed in mammals: nerve growth factor (NGF), brain-derived neurotrophic fac-
tor (BDNF), neurotrophin 3 (NT3) and neurotrophin 4 (NT4) (Reichardt, 2006). 
Various functions of neurotrophins are mediated by binding to neurotrophic tyro-
sine kinase (Trk) receptors and subsequent downstream signaling. There are three 
main types of Trk receptors: TrkA is a receptor for NGF, TrkB a receptor for 
BDNF and NT4, and TrkC is a receptor for NT3 (Lewin and Barde, 1996). Neuro-
trophic signaling is altered by binding to the low-affinity NGF receptor p75NTR, 
which is a member of the tumor necrosis receptor superfamily (Carter and Lewin, 
1997). p75NTR can form heteromeric receptor complexes with Trk receptors, but it 
can also act independently to modulate synaptic activity or switch between an-
tipodal cell programs such as survival or cell death (Chao, 2003; Reichardt, 2006). 
The survival actions of p75NTR are mediated by mature neurotrophins whereas 
apoptotic effects are triggered by precursors of NGF (proNGF) or BDNF 
(proBDNF) (Lee, et al., 2001). Binding of the pro-convertase-cleaved mature 
form of NGF to a receptor-complex of p75NTR and TrkA triggers signaling cas-
cades for cell survival. In contrast, a heteromeric complex of p75NTR with sortilin, 
initiated by the binding the pro-domain of proNGF to sortilin, selectively induces 
apoptosis (Nykjaer, et al., 2004). Specific sortilin-expression can selectively trig-
ger the cell-death of particular subsets of neuronal cells upon p75NTR-mediated 
pro-apoptotic signal induced by premature neurotrophins. A similar mechanism 
was shown for proBDNF, whose regulated secretion is also depending on sortilin 
(Chen, et al., 2005; Teng, et al., 2005). 
Different p75NTR-mediated signaling mechanisms occur at different subcellular 
localizations. While activation of the JNK-pathway takes place at the cell-surface 
(Reichardt, 2006), other signals caused by p75NTR require trafficking of the recep-
tor to recycling endosomes to be triggered (Bronfman, et al., 2003). The transport 
of p75NTR is not clearly understood, but it could be facilitated by sortilin. This 
assumption is strengthened by the facts that Sf9 cells – which do not express sor-
tilin – are unable to internalize p75NTR (Gargano, et al., 1997), and that proNGF is 
not endocytosed by cells expressing p75NTR but lacking sortilin (Nykjaer, et al., 
2004). Additionally, internalized proNGF can be processed in endosomes and sub-
sequently released in the form of mature NGF, which again activates signaling via 
extracellular signal-related kinase (ERK) (Boutilier, et al., 2008). 
To which extend this mode of action plays a role under physiological conditions 
remains unclear. However in pathophysiological conditions, such as Alzheimer’s 
disease, retrovirus-induced spongiform encephalomyelopathies, seizures or inju-
ries of the central nervous system, increased proneurotrophin-levels and increased 
co-expression of p75NTR and sortilin suggest a role for sortilin/p75NTR-mediated 
cell-death (Fahnestock, et al., 2001; Harrington, et al., 2004; Jansen, et al., 2007; 
Stoica, et al., 2008; Volosin, et al., 2008). In addition, transection of the sciatic 
nerve is accompanied by a selective elimination of neurons expressing both recep-
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tors (Arnett, et al., 2007), and during naturally occurring cell-death in the early 
phase of retinal development, proNGF forms a complex with sortilin and p75NTR 
(Nakamura, et al., 2007). 
1.1.4.2.2 Sortilin in GLUT4-containing Vesicles 
With the parallel discovery of sortilin by different groups, the receptor appeared in 
functionally different backgrounds right from the start. Morris et al. identified 
sortilin as being present in glucose transporter 4-containing vesicles of adipocytes 
(Morris, et al., 1998). 
Glucose transporter 4 (GLUT4), the major insulin-responsive glucose transporter, 
belongs to a large family of 12 membrane-spanning domain proteins called the 
facilitative glucose transporter proteins. Being highly expressed in striated muscle 
and adipose tissue, GLUT4 is responsible for the post-prandial removal of glucose 
from the circulation. In the basal state, the transporter undergoes a slow but con-
tinuous recycling between the plasma membrane and several intracellular com-
partments, with only a small fraction of the total GLUT4 protein pool localized to 
the plasma membrane. Upon acute insulin-treatment, however, the amount of the 
transporter expressed on the cell surface is increased up to ten times (Holman and 
Sandoval, 2001; Pessin, et al., 1999). 
Several lines of evidence show the importance of proper function of the Golgi-
localized -ear-containing Arf-binding proteins (GGA proteins) for the biosyn-
thetic sorting of Glut4 from the TGN into so-called insulin-responsive compart-
ments (IRCs) (Hou, et al., 2006; Li and Kandror, 2005). The cargo-binding do-
main of GGA (VHS domain) cannot associate with GLUT4 directly. Containing a 
VHS consensus-binding motif (DxxLL) in its cytosolic tail, sortilin has been 
shown to directly interact with GGA adaptor proteins (Nielsen, et al., 2001) and to 
play an important role in the formation of the specialized GLUT4 IRC in adipo-
cytes (Shi and Kandror, 2005). It was also demonstrated by surface-biotinylation, 
that the surface-expression of sortilin is upregulated in 3T3-L1 cells (Morris, et 
al., 1998). 
In 3T3L1 cells, IRCs are formed during the differentiation from the fibroblast to 
adipocyte state. IRCs form in concert with the induction of sortilin expression 
before the expression of GLUT4. Moreover, too early overexpression of GLUT4 
leads to rapid degradation of the transporter, whereas overexpression of sortilin 
stabilizes the GLUT4 protein, increases the formation of the IRC and promotes 
insulin-stimulated glucose uptake (Shi and Kandror, 2005). Supporting the role of 
sortilin as a cargo adaptor linking GLUT4 to GGA-coated transport vesicles, a 
direct interaction between the luminal domains of GLUT4 and sortilin was shown 
by chemical cross-linking and yeast two-hybrid studies (Shi and Kandror, 2007). 
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1.1.5 SORCS 
To this day, little is known about a subgroup within the mammalian VPS10p-
receptor group, that is formed by the sortilin-related VPS10p domain containing 
receptors SORCS1 (Hermey, et al., 2003; Hermey, et al., 1999), SORCS2 (Na-
gase, et al., 2000; Rezgaoui, et al., 2001) and SORCS3 (Hampe, et al., 2001; 
Hermey, et al., 2004; Kikuno, et al., 1999), depicted on the right side of figure 1. 
The neuronal expression of the mammalian SORCS proteins is well characterized. 
SORCS1 is expressed in neurons of the third and fifth layer of the cerebral cortex, 
in pyramidal neurons of the CA1 region of the hippocampus and in Purkinje cells 
of the cerebellum and in the olfactory tubercle (Hermey, et al., 2003; Hermey, et 
al., 2004; Hermey, et al., 2001). SORCS2 is expressed in neurons in layer 5 of the 
cerebral cortex, in pyramidal neurons in the CA2 region of the hippocampus, in 
the dentate gyrus and in Purkinje cells in lobules seven to nine of the cerebellum 
(Hermey, et al., 2004). SORCS3 can be found in layer five and six of the cerebral 
cortex, in the hippocampal CA1 region, in basket and stellate cells of the cerebel-
lum and in the mitral cell layer of the olfactory bulbs (Hermey, et al., 2004; 
Westergaard, et al., 2004). The differential neuronal expression of Sorcs1 and 
Sorcs3 in the hippocampus and dentate gyrus is regulated by synaptic activity, as 
studies based on kainic acid-induced seizures revealed (Hermey, et al., 2004). 
Extraneuronal expression of SORCS receptors has not been studied extensively 
yet. Northern blot analysis of different tissues suggests Sorcs1 expression in heart, 
liver, small intestine and kidney (Hermey, et al., 2003; Hermey, et al., 1999). 
Sorcs2 transcripts are found in lung, testis, heart, kidney and epithelial cells of the 
esophagus (Goldstein, et al., 2007; Rezgaoui, et al., 2001). 
In contrast to the other two mammalian VPS10p-receptors sortilin and SORLA, 
SORCS3 and probably SORCS2 are primarily expressed on the cell surface 
(Westergaard, et al., 2005). A more complex situation is true for SORCS1: The 
receptor is seen in different isoforms, which are localizing to different extents 
either towards the cell surface, to intracellular membranes, or both (Hermey, et al., 
2003; Nielsen, et al., 2008). 
1.1.5.1 Structure of the SORCSs 
The three SORCS receptors each contain an approximately 300 residues long leu-
cine-rich domain between the VPS10p domain and the transmembrane domain 
(cf. figure 1). This region harbors successive segments of imperfect leu-
cine/isoleucine/valine repeats (Hermey, et al., 1999). Similar repeats found in 
other receptors and soluble proteins (Dufau, 1998; Hauser, et al., 1997; Selfors, et 
al., 1998) have been implicated in protein-protein interactions (Jiang, et al., 1995; 
Kajava, et al., 1995; Kobe and Deisenhofer, 1995). 
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The cytosolic portion of SORCS1 is subject to alternative splicing (Hermey, et al., 
2003; Hermey and Schaller, 2000). Four variants of human SORCS1 are listed in 
the UniProt database. Three of these isoforms (2, 3 and 4) contain src homology 2 
(SH2) domain binding motifs (YxxØ), and di-leucine motifs, described as sort-
ing/internalization signals as well as binding sites of adaptor proteins in signal 
transduction pathways (Hermey, et al., 1999; Pawson and Scott, 1997; Takatsu, et 
al., 2001; Zhu, et al., 2001). Polyproline-motifs (PxxP) binding to src homology 3 
(SH3) domains can be found in all isoforms (Cohen, et al., 1995; Hermey, et al., 
1999; Pawson, 1995). The difference in composition of signalling motifs in the 
different receptor isoforms explains their abovementioned distinct subcellular 
distribution (Hermey, et al., 2003; Nielsen, et al., 2008). 
1.1.5.2 Function of the SORCSs 
Currently, little is known about the function of SORCS receptors. The platelet-
derived growth factor-BB (PDGF-BB) has been identified as ligand for SORCS1 
and SORCS3 (Hermey, et al., 2006), suggesting a role for these receptors in neu-
rogenesis (Mohapel, et al., 2005). SORCS3 additionally binds NGF and proNGF 
(Westergaard, et al., 2005). 
Concerning Sorcs1, two publications reported the mapping of the receptor gene to 
a type-2 diabetes locus affecting fasting insulin levels in humans and mice (Clee, 
et al., 2006; Goodarzi, et al., 2007). Obese BTBR mice, a mouse model for obe-
sity-induced diabetes type-2, carry a mutation within the Sorcs1 gene. Realtime-
PCR revealed that control animals express ten times as much Sorcs1 compared to 
BTBR mice (Clee, et al., 2006). 
Another genetic screen linked Sorcs1 with a locus associated with late-onset Alz-
heimer’s disease (Grupe, et al., 2006). However, the identified marker was not 
significant in all samples used in this study. So a potential involvement of 
SORCS1 in Alzheimer’s disease remains to be confirmed by other studies. 
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1.1.6 SORLA 
One of the best characterized members of the VPS10p-receptor family is SORLA 
(sortilin-related receptor, L[DLR class] A repeats-containing). This receptor, also 
known as LR11 (low-density lipoprotein receptor relative with 11 ligand-binding 
repeats), is an orthologue of the hydra HAB (head activator binding protein) 
(Hampe, et al., 2000; Jacobsen, et al., 1996). 
Similar to sortilin, the cytoplasmic tail of SORLA, if fused to the luminal domain 
of the cation-independent mannose 6-phosphate receptor (CI-MPR), can fully 
rescue a misrouting of lysosomal hydrolases in otherwise CI-MPR-deficient cells 
(Nielsen, et al., 2007). This goes along with the observation that in transfected 
cells, only 10% of the receptor molecules are located on the cell surface. A surplus 
of the receptor is located on intracellular membranes, mainly in the TGN and in 
early endosomes (Jacobsen, et al., 2001). 
SORLA is expressed in a variety of tissues, with highest expression the central 
nervous system. In the brain, SORLA expression has been shown in pyramidal 
neurons and glia of the frontal cortex, pyramidal neurons in the hippocampus, 
cerebral Purkinje cells and granule cells of the dentate gyrus (Nixon and Cataldo, 
2006). Outside the brain, expression of the receptor is found in liver, kidney, lung, 
testes, lymph nodes, uterus, adrenal and thyroid glands (Jacobsen, et al., 2001; 
Jacobsen, et al., 1996; Yamazaki, et al., 1996). 
1.1.6.1 Structure of SORLA 
SORLA shows all characteristics of the VPS10p family: an n-terminal VPS10p 
domain with the highly conserved 10-cystein domain and a cytosolic c-terminus 
with internalization signals. Additionally, this receptor shares elements typical for 
members of the low-density lipoprotein receptor (LDL-receptor) family such as 
complement type clusters (CR-domains), endothelial growth factor-like (EGF-
like) domain, and YWTD β-propeller (Nykjaer and Willnow, 2002). Thus, it is 
sometimes also annotated as member of the latter gene family. 
SORLA is an endocytotic receptor capable of binding and internalizing surface-
bound ligands such as neuropeptides, apolipoprotein E, lipoprotein lipase and the 
receptor-associated protein RAP (Jacobsen, et al., 2001; Jacobsen, et al., 2002; 
Schmidt, et al., 2007). Like most VPS10p domain receptors, the VPS10p domain 
of SORLA binds its own propeptide and therewith abolishes binding of ligands to 
this domain. But in contrast to neuropeptides, the binding of RAP, apolipoprotein 
E and lipoprotein lipase is not inhibited by the propeptide, demonstrating that dif-
ferent binding sites exist in the extracellular receptor domain (Jacobsen, et al., 
2001). 
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Within the 56 amino acid sequence of the cytoplasmic domain of SORLA, three 
sequence motifs are worth being mentioned (Jacobsen, et al., 2001; Jacobsen, et 
al., 1996; Schmidt, et al., 2007; Yamazaki, et al., 1996). Firstly, it harbors a 
FANSHY-motif – a motif similar to FDNPxY. FDNPxY or NPxY motifs found in 
many endocytotic receptors and essential for clathrin-mediated endocytosis (Chen, 
et al., 1990). The second interesting sequence is an acidic cluster motif 
(DDLGEDDED), identified as interaction site for PACS-1 (phosphofurin acidic 
cluster sorting protein-1), an adaptorprotein responsible for trans-Golgi network 
(TGN) retrieval (Wan, et al., 1998). The third motif with the sequence DDVPM 
has been reported to be involved in GGA-binding (Jacobsen, et al., 2002). 
 
 
Figure 2: Trafficking pathways of SORLA. After translation, SORLA passes the trans-Golgi 
network (TGN), where the propeptide is cleaved off (a). The mature receptor takes the constitutive 
secretory route to the cell surface (b) or leaves the TGN via anterograde transport towards early 
endosomes (c), which is mediated by interaction with adaptors of the GGA family. On the cell 
surface, SORLA molecules can be cleaved at juxtamembrane extracellular sites (Hermey, et al., 
2006) followed by -secretase cleavage, upon which the intracellular domain is released into the 
cytosol (d). Normally, however, re-internalization through clathrin-coated pits occurs upon interac-
tion with the AP-2 complex, routing the receptor to the early endosome compartment (e). From 
there it is trafficked retrogradely back to the TGN (f) probably by interaction with the retromer 
complex, SNX1 or PACS1 (in conjunction with AP-1).  The graphic was adopted from Willnow 
et. al (Willnow, et al., 2008). 
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Besides facilitating rapid internalization via the acidic cluster dileucine-like motif 
(DDLGEDDED) (Jacobsen, et al., 2001; Jacobsen, et al., 2002) and interacting 
with members of the GGA family (Jacobsen, et al., 2001; Jacobsen, et al., 2002; 
Schmidt, et al., 2007), the cytosolic tail of SORLA is also capable of binding the 
ubiquitous adaptor complexes AP-2. The interaction with AP-2 is obligatory for 
the receptor to undergo internalization towards the early endosome compartment 
(Nielsen, et al., 2007). From there, SORLA is retrogradely transported back to the 
TGN (Nielsen, et al., 2007; Seaman, 2004; Seaman, 2007). 
 
1.1.6.2 Function of SORLA 
SORLA binds ApoE and lipoprotein lipase as ligands with its complement type 
repeat domains (CR-domains) (Jacobsen, et al., 2001), therewith showing a high 
functional similarity to members of the LDL receptor family. Accordingly, it may 
play a role in cholesterol metabolism, as this is one key function of members of 
the LDL-receptor family (Nykjaer and Willnow, 2002). But SORLA clearly acts in 
more versatile ways: soluble SORLA has been identified as a marker for atherio-
sclerosis (Bujo and Saito, 2000; Matsuo, et al., 2009) and the receptor plays a role 
in smooth muscle migration (Jiang, et al., 2008; Zhu, et al., 2004). 
1.1.6.3 SORLA in Alzheimer’s disease 
To appreciate the contribution of SORLA to Alzheimer’s Disease (AD) patho-
genesis, it is important to review some molecular key elements of this disease. 
The amyloid precursor protein (APP), a type-1 membrane protein expressed in 
neuronal and non-neuronal cell types, is a key player in AD pathology. APP is 
subject to proteolysis by two pathways: the amyloidogenic and the non-
amyloidogenic pathway. The first one involves - and -secretase activity, finally 
leading to the production of A , the main component of amyloid plaques (also 
called senile plaques), a pathological hallmark of AD. The non-amyloidogenic 
pathway, defined by - and -secretase cleavage, does not generate the AD-typical 
A  (King and Scott Turner, 2004; Reinhard, et al., 2005). 
The involvement of SORLA in the progression of Alzheimer’s disease (AD) was 
first suggested by the finding, that the receptor is transcriptionally downregulated 
in patients with the sporadic form of AD (Scherzer, et al., 2004), but not in famil-
ial forms of this disease (Dodson, et al., 2006). Subsequently it was shown that 
SORLA colocalizes with APP to Golgi and to endosomal compartments and that 
overexpression of Sorla leads to reduced processing of APP into A  (Andersen, et 
al., 2005; Offe, et al., 2006). SORLA binds the carbohydrate-linked domain of 
APP with an epitope in its cluster of complement-type repeats (Andersen, et al., 
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2006). Similar to the situation in patients with sporadic AD, lack of Sorla expres-
sion in gene-targeted mouse models leads to increased A  production and senile 
plaque formation (Rohe, et al., 2008). 
In neurons, SORLA expression negatively correlates with A  production (Ander-
sen, et al., 2005; Nixon and Cataldo, 2006; Rogaeva, et al., 2007; Rohe, et al., 
2008; Schmidt, et al., 2007). Which molecular mechanisms are underlying these 
observations? Studies by several groups provided the relevant working hypothe-
sis. According to these models, SORLA controls the release of APP from the TGN 
to the cell-surface. This step is crucial for the processing of APP along both, the 
amyloidogenic and the non-amyloidogenic pathway (Andersen, et al., 2005; Ro-
gaeva, et al., 2007; Schmidt, et al., 2007). Confining APP to the TGN happens 
most likely by two mechanisms. The first is blockade of APP’s transit along the 
secretory pathway by retentive binding to SORLA within the TGN. The second 
mechanism involves re-routing of APP from early endosomes to the TGN in line 
with the ability of SORLA to shuttle between these two compartments (Schmidt, 
et al., 2007), which is depicted in figure 2 (c and f). Taken together, both mecha-
nisms confine APP to the TGN and the protein avoids -secretase activity residing 
in late endosomes, the starting point of the amyloidogenic APP processing path-
way. 
Shuttling SORLA between the TGN and early endosomes depends on GGAs and 
PACS1 (cf. figure 2 c and f). Disruption of the binding-motifs for these adaptors 
in the SORLA tail leads to missorting of the receptor (and APP) and subsequent 
acceleration of APP processing (Schmidt, et al., 2007). 
The mammalian retromer-complex, composed of Vps35, Vps29, Vps26 and sortin 
nexins 1 (SNX1) and 2 (SNX2), is another adaptor-complex that was reported to 
contribute to AD pathogenesis (Muhammad, et al., 2008; Seaman, 2005; Small, 
2008; Small, et al., 2005). It has been shown in baker’s yeast that the retromer can 
bind VPS10p (Nothwehr, et al., 2000), but a direct interaction of SORLA and the 
adaptor complex has not yet been reported. However, with such an interaction 
(figure 2 f), the neurodegenerative effects of retromer defects could be explained 
by missorted SORLA (Motoi, et al., 1999). 
 
Introduction 
 33 
1.2 SORLA in the kidney 
Given the important function of SORLA in the central nervous system, the ques-
tion for extraneuronal functions of the receptor remains. One possible focus is 
represented by the kidney. 
Even though initial publications did not suggest a renal expression for the receptor 
(Jacobsen, et al., 1996; Yamazaki, et al., 1996), refined analyses in later publica-
tions showed a clear transcriptional expression in the kidney (Hermans-
Borgmeyer, et al., 1998; Mörwald, et al., 1997). 
A further characterization of the renal SORLA expression was carried out by 
Irmgard Hermans-Borgmeyer and colleagues. The work of Riedel et al. was the 
first using immunological approaches to show not only receptor transcripts, but 
also localization of the protein itself to specific segments of the kidney (Riedel, et 
al., 2002). 
Using in-situ hybridization on embryonal and adult tissue sections, Sorla tran-
scripts were localized to tubular epithelial cells. Based on immunohistochemical 
colocalization studies with aquaporin 2 (AQP2) and vacuolar proton-ATPase, this 
former publication confined SORLA expression to one specific tubular region in 
the kidney: the cortical and medullary collecting duct (see 1.2.2) (Riedel, et al., 
2002). Similar to the situation in rat neurons, SORLA expression in renal cell 
types was predominatly found in vesicular structures in the cytosol. 
 
1.2.1 The kidney 
The kidney carries out different functions, most of them being essential for life 
(Brenner, 2007): These encompass the excretion of metabolic waste products, the 
excretion of bioactive substances that affect body function (a number of hormones 
are at least partially removed by renal processes), the regulation of red blood cell 
production (the kidney is a major source for erythropoietin, a peptide hormone 
involved in the control of erythrocyte production), regulation of vitamin D pro-
duction (the active form of vitamin D, 1,25-dihydroxyvitamin D3, is synthesized 
in the kidney), gluconeogenesis (besides most gluconeogenesis taking place in the 
liver, a substantial fraction occurs in the kidney, especially during prolonged fast-
ing periods). 
Another important function of the organ is the regulation of water and electrolyte 
homeostasis and therewith the regulation of arterial blood pressure. Maintaining 
this balance is a very crucial task, since the body’s input of water and electrolytes 
is variable. The kidney is able to regulate water and each of the essential minerals 
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independently, thereby adjusting fluctuating nutrition intake exactly to body 
needs. Because of the importance of this function, most renal ATP is used to ac-
complish the task of reabsorbing sodium (Na+), chloride (Cl-) and water. Usually 
less than one percent of the amount filtered at the renal corpuscle is excreted. 
These three substances undergo considerable tubular reabsorption, but normally 
no secretion. 
Renal maintenance of Na+ and water balance achieves regulation of blood volume 
which blood pressure ultimately depends on. Thus through volume control, the 
kidney participates in blood pressure regulation. Furthermore the kidney stimu-
lates the renin-angiotensin system (RAS) by generating renin and also possessing 
angiotensin converting enzyme (ACE) activity. 
In several renal segments, the reabsorption of electrolytes and water is under 
physiological control by neural, hormonal and paracrine inputs to maintain ho-
meostasis. 
 
1.2.2 The renal nephron 
The basic functional unit of the kidney is the nephron, depicted in figure 3. It con-
sist of the renal corpuscle (Bowman’s capsule and glomerulus) followed by vari-
ous tubular segments, each described by different physiological properties: the 
proximal tubule (proximal convoluted tubule and proximal straight tubule), the 
loop of Henle (descending thin limb, ascending thin limb and thick ascending 
limb containing macula densa), the distal convoluted tubule (sometimes divided in 
early and late distal convoluted tubule, DCT1 and DCT2) and the collecting duct 
system (connecting tubule and collecting duct which can be divided into a corti-
cal, an outer medullary, an inner medullary and a papillary portion). 
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Figure 3: The nephron. Blood is filtered at the glomerulus. While urine flows through proximal 
convoluted tubule, the loop of Henle (consisting of descending limb, thin ascending limb and thick 
ascending limb), distal convoluted tubule, connecting tubule and collecting duct, controlled trans-
port processes adjust urinary secretion of solutes to maintain homeostasis. Because of its non-
mesenchymal origin, the collecting duct system is often not considered as part of the nephron. On 
the contrary, some sources classify the connecting tubule (of mesenchymal origin) as part of the 
collecting duct system. Due to the fact that all segments from the glomerulus through the loop of 
Henle to the collecting duct form one single functional tubular intrarenal unit (even though with 
continuously changing functional and structural properties), and to clarify the abovementioned 
divergence in literature, this work refers to this structure – including the collecting duct system – 
as nephron. The figure is based on Brenner and Rector's The Kidney (Brenner, 2007). 
 
All nephrons are completely separate from each other from Bowman’s capsule 
through Henle’s loop to the initial collecting tubules. At this point, connecting 
tubules from several nephrons merge to form the cortical collecting tubules, which 
on their part form larger collecting ducts. 
The tubular epithelium of each segment of the nephron consists of a one-cell layer 
of one segment-specific cell type. Additionally, the segment-specific cells of the 
distal convoluted tubule, the connecting tubule as well as the collecting duct, are 
interspersed with different subtypes of another cell-type, the so-called intercalated 
cells. 
Each tubular segment of the nephron does possess distinctive physiological prop-
erties for its own specialized function. 
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The proximal tubule for example performs most electrolyte reabsorption in the 
kidney (around 65 percent of the Na+, Cl- and water filtered at the renal corpuscle 
and between 55 and 80 percent of the filtered K+ are reabsorbed in the entire 
proximal tubule) in a mainly non-modulated iso-osmotic fashion. 
In more distal segments, ion and water is being transported in an uncoupled man-
ner, allowing individual reabsorption of solutes. These processes, which are sub-
ject to strict hormonal regulation, are important for fine-tuning homeostasis of 
individual electrolytes. 
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1.3 Aim of this study 
The aim of this study was to understand the role of SORLA in the kidney. 
This goal should be achieved by determining the precise localization of the recep-
tor to specific nephron segments. Due to specialized functions of individual tubu-
lar segments, this knowledge should allow a detailed analysis of transport path-
ways possibly influenced by SORLA. 
A function of the receptor in these processes should be elucidated by investigating 
renal defects in mice lacking the Sorla gene. 
As SORLA is not exclusively expressed in the kidney, this thesis was furthermore 
concerned whether extra-renal factors controlling kidney function may be influ-
enced in mice lacking the receptor. 
In addition, I wanted to identify molecular mechanisms underlying the observed 
phenotypes. 
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2 Material and Methods 
2.1 Animal Experiments 
2.1.1 Mouse Husbandry 
All experiments involving animals were performed according to institutional and 
National Institutes of Health guidelines and had been approved by the local au-
thorities. Mice were kept at standard conditions at a 12/12 hour light/dark cycle 
and had access to food and tap water ad libitum (unless stated otherwise). 
2.1.2 Mouse Strains 
Several wild type strains were used for this study: 129Bl/6 (mixed genetic back-
ground, 129SvEmcTer and C57BL/6N), 129Balb/c (mixed genetic background, 
129SvEmcTer and Balb/cJ), 129SvJ and Balb/cJ. All lines were bred in-house. 
Table 1: Mouse strains with targeted disruption of the Sorla gene. 
Strain 
designation 
Source Genetic background 
SorLA18 generated in our lab as de-
scribed 
(Andersen, et al., 2005) 
129SvEmcTer and Balb/cJ 
SorLA27 generated in our lab as de-
scribed 
(Andersen, et al., 2005) 
129SvEmcTer and 
C57BL/6N 
SorLA39 generated in our lab as de-
scribed 
(Andersen, et al., 2005) 
129SvEmcTer and Balb/cJ 
SorLA × Balb/c generated in our lab Balb/cJ, backcrossed for 
>10 generations 
SorLA Ex255 provided by William C. 
Skarnes 
(Welcome Trust Sanger Center, 
UK) 
insertional mutagenesis of 
Sorl1 locus by lacZ reporter 
gene 
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Animals lacking Sorla gene expression (except SorLA Ex255) were obtained from 
the sources listed in table 1. All animals gave identical results when compared 
with age- and sex-matched control mice of corresponding genetic background, 
unless otherwise stated. 
2.1.3 Timed Matings 
Timed matings were set up in the evening to obtain embryos at different stages of 
development. The presence of a vaginal plug in the morning was considered as 
day 0.5 post coitum (dpc). The embryos were harvested by sacrificing pregnant 
mice. 
2.1.4 Physiological Parameters 
2.1.4.1 Collection of Urine and Blood 
Urine was collected by housing mice in individual metabolic cages. The animals 
had free access to tap water (except stated otherwise). The supply of chow was 
stopped during collection to prevent chow debris contaminating the urine. Urine 
was collected for 16 hours overnight and centrifuged at 8,500 rpm in a standard 
tabletop centriufuge. After discarding any pellet, volume or weight was measured 
and the urine was frozen at –20 °C until analyzed further. 
To collect blood, mice were anesthetized by ether and bleeded retro-orbitally by 
using a sterile glass Pasteur pipette. Immediately after withdrawal, the blood was 
chilled on ice and subsequently centrifuged at >10,000 × g for 10 min at 4 °C. 
Blood serum supernatants were stored at -20 °C for further analysis. 
The analysis of urine and blood was carried out either by the ‘Institut für La-
bormedizin’ (Helios-Klinikum Berlin-Buch) or by ‘Labor 28’ (Berlin). 
2.1.4.2 Blood Pressure Telemetry 
Blood pressure telemetry was performed by the of group of Dr. med. habil. Volk-
mar Groß (MDC / Charité Berlin) using a pressure-sensing catheter in the ab-
dominal aorta as described (Gross, et al., 2005). After surgery, mice were allowed 
10 days recovery before baseline blood pressure, heart rate and activity were re-
corded for 3 consecutive days. 
2.1.4.3 Endocrine Parameters 
Levels of renin, aldosterone and vasopressin in serum were measured by Irene 
Strauß (AG Michael Bader, MDC) or in the ‘Klinik für Nuklearmedizin’ (Helios 
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Klinikum Berlin-Buch), both using competitive radio immunosorbent assays 
(RIA). 
2.1.4.3.1 HPLC-Detection of Catecholamines and Serotonin 
Levels of serotonin (5-hydroxytryptophan) and catecholamines (dopamine, nore-
pinephrine and epinephrine) in tissues were measured using high-pressure liquid 
chromatography (HPLC). Mice were sacrificed by decapitation and the according 
organs were quickly removed, briefly rinsed in cold PBS and kept on ice during 
all following steps. 0.2 mol/l perchloric acid (1 ml per 100 mg tissue weight) was 
added and the organs were homogenized with an Ultra-Turrax (IKA, St. Augustin, 
Germany) and centrifuged for 20 min at 20,000 × g. The pellets containing pre-
cipitated protein was discarded, the supernatants were stored at –80 °C until ana-
lyzed by HPLC. 
Catecholamines were separated using a 125 mm × 3 mm I.D. column, packed with 
Nucleosil 100 C 18, particle size 3 µm at a temperature of 42 °C. The liquid phase 
consisted of 10 g/l citric acid, 4 g/l KH2PO4, 100 mg/l EDTA, 2%(v/v) acetonitril at 
pH 2.8 and had a flow rate of 0.7 ml/min. Electrochemical detection was carried 
out with an INTRO detector (ANTEC Leyden, The Netherlands) using a cell po-
tential of 800 mV. Retention times were around 2.2 min for norepinephrine, 
2.9 min for epinephrine and 4.9 min for dopamine, allowing a clear separation of 
these peaks. Concentrations were calculated from peak heights of the recordings 
by comparison standard curves created from peak heights of catecholamine solu-
tions with defined concentrations of the according catecholamine. The HPLC was 
carried out in the group of Dr. Wolf-Eberhard Siems (Leibniz-Institute for molecu-
lar Pharmacology, FMP Berlin) with the assistance of Dr. Winfried Krause. 
Serotonin was also separated using using a 125 mm × 3 mm I.D. column, packed 
with Nucleosil 100 C 18, particle size 3 µm at a temperature of 20 °C. The liquid 
phase consisted of 1.36 g/l KH2PO4 and 5%(v/v) methanol and had a flow rate of 
2 ml/min. Detection was carried out with a RF-10AXL fluorescence detector 
(Shimadzu, Japan) with excitation at a wavelength of 295 nm, measuring the 
emission at 345 nm. Concentrations were calculated from peak areas of the re-
cordings by comparison with standard curves created from peak areas of standard 
serotonin solutions. The HPLC was carried out in the group of Dr. Michael Bader 
(MDC). 
HPLC peaks heights and areas were calculated using the software of the corre-
sponding HPLC system (ANTEC Leyden, The Netherlands; Shimadzu, Japan) 
and the data was analyzed with Excel 2003 (Microsoft, USA). 
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2.1.5 Pharmacological Experiments 
2.1.5.1 Thiazide Treatment 
Mice were kept in metabolic cages for 10 hours. Hydrochlorothiazde was injected 
intraperitoneally (30 mg/kg body weight) at timepoints 0 and 5 hours. Urine was 
collected for 5 hours following each injection (from hour 0 to 5 and from hour 5 
to 10). Accordingly, control urine was collected from animals injected with 0.9% 
saline solution (B. Braun Melsungen, Germany). 
2.1.5.2 Eplerenone Treatment 
The mice received a daily dose of 200 mg eplerenone per kg body weight. The 
drug was either administered for two consecutive weeks via the chow (by replac-
ing the standard pellets with a dietary mash containing the drug), the drinking 
water (by replacing the normal water bottles) or via gavage twice a day. Control 
animals received dietary mash or water without eplerenone. 
2.1.5.3 Bumetanide Treatment 
Bumetanide treatment was carried out in thick ascending limb (TAL) tubules iso-
lated from the inner stripe of the outer renal medulla (ISOM). The isolation proc-
ess, modified from Kikeri et al. (Kikeri, et al., 1990), utilizes the high resistance 
of the TAL against collagenase. While this enzyme cocktail decomposes most the 
ISOM to individual cells, TAL tubules stay intact. Bumetanide-sensitive flux was 
determined by measuring uptake of radioactive rubidium (86Rb+), which was used 
as a substitute for K+. 
2.1.5.3.1 Isolation of the Inner Stripe of the Outer Renal Medulla 
Before use, all reagents (except anaesthetics) were oxygenized by bubbling with 
carbogen (5%(v/v) CO2, 95%(v/v) O2), unless stated otherwise. 
Mice were anaesthetized by intraperitoneal injections of 5 µl/g bodyweight 
Ketavet-Rompun-solution (400 µl 2% Rompun, 3.6 ml 10% Ketavet, ad 10 ml 
0.9% NaCl-solution; Bayer HealthCare, Leverkusen, Germany, Pfizer, USA, and 
B. Braun Melsungen, Germany respectively). When the animals were fully anaes-
thetized, kidneys were taken out of the abdominal cavity and the mice were sacri-
ficed by decapitation. Kidneys were placed in oxygenized ice-cold PBS and the 
kidney capsules were removed immediately. 
All following steps were carried out in ice-cold PBS: Kidney poles, containing 
only cortical tissue, were cut off and discarded. The remaining organs were sliced 
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into four equally thick transverse sections. Using a fine spring scissor, the ISOM 
was excised out of each section by cutting off the outer stripe of the medulla (to-
gether with the cortex) and the inner medulla/papillae. The u-shaped isolated 
ISOM was cut into small chunks (circa 1 mm3) and stored in oxygenized ice-cold 
PBS with continuous oxygen-supply until processed further. 
2.1.5.3.2 Enrichment of TAL Tubules 
The minced ISOM was transferred into pre-chilled 14 ml centrifuge tubes and 
kept on ice. Once all tissues were prepared, the tubes were moved to room-
temperature and 4 ml of oxygenized, 37 °C warm collagenase solution (0.8 mg/ml 
collagenase, crude type Ia in Dulbeccos’s Modified Eagle Medium; Sigma Aldrich 
and Promega, both USA) was added to each tube. Tissues were incubated on a 
rocking shaker (140 rpm) at room-temperature. 
After 10 minutes, the tissue fragments were suspended by pipetting several times 
up and down with a 10 ml tissue culture pipette. The suspension was allowed to 
settle for a few seconds to divide large, fast sedimenting chunks of undigested 
tissue from separated tubules and cells. While the supernatants, containing the 
digested portion, were transferred into fresh, ice-cold round-bottom centrifuge 
tube, fresh collagenase solution was added to the remaining undigested ISOM 
pellets. This procedure was repeated four to six times until no tissue sedimented 
within a few seconds after resuspendion anymore. 
Immediately after skimming, the supernatant containing isolated isolated TAL 
tubules was centrifuged for 4 min at 100 × g at 4 °C to separate contaminating 
cells of different origin. The supernatant containing non-TAL cells was discarded, 
and the pellet containing the larger TAL fragments was resuspended in 1 ml of 
recovery solution (0.1%(w/v) BSA, Cohn Fraction V in Dulbeccos’s Modified Ea-
gle Medium; Sigma Aldrich and Promega, both USA) and kept on ice. 
Fractions containing digested tubules of the same animal were pooled after resus-
pension in recovery solution. Subsequently, the cells were washed with ice-cold 
oxygenized basic flux solution (140 mM NaCl, 4.5 mM KCl, 0.5 mM RbCl, 
1 mM MgCl2, 1 mM CaCl2, 10 mM BaCl2, 10 mM NaH2PO4, 10 mM Na2SO4, 
5 mM HEPES, 5 mM Glucose in ultra-pure H2O, pH 7.0) twice by centrifugation 
(600 rpm, 4 °C, 4 min) and resuspension. 
2.1.5.3.3 Detection of Bumetanide-sensitive Uptake of 86Rb+ 
After centrifugation (600 rpm, 4 °C, 4 min) and resuspension in 37 °C warm oxy-
genized basic flux solution containing 1 µmol/l desmopressin (ddAVP) and 
1 mmol/l ouabain, tubules were allowed to recover for 5 min. ddAVP, acting simi-
lar to physiological vasopressin, has been reported to increase NKCC2 activity 
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(Gimenez and Forbush, 2003). Ouabain is a potent inhibitor of the basolateral 
Na+/K+-ATPase (Gimenez, et al., 2002). Ba2+-ions, abound in the basic flux solu-
tion, are blocking K+-channels (Taglialatela, et al., 1993). The TAL tubules of 
each animal were resuspended and immediately split into four parts with equal 
volume. 
The first part was spun down with a tabletop centrifuge for 10 min at max. speed. 
The pellet was weighted to measure the tubule mass (tubulocrit). 
Two portions were treated with 200 µl of 37 °C warm oxygenized basic flux solu-
tion containing 1 µM ddAVP, 1 mmol/l ouabain and 0.2 µCi/µl 86Rb+, either with 
or without 250 µmol/l bumetanide. As a passive control, the fourth part of the tu-
bules was incubated with the same volume of ice-cold oxygenized basic flux solu-
tion containing 1 µM ddAVP, 1 mmol/l ouabain and 0.2 µCi/µl 86Rb+ and incu-
bated on ice. After 5 min of incubation with the 86Rb+, all three reactions were 
stopped by addition of 800 µl of ice-cold SWG solution (140 mM potassium-
gluconate, 5 mM HEPES and 250 µM Bumetanide in ultra-pure water, pH 7.0). 
Four subsequent centrifugation (600 rpm, 4 °C, 4 min) and resuspension (in ice-
cold SWG solution) steps were carried out to remove extracellular 86Rb+. The 
SWG solution does only contain potassium-gluconate, therefore diluting all other 
ions. Together with the immediate chilling, addition of the buffer reduces all 
transport processes mediated by cotransporters (which require simultaneous avail-
ability of different electrolyte species for activity) and active transports (which are 
inhibited at low temperatures). The low temperature, the buffered pH and the 
physiological osmotic also pressure reduce passive transport by channels. 
After the final resuspension step, each portion of TAL tubules was either trans-
ferred onto a scintillator plate or suspended in 5 ml of scintillation liquid. The 
uptake of 86Rb+, an isotope emitting beta and gamma radiation, was measured as 
cpm (average counts per minute, measured over 10 min) on a LS-6000 liquid scin-
tillation counter (Beckman-Coulter, USA) in a completely open window (0 to 
1,000) with 100% efficiency according to manufacturer’s manual and Beckman-
Coulter Isotope Booklet for Liquid Scintillation Counters (November 12, 2002). 
The bumetanide-sensitive flux of each tubule preparation was calculated as cpm 
difference between treatment with and without bumetanide. For comparison be-
tween different experiments and animals, bumetanide-sensitive uptake was de-
scribed as percentage of uptake without addition of bumetanide. 
 
Material and Methods 
 44 
2.2 Microbiology 
2.2.1 Culture Media and Bacteria 
 
Table 2: Bacterial culture media. 
Name Broth Recipe Agar Recipe 
LB 
(Luria-Bertoni me-
dium) 
Tryptone  10%(w/v) 
Yeast extract 
 05%(w/v) 
NaCl   10%(w/v) 
in distilled water. 
pH 7.5 
See broth recipe, 
additional Agar 15%(w/v) 
 
if necessary: 
ampicillin sodium salt 
100 µg/ml 
SOC Tryptone 
 .020%(w/v) 
Yeast extract 
 .005%(w/v) 
NaCl  
 00.5%(w/v) 
KCl  
 0.17%(w/v) 
MgCl 
 0.95%(w/v) 
Glucose 
 03.6%(w/v) 
in distilled water. 
pH 7.0 
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Table 3: Escherichia coli strains. 
Name Genotype 
E. coli DH5  F-, φ80dlacZΔM15, Δ(lacZYA-argF)U169, deoR, 
recA1, endA1, hsdR17(rk-, mk+), phoA, supE44, λ-, 
thi-1, gyrA96, relA1 
E. coli HB101 F- mcrB mrr hsdS20(rB- mB-) recA13 leuB6 ara-14 
proA2 lacY1 galK2 xyl-5 mtl-1 rpsL20(SmR) glnV44 
λ- 
E. coli XL1-blue endA1 gyrA96(nalR) thi-1 recA1 relA1 lac glnV44 
F'[ ::Tn10 proAB+ lacIq Δ(lacZ)M15] hsdR17(rK- mK+) 
E. coli NEB Turbo 
Competent 
F' proA+B+ lacIq ΔlacZM15/fhuA2 Δ(lac-proAB) glnV 
gal R(zgb-210::Tn10) Tets endA1 thi-1 Δ(hsdS-
mcrB)5 
 
2.2.2 Generation of Electrocompetent Cells
To generate electrocompetent E. coli, cells of a fresh overnight culture were used 
to inoculate 1 l of LB medium at an OD600 of less than 0.1. The culture was incu-
bated under vigorous shaking at 37 °C until the OD600 reached 0.5. The cell sus-
pension was chilled on ice for 20 min and cell harvested by 15 min centrifugation 
at 4,000 × g and 4 °C. The pellet was resuspended in 1 l of ice-cold sterile 10% 
glycerol and centrifuged again (see above). This step was repeated again with 
500 ml and 20 ml. After the final centrifugation step, the pellet was resuspended 
in 2 ml of ice-cold 10% glycerol, aliquoted and stored at –80 °C. 
2.2.3 Transformation of Bacteria 
The cells and all materials/reagents needed (except SOC medium) were precooled 
on ice. 40 µl of electrocompetent E. coli were gently mixed with 2 µl of DNA. 
After 5 min incubation on ice, the cells were electroporated (R=200 Ω, C=25 µF, 
V=1.8 kV), immediately cooled down on ice, washed out of the cuvette with SOC 
medium, transferred into a new rection tube and incubated for 30 min at 37 °C. 
Cells were harvested by centrifugation for 5 min at 2,500 × g, plated on a LB agar 
plate and incubated at 37 °C overnight. For blue-white screening (e.g. after liga-
tion of DNA into a vector backbone, vide infra), LB agar plates were supple-
mented with 80 µg/ml X-gal and 0.5 mmol/l IPTG. 
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2.2.4 Yeast Two-hybrid Assay 
The yeast two-hybrid screen was carried out by Heike Göhler in the lab of Erich 
Wanker (MDC), as desctibed (Wanker, et al., 1997). For that purpose, the cDNA 
sequence coding for the cytosolic domain of human SORLA (including the native 
stop codon) was amplified by PCR using the Phusion enzyme (Finnzymes, 
Finland) as described below. Primers SorlaF and SorlaR (table 4, Eurogentec, 
Belgium) were used in a PCR program with an annealing temperature of 62 °C to 
amplify the 178 bp long product. 
 
Table 4: Primers used for cloning of the carboxy-terminus of human SORLA into 
pBTM117c. 
Name Sequence 
SorlaF (amplification 
primer) 
5'-ACGTCGACGCGGAGGCTGCAGAG-3' 
SorlaR (amplification 
primer) 
5'-GAGCGGCCGCTCAGGCTATCACCAT-3' 
BTMs (sequencing 
primer) 
5'-TCGTAGATCTTCGTCAGCAG-3' 
BTMas (sequencing 
primer) 
5'-GGAATTAGCTTGGCTGCAGC-3' 
 
PCR product and bait vector pBTM117c (table 5) were digested with the restric-
tion enzymes SalI and NotI (New England Biolabs, USA), and ligated as de-
scribed later. The miniprep DNA of an overnight culture inoculated with a single 
colony was sequenced with the primers BTMs and BTMas (table 4, Heike Göhler, 
MDC) to assure proper PCR amplification and ligation results. The sequencing 
method is described below. Cloning of the insert into the prey vector pACT4-1b 
was carried out accordingly. 
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Table 5: Vectors used in the yeast two-hybrid screen. 
Name Size Characteristics 
pBTM117c 9.5 kb promoter ADH1; fusion protein LexA; auxotrophy marker 
TRP1; 
ampicillin resistance (Wanker, et al., 1997) 
pACT4.1b 7.8 kb promoter ADH1; fusion protein GAL4-AD; auxotrophy 
marker LEU2; 
ampicillin resistance (Erich Wanker, MDC, unpublished) 
 
2.3 Nucleic Acid Experiments 
2.3.1 Polymerase Chain Reaction 
Polymerase chain reaction (PCR) was used to selectively amplify a specific DNA 
sequence from nucleic acid templates. Two enzymes were used for this work: 
Thermus aquaticus (Taq) Polymerase (Invitrogen, USA) and Phusion high-fidelity 
polymerase (Finnzymes, Finland). Reverse transcription PCR is described later. 
Taq polymerase reactions were set up in a 25 µl scale, consisting of 0.5 µl tem-
plate DNA, 0.2 mmol/l dATP, 0.2 mmol/l dTTP, 0.2 mmol/l dCTP, 0.2 mmol/l 
dGTP, 0.025 U/µl Taq Polymerase (Invitrogen, USA), 5 mmol/l MgCl2, and 
0.3 µmol/l of each forward and reverse primer in PCR Buffer (Invitrogen, USA). 
The PCR program was set up at a PTC-200 thermal cycler (MJ Research, USA) as 
follows: full denaturing of DNA template 5 min at 95 °C, 40 cycles with 30 sec 
denaturing at 95 °C, 1 min annealing at a temperature 2 K below the calculated 
melting-temperature of the PCR-primers (unless otherwise stated) and 1 min/kb 
elongation at 68 °C. A 10 min elongation step at 68 °C followed the cycling (table 
6). 
Phusion polymerase reactions were set up in a 25 µl scale, consisting of 0.25 µl 
template DNA, 0.2 mmol/l dATP, 0.2 mmol/l dTTP, 0.2 mmol/l dCTP, 0.2 mmol/l 
dGTP, 0.02 U/µl Phusion Polymerase (Finnzymes, Finland), 3% DMSO, and 
0.5 µmol/l of each forward and reverse primer in Phusion HF buffer (Finnzymes, 
Finland). The PCR program was set up at a PTC-200 thermal cycler (MJ Re-
search, USA) as follows: full denaturing of DNA template 1 min at 98 °C, 40 cy-
cles with 5 sec denaturing at 98 °C, 20 sec annealing at a temperature 2 K below 
the calculated melting-temperature of the PCR-primers (unless stated otherwise) 
and 20 sec/kb elongation at 72 °C. A 10 min elongation step at 72 °C followed the 
cycling (table 6). 
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Table 6: PCR programs for Taq polymerase and Phusion polymerase. Tm: melting tempera-
ture of PCR primers. 
Taq polymerase Phusion polymerase 
95 °C 5 min  98 °C 1 min  
95 °C 30 sec  98 °C 5 sec  
(Tm-2) °C * 1 min 40 × (Tm-2) °C * 20 sec 40 × 
68 °C 1 min/kb  72 °C 20 sec/kb  
68 °C 10 min  72 °C 10 min  
* (depending on the primer pair used) 
 
2.3.2 Plasmid DNA Extraction 
2.3.2.1 From Bacteria 
A single E. coli colony was picked from a LB agar plate used to inoculate a 5 ml 
LB culture, which was grown overnight at 37 °C with vigorous shaking. 
If small amounts of DNA were sufficient, sells were collected by centrifugation 
(5 min at 14,000 × g) and the pellet was processed using a Plasmid Mini Kit 
(Qiagen, The Netherlands). For larger amounts, the overnight culture was used to 
inoculate a 250–500 ml culture. The cells of that culture were centrifuged (as 
above) and subjected to a Plasmid Midi Kit (Qiagen, The Netherlands). Both kits 
use an alkaline lysis step and a subsequent anion exchange chromatography to 
purify plasmid DNA. They were used according to the Qiagen Plasmid Purifica-
tion Handbook (August 2003). 
Concentration and purity of the purified DNA was measured photometrically by 
using a NanoDrop ND-1000 (NanoDrop Technologies, USA) as described by Gal-
lagher et al. (Gallagher and Desjardins, 2006). DNA was stored at –20 °C. 
2.3.2.2 From Agarose Gels 
Bands of interest were narrowly cut out under a UV lamp. DNA was purified from 
the gel slices by using the High Pure PCR Product Purification Kit (Roche Diag-
nostics, Mannheim, Germany) according to product manual. 
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2.3.3 Total RNA Extraction 
RNase-free solutions were used for all subsequent steps unless stated otherwise. 
Mice were sacrificed, corresponding tissues removed, briefly rinsed in ice-cold 
PBS, and either prozessed on ice immediately or snap-frozen in liquid nitrogen. 
Per 100 mg of tissue, 1 ml of ice-cold Trizol (Invitrogen, USA) was added. Or-
gans were homogenized with an Ultra-Turrax (IKA, St. Augustin, Germany). 1 ml 
of the homogenate was added to 0.2 ml trichloromethane (room-temperature) and 
mixed vigorously, followed by 5 min incubation at room-temperature. The sus-
pension was mixed for 10 min at 12,000 × g at 4 °C. The upper phase was col-
lected and gently mixed with 500 µl isopropanol for 10 min at room-temperature 
to precipitate the RNA. It was pelleted by centrifugation (12,000 × g, 4 °C, 
10 min) and washed by vortexing in 75% ethanol. After a final centrifugation 
(7,500 × g, 4 °C, 10 min), the pellet was briefly air dried at room-temperature and 
dissolved in RNase-free water. 
To remove contaminating DNA, 100 µg of RNA were digested with 20 U RNase-
free DNase I (Roche Diagnostics, Mannheim, Germany) for 20 min at 37 °C. En-
zyme and contaminants resulting from this process were removed using the 
RNeasy Mini Kit (Qiagen, The Netherlands) following the RNA cleanup method 
described in the Qiagen RNeasy Mini Handbook (June 2001). 
RNA concentration and purity was determined photometrically by using a Nano-
Drop ND-1000 (NanoDrop Technologies, USA) as described by Gallagher et al. 
(Gallagher and Desjardins, 2006). RNA quality and degradation was determined 
by electophoresis on a Agilent 2100 Bioanalyzer with elektrophoresis setup using 
a RNA 6000 Nano Kit (Agilent Technologies, USA), RNAs with RNA integrity 
number values of 8 or higher were considered as intact. 
 
2.3.4 Enzymatic DNA Restriction 
DNA was incubated with 0.5 U restriction enzyme per µg DNA for 2 h or over-
night. All restrictions enzymes were obtained from New England Biolabs, USA. 
Digestions were carried out using buffers and reaction temperatures as recom-
mended in the company’s catalog (New England Biolabs, USA). Digested DNA 
was purified either directly by ion exchange columns (High Pure PCR Product 
Purification Kit; Roche-Diagnostics, Mannheim, Germany), or by agarose gel 
electrophoresis and subsequent column purification. 
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2.3.5 Agarose Gel Electrophoresis 
To separate DNA molecules according to their molecular weight, the samples 
were loaded onto agarose gels and stained with ethidium bromide as described in 
‘Molecular cloning: a laboratory manual’ (Sambrook, et al., 1989). For small RT-
PCR DNA fragments with an approx. size of 100 bp, 4% gels were prepared using 
Phor Agarose (Biozym Scientific, Hessich Oldendorf, Germany, cat. No. 850180). 
2.3.6 DNA Ligation 
Ligation of DNA fragments into a linearized vector backbone was performed 
solely with molecules having complementary overlaps at the 5’-/3’-ends (‘sticky’ 
ends) by using T4 DNA ligase (Invitrogen, USA). Prior to ligation, 5'-
phosphoester were hydrolyzed, to prevent religation of linearized vectors. To do 
so, alkaline phosphatase from calf intestine (Roche Diagnostics, Mannheim, Ger-
many) was used according to manufacturer's instructions. After dephosphoryla-
tion, samples were cleaned with PCR Product Purification Kit (Roche Diagnos-
tics, Mannheim, Germany). Vector and insert were mixed in a molar ratio of 1:3 to 
1:9, the reaction was set up as described in Invitrogen’s package insert and the 
ligation was incubated at 16 °C overnight. 
Ligation into readily linearized pGEM-T Easy vector (pGEM-T Easy Vector Sys-
tem; Promega, USA) was carried out as recommended in the manufacturer’s man-
ual. Prior to ligation, PCR products amplified with Phusion high fidelity DNA 
polymerase (Finnzymes, Finland), were treated with 0.5 U/µl Taq polymerase and 
0.2 mmol/l dATP in PCR buffer for 30 min at 68 °C to create 3’-adenosine-
overhangs. 
Ligated DNA was used for the transformation of electrocompetent E. coli. 
2.3.7 DNA Sequencing 
DNA was sequenced using a modified chain-termination method (Sanger, et al., 
1977). The presence of fluorescence-labeled dideoxy-nucleotides in the reaction 
leads to termination of the strand extension, labeling the terminating nucleotide. 
The reaction was carried out using the BigDye Terminator v3.1 Cycle Sequencing 
Kit (Applied Biosystems, USA) according to the kit’s manual. The reaction was 
performed in a PTC-200 thermal cycler (MJ Research, USA) as follows: 1 min 
initial template denaturation at 96 °C and 25 cycles with 10 sec denaturation 
(96°C), 5 sec primer annealing (55 °C) and 4 min elongation (60 °C). Surplus 
primer and (dideoxy-) nucleotides were removed by size-exclusion chromatogra-
phy on a Sephadex G-50 column (GE Healthcare, USA). 
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The purified sample was sequenced on a ABI PRISM 377 DNA Sequencer (Ap-
plied Biosystems, USA) in the group of Norbert Hübner (MDC). Sequences were 
analyzed using Lasergene 7.0 Suite (DNASTAR, USA) and ClustalX 
(http://www.clustal.org/). 
 
2.3.8 Northern Blot 
Northern blot probes were labeled by incorporation of 32P-labeled ATP (Perkin 
Elmer, USA). pcDNA3.1 Vectors (Invitrogen, USA) containing full-length 
cDNAs of the Sorla and Sortilin were already available in our group. 
Inserts of both vectors were cut out with PmeI (New England Biolabs, USA) ac-
cording to manufacturers recommendations and isolated by agarose gel electro-
phoresis and subsequent purification as described above. Resulting DNA frag-
ments were used as template for the Prime-It II Random Labeling Kit (Stratagene, 
USA). The labeling with random nonamers was carried out as described in the 
kit’s manual. The generated 32P-labeled DNA probe fragments were purified using 
NucAway Spin Columns (Applied Biosystems, USA) as described in the column’s 
instructions. 
A premade human adult 12-lane Multiple Tissue Northern Blot membrane (Clon-
tech, USA) was blocked, hybridized and washed according to manufacturer’s in-
structions. The membrane was wrapped in saran wrap (SC Johnson, USA) and 
transferred together with an isotope detection imaging plate (Fujifilm, Japan) into 
a cassette. After exposure, the imaging plate was scanned with a Fluorescent Im-
age Analyzer FLA-3000 (Fujifilm, Japan). 
 
2.3.9 In situ Probe Synthesis 
For the in situ probes for the detection of transcripts of Sorla and Sortilin, tem-
plates of 976 and 991 bp length respectively were amplified from murine cDNA 
of both genes. A sequence spanning from Sorla exon 42 to the last exon 48 was 
amplified using primers Sorla_probe_F and Sorla_probe_R listed in table 7. PCR 
amplification with Taq polymerase (Invitrogen, USA) was performed with an an-
nealing temperature of 50 °C as described above. Primers Sortilin_probe_F and 
Sortilin_probe_R were used with an annealing temperature of 53 °C to amplify an 
untranslated region near the 5’-end of the Sortilin cDNA. 
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Table 7: Primers used for cloning of the carboxy-terminus of human SORLA into 
pBTM117c. Primers were ordered from Eurogentec, Belgium. 
Name Sequence 
Sorla_probe_F 5'-TGCCACATCCTTCCTTGAC-3' 
Sorla_probe_R 5'-AGCATCTTCATCGTCCTCT-3' 
Sortilin_probe_F 5'-GGCATCGCTCATTTTAT-3' 
Sortilin_probe_R 5'-TGCCTTTGCTGTATGGT-3' 
SP6 (sequencing primer) 5'-TATTTAGGTGACACTATAG-3' 
T7 (sequencing primer) 5'-TAATACGACTCACTATAGGG-3' 
Both amplicons were purified and cloned into the pGEM-T Easy vector (Promega, 
USA). After picking a colony, plasmid DNA from a 5 ml overnight culture was 
isolated (vide supra) and sequenced using the SP6 and T7 primers (table 7). Con-
firmed clones were grown up in a 250 ml culture and subjected to midiprep plas-
mid isolation (see above). 
Digoxigenin (DIG)-labeled probes for in situ hybridization (ISH) were generated 
by in vitro transcription (IVT) with T7 or SP6 polymerase using the DIG labeling 
kit (Roche Diagnostics, Mannheim, Germany). Template DNA plasmids were 
linearized either between insert and T7 promoter or between insert and SP6 pro-
moter using suitable restriction enzymes (New England Biolabs, USA). After 
heat-inactivating restriction enzymes, 1 µg of each linearized plasmid was used 
for the IVT reaction, which was performed as described in the manufacturer’s 
instructions. Enzyme and residual contaminants resulting from this process were 
removed using the RNeasy Mini Kit (Qiagen, The Netherlands) following the 
RNA cleanup method described in the Qiagen RNeasy Mini Handbook (June 
2001). RNA quality and degradation was determined by electophoresis on a 
Agilent 2100 Bioanalyzer with elektrophoresis setup using a RNA 6000 Nano Kit 
(Agilent Technologies, USA). 
2.3.10 cDNA Synthesis 
First-strand synthesis of mRNA (reverse transcription polymerase chain reaction 
or RT-PCR) was carried out using SuperScript II reverse transcriptase (Invitrogen, 
USA) and oligo(dT)12-18 primers with 1 µg of total RNA as template according to 
manufacturer’s instructions (Rev. Date: November 11, 2003). Two control reac-
tions were set up for each batch: a control with water instead of RNA to check for 
contamination of the reagents, and a reaction with water instead of reverse-
transcriptase to check for DNA contamination in the RNA preparation. 
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2.3.11 Quantitative Real-time PCR 
Due to the exponential nature of polymerase chain reaction (PCR) amplifications, 
the quantification of the amplicon after each cycle can be used to calculate the 
initial amount of template. To do so, quantitative real-time PCR (here also referred 
to as TaqMan) was carried out using gene of interest-specific DNA probes 5’-
linked to a fluorescent dye –6-FAM (carboxyfluorescein) – and 3’-linked to a 
quencher – either BHQ-1 (black hole quencher 1) or MGB (minor groove binder). 
Excitation of the dye does not lead to fluorescence, as all emitted light is reab-
sorbed by the quencher in the dye’s close vicinity. 
The probe hybridizes specifically to an exon-exon-boundary of the template 
cDNA. A Thermus aquaticus (Taq)-polymerase based PCR-reaction using specific 
PCR primers, situated up and downstream of the probe, initiates amplification. 
During this process, the 5’ to 3’ exonuclease activity of the polymerase digests the 
probe, separating fluorophor and quencher. As the quencher molecules are not 
able to absorb light emitted by distant fluorescin groups, the amount of PCR 
product can be indirectly determined by fluorescence measurements after each 
cycle. The combination of a primer pair and a probe specific for the cDNA of a 
single gene of interest is called assay. 
Relative gene expression was determined using the cT method. The used detec-
tion system plotted the fluorescence intensity over the PCR cycles. The number of 
cycles, after which the signal erupts exponentially above a set threshold is called 
cT. The cT represents a logarithmic measure for the amount of template of the 
cDNA of interest. To normalize the cT of the gene of interest, the difference to the 
cT of the cDNA of the housekeeper gene glyceraldehyde-3-phosphate dehydro-
genase () – the cT – is calculated. The antilogarithmic value of the cT is a value 
for the expression of the gene of interest relative to the expression of Gapdh. 
Standard deviation of cT was calculated by taking the square root of the sum of 
the squared standard deviations of both individual cT values. 
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Table 8: Primers and probes used for TaqMan quantitative real-time PCRs. 
 
Gene of interest Sequence / Assay ID Supplier 
Gapdh Forward primer 
Reverse primer 
Probe* 
5’-GGCAAATTCAACGGCACAGT-3’ 
5’-AGATGGTGATGGGCTTCCC-3’ 
5’-AAGGCCGAGAATGGGAAGCTTGTCATC-3’ 
 
Eurogentec, Belgium 
Sorla Forward primer 
Reverse primer 
Probe* 
5’-TGAACGCAACTGCTTGTATTGG-3’ 
5’-CCAGGCCGGAATTGATGAT-3’ 
5’-CCAGCGTCTCTGCTTGAACGGGAG-3’ 
 
Eurogentec, Belgium 
Sortilin Forward primer 
Reverse primer 
Probe* 
5’-GAGTTCTGTCTGTACGGCAAGGA-3’ 
5’-ACTTCTCTGGCGGGATTCATC-3’ 
5’-AGCACCTGACAACAAATGGGTACCGG-3’ 
 
Eurogentec, Belgium 
Sorcs1  Gene Expression Assay (185558947) 
Mm00491259_m1 
 
Applied Biosystems, 
USA 
Sorcs2  Gene Expression Assay (185558947) 
Mm00473050_m1 
 
Applied Biosystems, 
USA 
Sorcs3  Gene Expression Assay (185558947) 
Mm00458702_m1 
 
Applied Biosystems, 
USA 
Atm  Gene Expression Assay (185558947) 
Mm00431867_m1 
 
Applied Biosystems, 
USA 
Ifi202b  Gene Expression Assay (185558947) 
Mm00839397_m1 
 
Applied Biosystems, 
USA 
Mfap1A  Gene Expression Assay (185558947) 
Mm01625090_s1 
 
Applied Biosystems, 
USA 
Mfap1A/B  Gene Expression Assay (185558947) 
Mm00849648_gH 
 
Applied Biosystems, 
USA 
Pttg1  Gene Expression Assay (185558947) 
Mm00479224_m1 
 
Applied Biosystems, 
USA 
Sord  Gene Expression Assay (185558947) 
Mm01730221_mH 
 
Applied Biosystems, 
USA 
Ddc  Gene Expression Assay (185558947) 
Mm00516688_m1 
 
Applied Biosystems, 
USA 
Dbh  Gene Expression Assay (185558947) 
Mm00460472_m1 
 
Applied Biosystems, 
USA 
Pnmt  Gene Expression Assay (185558947) 
Mm00476993_m1 
 
Applied Biosystems, 
USA 
Th  Gene Expression Assay (185558947) 
Mm00447557_m1 
 
Applied Biosystems, 
USA 
Slc18a1  Gene Expression Assay (185558947) 
Mm00461868_m1 
 
Applied Biosystems, 
USA 
* Probes were labelled with 6-FAM at the 5’ and with BHQ-1 at the 3’-end. 
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All TaqMan runs were performed in single-plex reactions – using only one assay 
per reaction – and were carried out in triplicates using the standard TaqMan-PCR 
program (denaturing of hot-start Taq polymerase for 15 min at 95 °C, 40 cycles 
with 15 sec denaturing at 95 °C and 1 min annealing and elongation at 60 °C) at 
an ABI Prism 7000 Sequence Detection System (Applied Biosystems, USA). 
Each reaction was set up in a 20 µl scale, consisting of 5 µl cDNA, 10 µl qPCR 
MasterMix Plus (Eurogentec, Belgium), 0.4 µg/µl BSA (Sigma-Aldrich, USA), 
0.25 µmol/l probe and 0.9 µmol/l of each forward and reverse primer. The sources 
primers and probes were obtained from, are listed in table 8. The data was ana-
lyzed using SDS 7000 Software 1.2.3 (Applied Biosystems, USA) and Excel 2003 
(Microsoft, USA). 
 
2.3.12 DNA Microarray-based Gene Expression Analysis 
Microarray technology allows high-throughput analysis of nucleic acid hybridiza-
tion events. In this work, DNA microarrays from Affymetrix (USA) – solid chips 
carrying an array of more than 14,000 sets of covalently bound oligomeric cDNA 
probes – were used to collect semi-quantitative, expression data of more than 
39,000 transcripts per sample. The used nucleotides are labeled, positive hybridi-
zation can be detected by a scanner. 
The Affymetrix platform uses biotin-labeled cRNA synthesized from the sample 
RNA for hybridization. For that purpose, cDNA is synthesized from sample RNA 
– using oligo(dT)-primers carrying a T7-promoter sequence for first strand syn-
thesis to only use mRNA as template. In a subsequent T7 RNA polymerase in-
vitro transcription (IVT) step, cRNA is synthesized from the cDNA template – 
applying biotinylated ribonucleotide analogues for labeling of the product. The 
IVT provides signal amplification, as several labeled product molecules are syn-
thesized per template cDNA molecule. Due to this amplification cycle, the label-
ing method is called one-cycle target labeling. 
If the starting amount of RNA is very low, an additional IVT step can be included. 
The first IVT is carried out without biotin-labeling, the emerging cRNA is em-
ployed in a second cDNA synthesis – using random primers as mRNA enrichment 
is not necessary and T7 promoter already exists – and a second IVT cycle with 
biotinylated nucleotides produces the labeled cRNA for hybridization. This 
method is called two-cycle target labeling. 
The labeled cRNA is fragmented and hybridized onto the microarray. After hy-
bridization, a streptavidin-conjugated fluorescing dye (phycoerythrin) is added 
and the chips are scanned. The workflow of both labeling methods is depicted in 
figure 4. 
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Figure 4: Workflow of target labeling for Affymetrix analysis as performed for expression 
analysis in kidney and adrenal gland. Hybridization and scanning was carried out at the Affy-
metrix core facility (MDC). Picture adopted from Affymetrix GeneChip Expression Analysis 
Technical Manual P/N 702232 Rev. 3. 
 
RNA was purified as described above. All further processing steps were carried 
out according to Affymetrix’s manual (GeneChip Expression Analysis Technical 
Manual P/N 702232 Rev. 2). For kidney samples, 2 µg of total RNA were labeled 
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with a GeneChip One-Cycle Target Labeling Kit (Affymterix, USA, part number 
900493). For adrenal gland samples, the labeling of 100 ng RNA was carried out 
using a GeneChip Two-Cycle Target Labeling Kit (Affymterix, USA, part number 
900494) and MEGAscript T7 Kit (Ambion/Applied Biosystems, USA, part num-
ber AM1333). Labeled cRNA was hybridized to GeneChip Mouse Genome 430 
2.0 Arrays (Affymetrix, USA, part number 900496) and the chips were scanned 
using a GeneChip Scanner 3000 (Affymetrix, USA). Hybridization and scanning 
was performed at the Affymetrix core facility (MDC). 
The array data was normalized using either the RMA or gcRMA algorithm (Bol-
stad, et al., 2003; Irizarry, et al., 2003; Wu and Irizarry, 2004). gcRMA-
normalized data was analyzed using GeneSpring GX (Agilent, USA); RMA-
normalized data was analyzed using Excel 2003 (Microsoft, USA) and PASW 
Statistics 17 (SPSS, USA). p-values were calculated using either Student’s or 
Welch’s t-test (Welch, 1947). False-positive correction (multiple testing) was done 
by applying the Benjamini-Hochberg false discovery rate algorithm (Benjamini 
and Hochberg, 1995). 
 
2.4 Histology 
2.4.1 Cryosections 
Organs were removed, briefly rinsed in ice-cold PBS and snap-frozen in liquid 
nitrogen until dissection. Prior to sectioning, frozen tissues were transferred to 
Tissue-Tek O.C.T. Compound (Sakura, Japan) and cooled down on dry ice. 
Solid blocks of Tissue-Tek containing the tissues were dissected at 10 µm with a 
HM 355 S rotary cryotome (Microm/Thermo Fisher Scientific, Walldorf, Ger-
many). The sections were mounted on SuperFrost Plus, air-dried for 30 min at 
room-temperature and stored at –80 °C. 
2.4.2 Paraffin Sections 
Embryos were sacrificed at embryonal day 14.5 (E14.5) and briefly rinsed in ice-
cold PBS. After cutting off the limbs, embryos were punctured at forehead and 
frontal abdominal cavity. Specimens were fixed for 2 h at room-temperature in 
4%(w/v) PFA. 
Kidneys of adult animals were fixed in situ by perfusion with 4% formaldehyde, 
removed and additionally fixed for in 4% formaldehyde at 4 °C overnight. The 
samples were dehydrated by transfer through a series of graded ethanol/PBS solu-
tions (70%, 80%, 90%, 96%, 100% ethanol in PBS, respectively) for 2 h per step. 
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The tissues were incubated twice for 2 h each in Roti-Histol (Carl Roth, 
Karlsruhe, Germany). Preinfiltration with paraffin was carried out for 2 h at 67 °C 
and a final infiltration step in fresh 67 °C paraffin followed overnight. Specimens 
were embedded in metal molds and stored at 4 °C until processed. 
The solid paraffin blocks containing the samples were sectioned at 5 µm on a ro-
tary microtome (Leica Geosystems, Switzerland). Slides were stored at 4 °C until 
further use. 
2.4.3 In situ Staining of Sections 
In situ hybridization was carried out on paraffin sections. All reagents used were 
RNase-free, all incubation steps were performed at room-temperature unless 
stated otherwise. Paraffin was dissolved by dipping the object slides with the sec-
tions two times for 5 min into Roti-Histol (Carl Roth, Karlsruhe, Germany). The 
sections were hydrated by transfer through an ethanol series (100%, 96%, 90%, 
80%, 70%, 40%, 0% ethanol in PBS, 2 min each). Sections were postfixed for 
10 min in 4%(w/v) PFA (paraformaldehyde in PBS) at 4 °C, followed by two PBS 
washing-steps, 5 min each. Endogenous peroxidase activity was inactivated by 
bathing in 1% hydrogen peroxide in methanol for 20 min. After another two 
rounds of PBS-washing, endogenous phosphatase activity was quenched by incu-
bating the sections in 0.2 mol/l HCl for 8 min and washing as before. Permeabili-
zation was achieved by treatment with 10 µg/ml proteinase K in 10 mmol/l Tris-
HCl (pH 7.5) for 10 min. 
After one washing step in PBS for 5 min, the sections were bathed in 0.1 mol/l 
triethanolamine for 2 min and subsequently acetylated by incubation for 10 min in 
0.25% acetic anhydride in 0.1 mol/l triethanolamine. 
The sections were washed twice in 2x SSC buffer (20x SSC buffer is 3 mol/l NaCl 
and 300 mmol/l sodium citrate, pH 7.0) for 10 min each and air-dried. Hybridiza-
tion buffer (50%(v/v) formamide, 2x SSC, 0.02%(w/v) BSA, 0.02%(w/v) polyvi-
nylpyrrolidone, 0.02%(w/v) ficoll, 10%(w/v) dextrane sulfate, 0.5 mg/ml yeast tRNA 
and 0.5 mg/ml hydrolyzed salmon sperm DNA) was mixed with digoxigenin-
labeled probes (20 ng/ml final concentration) and 200 µl of this mix were dis-
pensed on the sections. The sections were covered with cover slips and stored 
inside a humid box. The probes were allowed to hybridize in a hybridization oven 
overnight at 60 °C. The hybridization temperature was chosen due to the calcu-
lated melting temperatures of ca. 62 °C for both Sorla and Sortilin probes in a 
buffer containing 50% formamide and 2x SSC (calculated using the Lasergene 
Suite, DNASTAR, USA) and the requirement for stringent binding. The following 
day, the sections were washed in 2x SSC for 10 min at 45 °C. Two subsequent 
stringency washes in 50% fomamide 1x SSC at 60 °C for 20 min each were fol-
lowed by one bath in 60 °C warm 0.2x SSC for 20 min. 
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Sections were briefly washed in was buffer (100 mmol/l maleic acid, 150 mmol/l 
NaCl, 0.3%(v/v) Tween-20, pH 7.5) and incubated for 30 min at 37 °C in blocking 
buffer 1 containing 1%(w/v) blocking reagent (Roche Diagnostics, Mannheim, 
Germany, cat. No. 1096176) and 0.05%(w/v) avidin in wash buffer. 
After a brief rinse with wash buffer, the sections were incubated for 1 h in anti-
DIG-HRP (Abcam, USA) diluted 1:100 in blocking buffer 1 containing 
0.005%(w/v) biotin. The antibody-solution was removed by washing three times in 
wash buffer for 5 min each. Sections were blocked with blocking buffer 2 
(0.5%(w/v) renaissance blocking reagent, NEN Life Science, USA, in 150 mmol/l 
NaCl and 100 mmol/l Tris-HCl, pH 7.5) for 30 min at 37 °C. Biotinyl-Tyramide 
was diluted 1:70 in amplification diluents (both NEN Life Science, USA), added 
to the sections and incubated for 10 min in the dark. Slides were washed three 
times in wash buffer, 5 min each. The samples were incubated with streptavidin-
AP (Perkin Elmer, USA), diluted 1:750 in blocking buffer 1, for 1 h in a dark box. 
After three 5 min washes with wash buffer and a 10 min wash with detection 
buffer (10 mmol/l NaCl, 100 mmol/l Tris-Hcl, 50 mmol/l MgCl2, pH 9.5), the 
staining was developed in substrate solution (337 µg/ml NBT, 175 µg/ml BCIP, 
5 mmol/l levimasole in detection buffer) 5 min to 4 h and stopped in TE buffer 
(10 mmol/l Tris-HCl, 1 mmol/l EDTA, pH 7.5). The slides were rinsed in water 
and dehydrated through an Ethanol/PBS series and mounted with Roti-Histokitt 
(Carl Roth, Karlsruhe, Germany). 
2.4.4 Staining of LacZ Reporter Gene Activity 
Cryosections of kidneys from adult Sorla Ex255 mice were thawed and briefly 
rinsed in PBS. The sections were incubated in X-gal staining solution (100 µg/ml 
X-gal in 5 mmol/l potassium ferrocyanide, 5 mmol/l potassium ferricyanide, 
0.1%(w/v) Triton X-100, 0.1 mol/l sodium phosphate, pH 7.5), until the staining 
became visible. Reactions were stopped by brief rinsing in PBS and pictures were 
taken immediately. 
2.4.5 Immunohistochemistry 
2.4.5.1 Staining of SORLA in Adrenal Glands 
Frozen sections were fixed in –20 °C cold acetone for 5 min. After washing in 
PBS (3x 5 min), endogenous peroxidase activity was quenched by treatment with 
0.3% hydrogen peroxide in PBS for 5 min, followed by another PBS wash (3x 
5 min). The sections were blocked using the Biotin Blocking System (Dako, 
Denmark) according to manufacturer’s manual. The tissues were permeabilized 
for 5 min in 0.2%(w/v) Triton X-100, washed in PBS as before and blocked with 
3% FCS in PBS for 1 h. After a brief PBS wash (1x 5 min), anti-SORLA antibody 
(from goat, diluted 1:500 in PBS containing 3% FCS) was applied for 1 h fol-
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lowed by PBS wash (3x 5 min). The sections were incubated with a biotinylated 
secondary antibody (anti-goat), diluted 1:500 in PBS, for 30 min. After briefly 
washing with PBS (1x 5 min), an avidin-biotinylated horseradish peroxidase-
complex (ABC; Vectastain Elite ABC Kit, Vector Laboratories, USA; used ac-
cording to manual) was added for 30 min. After eliminating non-bound complex 
by washing with PBS (3x 5 min), the antibody-ABC complex was stained by ap-
plying development solution containing AEC (3-amino-9-ethylcarbazole) for 5 to 
10 min. Development of the staining was stopped by rinsing the sections in dis-
tilled water. Nuclei were counterstained using Mayer’s hematoxylin staining for 
1 min, followed by washing with tap water. Sections were mounted using aqueous 
fluorescence mounting medium (Dako, Denmark). Pictures were taken using a 
brightfield microscope (BX51; Olympus, Japan) with an attached CCD-camera 
(SPOT RT Slider; Diagnostic Instruments, USA). 
2.4.5.2 Immuno-staining in Kidney Sections 
Murine adult kidney sections were deparaffinized by transferring the object slides 
with the sections two times for 5 min each into Roti-Histol (Carl Roth, Karlsruhe, 
Germany). The sections were hydrated by transfer through an ethanol series 
(100%, 96%, 90%, 80%, 70%, 40%, 0% ethanol in PBS, 2 min each). Sections 
were postfixed for 10 min in 4%(w/v) PFA (paraformaldehyde in PBS) at 4 °C, fol-
lowed by two PBS washing-steps, 5 min each. The tissues were permeabilized for 
5 min in 0.2%(w/v) Triton X-100, washed in PBS as before and blocked with 3% 
FCS (donkey serum for fluorescence stainings) in PBS for 1 h, followed by a brief 
PBS wash (1x 5 min). 
For detection of SORLA, anti-SORLA antibody (from goat, diluted 1:500 in PBS 
containing 3% FCS) was applied for 2 h followed by PBS wash (3x 5 min). The 
sections were incubated with an HRP-conjugated secondary antibody (anti-goat), 
diluted 1:500 in PBS. After washing with PBS (3x 5 min), the staining was devel-
oped by adding diaminobenzidine (DAB Substrate Kit; Vectorlabs, USA, used 
according to manufacturer’s instructions) until the staining was sufficient. Devel-
opment of the staining was stopped by rinsing the sections in distilled water. Nu-
clei were counterstained using Mayer’s hematoxylin staining for 1 min, followed 
by washing with tap water. Sections were dehydrated using an ethanol series (as 
described above) and mounted using Roti-Histokitt (Carl Roth, Karlsruhe, Ger-
many). Pictures were taken using a brightfield microscope (BX51; Olympus, Ja-
pan) with an attached CCD-camera (SPOT RT Slider; Diagnostic Instruments, 
USA). 
For fluorescence co-staining of NKCC2 and SPAK, anti-NKCC2 antibody (from 
rabbit, diluted 1:250) and anti-SPAK / anti-phospho-SPAK (both from sheep, di-
luted 1:500) were applied at 4 °C overnight. The next day, sections were rinsed in 
PBS (3x 5 min) and incubated for 1 h with corresponding fluorescence-labeled 
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secondary antibodies (Alexa Fluor 488-conjugated anti-rabbit, Alexa Fluor 555-
conjugated anti-sheep; both Invitrogen, USA), diluted 1:1,000 each. Finally, sec-
tions were washed in PBS (3x 5 min), mounted using Vectashield mounting me-
dium (Vector Labs, USA) and coverslips. Fluorescence pictures were taken using 
a confocal laser scanning microscope (TCS SP2; Leica Microsystems, Germany). 
 
2.5 Protein Biochemistry 
2.5.1 Enrichment of Membrane Proteins 
The following protocol was used to enrich proteins that are directly or indirectly 
bound to the cellular membrane system. All solutions were complemented with 
protease-inhibitors (Complete Protease Inhibitor; Roche Diagnostics, Mannheim, 
Germany) and phosphatase-inhibitors (Halt Phosphatase Inhibitor Cocktail; 
Pierce, USA) and carried out on ice unless otherwise stated. Organs were taken 
out and weighted after residual adipose tissue was removed. After a brief rinse in 
PBS, the organs were snap-frozen in liquid nitrogen and stored at –80 °C until 
processed. The frozen organs were pestled in a cold mortar containing some liquid 
nitrogen. The ground material was transferred into a 1.5 ml reaction tube by add-
ing 1 ml of sucrose buffer (20 mmol/l Tris-HCl, 2 mmol/l MgCl2, 0.25 mmol/l 
sucrose, pH 7.5) per 100 mg tissue weight and pipetting the melted solution. The 
suspension was sonicated for 20 sec and centrifuged for 10 min at 1,000 × g at 
4 °C to remove nuclei. The supernatant was spun for 30 min at 20,000 × g (also 
4 °C), enriching cell membrane in the pellet. The supernatant of this step was cen-
trifuged at 100,000 × g to enrich vesicular membranes in the pellet. 20,000 × g 
and 100,000 × g pellets were collected, the other fractions were discarded. Pellets 
were dissolved in RIPA buffer (50 mmol/l Tris-HCl, 150 mmol/l NaCl, 0.5%(w/v) 
deoxycholate, 1%(w/v) NP40, 0.1%(w/v) SDS). 
2.5.2 Total Protein Preparation 
For the preparation of total protein, organs were taken out and excessive fat re-
moved. The organs were weighted and homogenized on ice in 1 ml/100 mg ho-
mogenization buffer (50 mmol/l Tris-HCl, 1 mmol/l EGTA, 1 mmol/l EDTA, 
1%(w/v) Triton X-100, 1 mmol/l sodium orthovanadate, 50 mmol/l sodium fluoride, 
5 mmol/l sodium pyrophosphate, 0.27 mol/l sucrose, 0.1% 2-mercaptoethanol, pH 
7.5) complemented with protease-inhibitors (Complete Protease Inhibitor; Roche 
Diagnostics, Mannheim, Germany) and phosphatase-inhibitors (Halt Phosphatase 
Inhibitor Cocktail; Pierce, USA) using an Ultra-Turrax (IKA, St. Augustin, Ger-
many). The samples were incubated for 20 min on ice and afterwards centrifuged 
for 10 min at 10,000 × g at 4 °C. Pellets were discarded, supernatants were frozen 
in liquid nitrogen and stored at –80 °C. 
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2.5.3 Protein Concentration Estimation 
The concentration of proteins was estimated using either a Bradford (Bio-Rad 
Protein Assay; Bio-Rad, USA) or a BCA (BCA Protein Assay Kit; Pierce, USA) 
assay (Bradford, 1976; Smith, et al., 1985). These assays strongly rely on similar 
properties (e.g. sequence of amino-acid residues, surface charges, etc.) of the pro-
tein of interest and a standard of known concentration. As most protein solutions 
measured were of unknown composition, the cheaply available globular protein 
BSA (Sigma-Aldrich, USA) was used as a standard, resulting in estimation (not 
exact determination) of the protein concentration. Both assays were carried out as 
described in manufacturers’ protocols. BSA standards were used for protein prepa-
tions. Concentrations of peptide solutions were only compared to each assay other 
using the BCA assay to estimate coupling efficiency (vide infra). This was neces-
sary due to the lack of proper controls, as peptides with a different primary struc-
ture can have very different Cu2+ reduction properties. 
2.5.4 SDS Polyacrylamide Gel Electrophoresis 
SDS polyacrylamide gel electrophoresis (SDS PAGE) was carried out to separate 
proteins according to their electrophoretic mobility (mainly influenced by size, 
struture and charge) in a charge-independent manner (Shapiro, et al., 1967). The 
detergent SDS denatures proteins and gives them a negative net charge. As a re-
sult, the electrophoretic mobility is mostly depending on the size of the protein. 
Samples and polyacrylamide gels were prepared as described in ‘Molecular clon-
ing: a laboratory manual’ (Sambrook, et al., 1989). Before applying to the gel, 
samples were mixed with sample buffer (final concentrations: 50 mmol/l Tris-
HCl, 2%(w/v) SDS, 0.01%(w/v) bromophenol blue or orange G, 10% glycerol, 
100 mmol/l 2-mercaptoethanol, pH 6.8) and denatured for 5 min at 96 °C. The 
gels were run in a glycine buffer (196 mmol/l glycine, 0.1%(w/v) SDS, 50 mmol/l 
Tris-HCl, pH 8.4) at 45-100 V. 
For total protein staining, gels were either stained with Imperial Protein Stain 
(Pierce, USA) as recommended by manufacturer or with Coomassie blue G250. 
For the latter method, gels were fixed for 2 h in an aqueous solution containing 
50% ethanol and 10% acetic acid. Afterwards, the gels were stained overnight in 
freshly prepared Coomassie staining solution (770 mg/l Comassie blue G250, 
582 mmol/l ammonium sulfate, 0.92% ortho-phosphoric acid, 23% methanol in 
ultra-pure water). The next day, the gels were destained ca. 10x in distilled water 
(5 min each). 
For specific immunostaining, gels were subjected to Western blotting (described 
below). 
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2.5.5 Western Blotting 
Western blotting is a technique for immunological detection of proteins. After an 
electrophoresis, the separated proteins are transferred to a membrane and probed 
with an antibody specific for the protein of interest.
Wet transfer from polyacrylamide gel to Hybond-C nitrocellulose membrane (GE 
Healthcare, USA) was carried out in permanently cooled transfer buffer 
(25 mmol/l Tris-HCl, 192 mM Glycine, pH 8.4) at 95 V for 2 h or at 20-30 V 
 
Table 9: List of primary antibodies. Target-peptide sequences are listed from amino- to carboxy-
terminus. A lower case ‘p’ indicates phosphorylation of the following amino acid. 
Target protein (and -sequence for peptide antibodies) Source / Supplier Species 
Actin Sigma-Aldrich, USA rabbit 
Barttin Santa Cruz Biotechnology, USA goat 
ENaC  AlphaDiagnostics International, USA rabbit 
ERK1/2 Cell Signaling Technologies, USA rabbit 
GAPDH Abcam, UK rabbit 
KCC4 Abcam, UK goat 
Na+/K+-ATPase Abcam, UK mouse 
NCC CHTKRFEDMIAPFRLNDGFKD Dario Alessi (Dundee, UK) sheep 
pNCC T55 HPSHLTHSSTFCMRpTFGYNT Dario Alessi (Dundee, UK) sheep 
pNCC T60 RTFGYNpTIDVVPT Dario Alessi (Dundee, UK) sheep 
pNCC S91 TLADLHpSFLKQEG Dario Alessi (Dundee, UK) sheep 
NHE3 Chemicon, USA rabbit 
NKCC2 EYYRNTGSVSGPKVNRPSLQE self-designed (Eurogentec, Belgium) rabbit 
pNKCC2 YYLQpTFGHNpTMDAVP S. Bachmann (Berlin, Germany) rabbit 
ROMK (Kir1.1) Chemicon, USA rabbit 
SORLA J. Gliemann (Aarhus, Denmark) goat 
SPAK QSLSVHDSQAQPNAN Dario Alessi (Dundee, UK) sheep 
pSPAK S373 RRVPGSpSGHLHKT Dario Alessi (Dundee, UK) sheep 
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overnight. To test for efficiency of the transfer and artifacts (e.g. from bubbles), 
protein on the membrane was reversibly stained with a 0.1%(w/v) Ponceau S 
(Sigma-Aldrich, USA) solution in 5% acetic acid. The membrane was blocked for 
2 h with 5%(w/v) skimmed milk powder in PBS containing 0.05% Tween-20 
(PBST). Antibodies (listed in table 9) were diluted 1:100 to 1:1,000 in 5% 
skimmed milk/PBST and applied to the membrane overnight at 4 °C on a rocking 
shaker. The next day, the membrane was washed in PBST (3x 5 min) and a corre-
sponding secondary antibody conjugated to horseradish peroxidase (anti-sheep 
antibody from Abcam, USA, all others from Sigma-Aldrich, USA), diluted 
1:2,000 in 5% skimmed milk/PBST, was added. After 1 to 2 h, the membrane was 
washed in PBST (3x 10 min) and incubated with luminol (Super Signal West 
Femto substrate; Pierce, USA). Protein bands were detected using a CCD camera 
(Fujifilm LAS-1000; Fujifilm, Japan). 
2.5.6 Peptide Pulldown 
Peptides of the cytosolic tail of human SORLA (table 10; obtained from Eurogen-
tec, Belgium) were dissolved in ultra-pure water (1 mg peptide in 200 µl H2O), 
peptide 1 was soaked in 4 µl DMSO prior to dissolving in water). The peptides 
were coupled to iodoacetyl-activated agarose (SulfoLink Coupling Resin; Pierce, 
USA) according to the SulfoLink manual (Doc. No. 0527; Pierce, USA). As con-
trol for unspecific binding to the resin, one batch of beads was treated in parallel 
as described, but without adding any peptide. Binding efficiency was estimated by 
applying a BCA assay (vide supra) on samples of the peptide solution before and 
after coupling to the sepharose. A signal decrease (and therewith a decrease of 
peptide in solution) of >90% was considered as efficient coupling. After the cou-
pling, free binding sites were blocked by incubation in 50 mM cysteine. 
Table 10: List of peptides covering the cytosolic tail sequence of human SORLA. All peptides 
were synthesized with an amino-terminal CGGG linker. Internal peptides were masked with an 
amido-group instead of a carboxy-group. Amino acid numbers are quoted as position in unproc-
essed SORLA (beginning counting with the initial M of the signal peptide). 
Peptide Sequence Corresponding SORLA Sequence 
Peptide 1 NH2-CGGG PMITGFSDDVPMVIA-COOH amino acids 2200 to 2214 
Peptide 2 NH2-CGGG DDLGEDDEDAPMITG- CONH2 amino acids 2190 to 2204 
Peptide 3 NH2-CGGG RLGSAIFSSGDDLGE- CONH2 amino acids 2180 to 2194 
Peptide 4 NH2-CGGG TAFANSHYSSRLGSA- CONH2 amino acids 2170 to 2184 
Peptide 5 NH2-CGGG TKHRRLQSSFTAFAN-CONH2 amino acids 2160 to 2174 
Animals were sacrificed and kidneys were removed rapidly, rinsed briefly in PBS 
and homogenized with an Ultra-Turrax (IKA, St. Augustin, Germany) in 1 ml ice-
cold RIPA buffer containing 0.2% SDS (0.2%(w/v) SDS, 0.1%(w/v) sodium deoxy-
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cholate, 1%(w/v) NP-40, 150 mmol/l NaCl, 50 mmol/l Tris-HCl, 2 mmol/l 2-
mercaptoethanol, 5 mmol/l EDTA, pH 7.4) or DOC buffer (10% sodium deoxy-
cholate, 500 mmol/l Tris-Cl, pH 7.4) per 50 mg tissue. After incubating the ho-
mogenates for 10 min on ice, they were sonicated. To enrich cytosolic proteins, 
the lysates were cleared by centrifugation at 126.200 × g for 30 min at 4 °C. Pro-
tein concentrations were estimated by performing a BCA assay (with comparison 
to a BSA standard). 
1 mg of protein was incubated at 4 °C overnight with 50 µl of settled peptide-
coupled resin on a rotating wheel. The next day, the column was washed 5x for 
5 min with 1 ml of RIPA or DOC buffer each. Bound proteins were eluted by in-
cubating the beads in 20 µl 4x SDS-PAGE sample buffer (200 mmol/l Tris-HCl, 
8%(w/v) SDS, 0.04%(w/v) bromophenol blue or orange G, 40% glycerol, 200 mmol/l 
2-mercaptoethanol, pH 6.8) at 95 °C for 5 min. Eluted samples were subjected to 
SDS polyacrylamide gel electrophoresis as described above. Proteins were stained 
either with Comassie blue G250 (Sigma-Aldrich, USA) or with Imperial Stain 
(Pierce, USA). Interesting bands were cut out and the gel pieces were stored at 
4 °C in 1% acetic acid. Mass spectrometry (MS) for protein/peptide identification 
was carried out either by Gunnar Dittmar (MDC MS core facility), Heike 
Stephanowitz (Leibniz-Institute for Molecular Pharmacology, FMP Berlin) or 
Bent Honoré (Aarhus, Denmark). Only identified candidates assessed as ‘signifi-
cantly present’ in the corresponding sample with the used MS setup were consid-
ered for further analysis. 
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2.6 Special Reagents, Kits and Consumables 
Table 11: List of special chemicals, kits and consumables used. 
Name Supplier 
Acetic anhydride Sigma Aldrich, USA, cat. No. A6404 
Alexa Fluor 488 donkey anti-rabbit IgG (H+L) Invitrogen, USA, cat. No. A-21206 
Alexa Fluor 555 donkey anti-sheep IgG (H+L) Invitrogen, USA, cat. No. A-21436 
Ampicillin, sodium salt Merck, Darmstadt, Germany, cat. No. 171255 
Anti-digoxigenin antibody, HRP-conjugate Abcam, UK, cat. No. ab6212 
anti-sheep antibody, HRP-conjugated Abcam, UK, cat. No. ab8527 
Avidin Sigma Aldrich, USA, cat. No. A9275 
Barium chloride dihydrate Sigma Aldrich, USA, cat. No. B0750 
BCA protein assay kit Pierce, USA, cat. No. 23225 
BigDye Terminator v3.1 cycle sequencing kit Applied Biosystems, USA, cat. No. 4337456 
Bio-Rad Protein Assay dye reagent concentrate Bio-Rad, USA, cat. No. 500-0006EDU 
Biotin Sigma Aldrich, USA, cat. No. B4501 
Biotin-Blocking System Dako, Denmark, cat. No. X0590 
Bovine serum albumin - fraction V (BSA) Sigma Aldrich, USA, cat. No. 85040C 
Bumetanide Sigma Aldrich, USA, cat. No. B3023 
Collagenase, crude type Ia Sigma Aldrich, USA, cat. No. C2674 
Complete protease inhibitor cocktail tablets Roche Diagnostics, Mannheim, Germany, 
cat. No. 04693116001 
Coomassie Brilliant Blue G 250 Sigma Aldrich, USA, cat. No. 27815 
D+ glucose Sigma Aldrich, USA, cat. No. 49138 
DAB substrate kit for peroxidase Vector Labs, USA, cat. No. SK-4100 
dATP, [α-32P] Perkin Elmer, USA, cat. No. BLU012H250UC 
[deamino-Cys1, D-Arg8]-Vasopressin, 
acetate salt 
Sigma Aldrich, USA, cat. No. V1005 
DIG RNA labeling kit (SP6/T7) Roche Diagnostics, Mannheim, Germany, 
cat. No. 11175025910 
DNase I recombinant, RNase-free Roche Diagnostics, Mannheim, Germany, 
cat. No. 4716728 
GeneChip mouse genome 430 2.0 array Affymetrix, USA, cat. No. 900496 
GeneChip one-cycle target labeling kit Affymetrix, USA, cat. No. 900493 
GeneChip two-cycle target labeling kit Affymetrix, USA, cat. No. 900494 
Halt phosphatase inhibitor cocktail Pierce, USA, cat. No. 78420 
HEPES Sigma Aldrich, USA, cat. No. H4034 
High Pure PCR product purification kit Roche Diagnostics, Mannheim, Germany, 
cat. No. 11732668001 
Hybond-C Extra GE Healthcare, USA, cat. No. RPN203E 
Hydrochlorothiazide Sigma Aldrich, USA, cat. No. H4759 
illustra Sephadex G-50 DNA grade F GE Healthcare, USA, cat. No. 17-0573-01 
Imperial protein stain Pierce, USA, cat. No. 24615 
IPTG Fermentas, Canada, cat. No. R0391 
Kodak BioMax MR-1 Perkin Elmer, USA, cat. No. 8222648001EA 
MEGAscript T7 Kit Applied Biosystems, USA, cat. No. AM1333 
NucAway spin columns Applied Biosystems, USA, cat. No. AM10070 
O.C.T.™ Compound; cryo mounting medium Sakura, Japan, cat. No. 4583 
Ouabain octahydrate  Sigma Aldrich, USA, cat. No. 75640 
Perchloric acid 70% Merck, Darmstadt, Germany, cat. No. 100514 
pGEM-T Easy vector system  Promega, USA, cat. No. A1360 
Phosphatase, alkaline Roche Diagnostics, Mannheim, Germany, 
cat. No. 713023 
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Name Supplier 
Phusion high-fidelity DNA polymerase Finnzymes, Finland, cat. No. F-530 
Plasmid midi kit Qiagen, The Netherlands, cat. No. 12143 
Plasmid mini kit Qiagen, The Netherlands, cat. No. 12123 
Ponceau S Sigma Aldrich, USA, cat. No. P3504 
Potassium D-gluconate Sigma Aldrich, USA, cat. No. G4500 
Prime-It II random primer labeling kit Stratagene, USA, cat. No. 300385 
qPCR MasterMix Plus Eurogentec, Belgium, 
cat. No. RT-QP2X-03-075+ 
Renaissance blocking reagent NEN Life Science, USA 
RNA 6000 Nano kit Agilent Technologies, USA, cat. No. 5067-1511 
RNeasy mini kit Qiagen, The Netherlands, cat. No. 74106 
Roti-Histokitt Carl Roth, Karlsruhe, Germany, cat. No. 6638.1 
Roti-Histol Carl Roth, Karlsruhe, Germany, cat. No. 6640.2 
Rubidium chloride Sigma Aldrich, USA, cat. No. R2252 
Rubidium-86 radionuclide (86Rb) Perkin Elmer, USA, cat. No. NEZ072005MC 
Skimmed milk powder different suppliers 
Streptavidin, alkaline phosphatase conjugate Perkin Elmer, USA, cat. No. NEL751001EA 
SulfoLink coupling resin Pierce, USA, cat. No. 20401 
SuperFrost Plus object slides Menzel Gläser, Braunschweig, Germany, 
cat. No. J1800AMNZ 
SuperScript II reverse transcriptase Invitrogen, USA, cat. No. 18064 
SuperSignal West Femto 
maximum sensitivity substrate 
Pierce, USA, cat. No. 34095 
T4 DNA ligase Invitrogen, USA, cat. No. 15224-041 
Taq DNA polymerase Invitrogen, USA, cat. No. 10342-020 
Trichloromethane Carl Roth, Karlsruhe, Germany, cat. No. 3313 
TRIzol Invitrogen, USA, cat. No. 15596-018 
VECTASHIELD mounting medium Vector Labs, USA, cat. No. H-1000 
VECTASTAIN Elite ABC kit Vector Labs, USA, cat. No. PK-6200 
X-gal Invitrogen, USA, cat. No. 15520018 
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3 Results 
3.1 Renal expression profile of Sorla 
Using Northern blot analysis, I initially tested the expression pattern of Sorla in 
human tissue. Figure 5 A shows expression of SORLA predominantly in brain, to 
considerable amounts in leukocytes, liver, kidney, heart, spleen, and thymus, and 
to lower extent in small intestine, placenta and lung. As a control, I investigated 
the transcriptional expression pattern of the related VPS10p receptor sortilin (fig-
ure 5 B). While also showing highest expression in the brain, SORTILIN is also 
transcribed considerably in heart, kidney and placenta. Weak expression of 
SORTILIN was found in lung, skeletal muscle, colon, small intestine and liver. 
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Figure 5: Northern blot for (A) SORLA, (B) SORTILIN and (C) ACTB (beta-actin). Highest 
expression of SORLA and SORTILIN is seen in the brain. Both genes are also expressed in the 
kidney. Arrowheads indicate the expected transcript size. 
To assess the expression of Sorla throughout renal development, quantitative real-
time-PCR (TaqMan®) experiments were performed on cDNAs obtained from 
whole kidney (and brain as control) RNA of mouse embryos at day E12.5 (embri-
onic day 12.5, also referred to as 12.5 dpc, days post coitum), E15.5, E17.5, neo-
natal mice and adult (12 weeks of age) murine kidneys. 
The specificity of the primer/probe pairs used for the TaqMan experiments was 
confirmed by agarose gel electrophoresis of the amplicons. The single PCR prod-
uct was excised from the gel, purified and ligated into the pGEM-T Easy vector 
for DNA-sequencing. Using the nblast algorithm (part of NCBI Blast!), the ob-
tained sequences were compared with the NCBI nucleotide collection (nr/nt) and 
the NCBI mouse genomic plus transcript (Mouse G+T) databases, resulting in 
perfect matches for the regions of interest within the murine forms of the accord-
ing VPS10p receptor family member transcript sequence (corresponding Sorla-
sequence shown in figure 6). 
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junction exon 17/18
TCCAGCGTCTCTGCTTGAACGGGAGCACAGGGCAGGAGGTGATCATCAATTCCGGCCTGG
junction exon 18/19
GCTTTAAAAAGATCGAGGTAGCTAATCCAGATGGTGACTTCCGACTGACAATCGTCA-3'
start of Sorla exon 19
5'-ACTTGGCCTCGGGAGCCACAGAGCAGCTTCCTCTCTCGGGGCTGCGGGCGGCTGTGG
end of Sorla exon 17
CCCTGGACTTTGACTATGAACGCAACTGCTTGTATTGGTCTGACCTGGCGCTGGACACCA
AGACCGTGGAGGCTTTGGCCTTCGAACCCCTCAGCCAATTACTTTACTGGGTGGATGCCG
 
Figure 6: Partial sequence of the Sorla cDNA covering the template region for realtime PCR. 
The forward primer sequence and the reverse complement sequence of the reverse primer are 
marked in blue. The probe sequence is marked in red. The PCR product, confirmed by sequencing, 
is shown in bold letters. 
 
Representing the data of three individual experiments, figure 7 A, shows that 
Sorla is expressed throughout kidney development with a distinct increase of ex-
pression between E12.5 and E15.5. In the adult, Sorla is the Vps10p receptor gene 
with the strongest renal expression. Sortilin is expressed at somewhat lower lev-
els, yet consistent throughout kidney development. None of the three Sorcs tran-
scripts is expressed in the adult and the embryonic expression of Sorcs1 and 
Sorcs3 is rather low. It is remarkable, however, that the expression level of Sorcs2 
is comparably high in the developing kidney with a peak around E15.5. Figure 7 
B shows the expression pattern in brain. All receptors are highly expressed during 
CNS development. In the adult mouse, Sorla and Sortilin show the highest ex-
pression of all Vps10p receptors in whole brain. 
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Figure 7: Transcriptional expression of all members of the VPS10p receptor family in the 
developing kidney (A) and brain (B) relative to Gapdh. Whereas all members of the VPS10p 
receptor family are expressed in the brain between embryonic day 12.5 (E12.5) and adulthood, 
only mRNAs of the Sorla- and the Sortilin-gene are detectable in the adult kidney. Error bars rep-
resent standard error of the mean. 
 
Having established the expression of Sorla in the embryonic and adult kidney, my 
interest turned towards the exact sites of expression of the receptor in this organ. 
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To localize its expression in the embryonic kidney, in-situ hybridization was car-
ried out on sagittal paraffin-sections of E14.5 mouse embryos. Representative 
experiments are shown in figure 8. Transcripts of Sorla (A) and Sortilin (B) are 
located in tubular structures, resembling collecting ducts of the developing kidney. 
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Figure 8: In-situ hybridization of Sorla transcripts (A) and Sortilin transcripts (B) in the 
murine embryonic kidney. Left site: sagittal paraffin section of an E14.5 embryo indicating the 
area magnified on the right (magnification: 20x). Right site: area indicated on the left, showing the 
kidney (200x). C: control with a mixture of sense probes for Sorla and Sortilin. 
 
The expression of Sorla in renal tubules suggested a function in transport proc-
esses in distinct nephron segments. To better localize the renal expression of Sorla 
in the adult, I made use of a mouse model with insertion of a -galactosidase 
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(lacZ) reporter gene into the murine Sorla gene locus (Mitchell, et al., 2001; Rohe, 
et al., 2008). In this mouse line, expression of lacZ is controlled by the endoge-
nous Sorla gene promoter, thus reflecting the expression of the sorting receptor 
(figure 9 A). To ascertain the exact sites of expression, coronal kidney sections of 
adult wild type mice were immunostained with an antibody against the extracellu-
lar portion of the receptor. Collectively these findings, as exemplified in figure 9, 
demonstrated expression of Sorla in the distal nephron, from the thick ascending 
limb of Henle’s loop through the distal convoluted tubule and connecting tubules 
to the collecting duct. 
 
3.2 Electrolyte homeostasis 
Expression of Sorla in the collecting duct has been reported before (Riedel, et al., 
2002). In addition, I demonstrated that Sorla is also expressed in the thick ascend-
ing limb of the loop of Henle, in the distal convoluted tubule and in the connect-
ing tubule of the adult kidney. 
Each nephron segments fulfills an essential and distinct function in renal physiol-
ogy. The thick ascending limb of Henle's loop is involved in active reabsorption of 
approximately 25% of sodium and potassium, while the distal convoluted tubule 
is responsible for the reabsorption of 5% of the filtered sodium and chloride from 
tubular fluid. An important task mainly accomplished by the nephron segments 
expressing Sorla is also the maintenance of fluid homeostasis. Mechanisms regu-
lating water homeostasis include the dilution of tubular fluid in the water-
impermeable ascending limb of Henle’s loop and the activity of the kidney-
specific sodium-potassium-chloride cotransporter (NKCC2). As a result, the hy-
pertonic tubular fluid leaving the descending limb is converted into a distinctly 
hypotonic state. Thus, in contrast to the situation in the proximal tubule, the reab-
sorption of water and electrolytes is uncoupled in the distal nephron. In addition, 
water reabsorption in the collecting duct is highly regulated by vasopressin. This 
hormone triggers water reabsorption. In its absence, the collecting duct is almost 
water-impermeable. 
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Figure 9: Sorla expression in the adult nephron. A: Detection of Sorla-gene expression in cor-
tex and inner stripe of the outer medulla (ISOM) based on activity of a beta-galactosidase reporter 
gene inserted into the murine Sorla gene locus. B, C, D: Immunohistological staining of SORLA 
in thick ascending limb (TAL) of Henle’s loop, distal convoluted tubule (DCT), connecting tubule 
(CNT) and cortical collecting duct (CCD) on paraffin sections. Arrowheads mark SORLA-specific 
staining in perinuclear vesicular structures. E: Schematic drawing of nephric segments based on 
‘Brenner and Rector's The Kidney’ (Brenner, 2007), areas expressing SORLA are marked in grey. 
Magnifications: 40x for A, 1000x for C-D. 
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To gain insight into possible functions of SORLA in tubular transport processes, I 
measured urinary concentrations of sodium (Na+), chloride (Cl-), potassium (K+) 
and calcium (Ca2+) ions in mice genetically deficient for the receptor. This mouse 
model has previously been generated in our group (Andersen, et al., 2005). Two 
receptor-deficient strains harboring the same targeted gene disruption were being 
bred in our group: the strain SorLA27 was kept on a hybrid 129SvEmcTer × 
C57BL/6N (129Bl/6) background, SorLA18 was kept on a hybrid 129SvEmcTer 
× Balb/c (129Balb/c) background. For the experiments in this study, both strains 
and corresponding wild type hybrid lines were used. The results shown are repre-
sentative for both backgrounds unless stated otherwise. 
By comparison of Sorla(-/-) animals with wild type mice of the same genetic back-
ground (Sorla(+/+)), the specific effects of receptor deficiency on renal functions 
can be studied. In parallel, the animals’ ability to concentrate water was stressed 
by thirsting for 24 hours to check SORLA’s influence on any of the abovemen-
tioned volume regulation mechanisms. 
Table 12: Urine volume and urinary electrolyte concentrations. A: Urine of wild type and 
Sorla(-/-) animals was collected for 16 hours overnight in metabolic cages with free access to drink-
ing water. B: After a preliminary thirsting period of eight hours, animals were kept in metabolic 
cages without water and urine was collected for 16 hours overnight. Values are shown ± standard 
error of the mean; p-values were calculated using Student’s t-test. 
Sorla(+/+) Sorla(-/-)  
A: basal conditions  
volume (ml) 1.6 ± 0.7 1.5 ± 0.8  
Na+ (mmol/l) 93 ± 3.5 102 ± 4.6  
Cl- (mmol/l) 75 ± 2.6 94 ± 4.5 p < 0.001 
K+ (mmol/l) 119 ± 6.7 189 ± 19 p < 0.001 
Ca2+ (mmol/l) 1.2 ± 0.1 2.1 ± 0.1 p < 0.001 
B: water deprivation  
volume (ml) 0.6 ± 0.3 0.5 ± 0.2  
Na+ (mmol/l) 121 ± 7.2 174 ± 16.8 p < 0.01 
Cl- (mmol/l) 130 ± 8.1 189 ± 19.1 p < 0.01 
K+ (mmol/l) 224.7 ± 28.2 230.7 ± 19.5  
Ca2+ (mmol/l) 1.4 ± 0.1 2 ± 0.1 p < 0.01 
Under basal conditions, absence of SORLA resulted in an increase in the secretion 
of K+ by 60% and of Ca2+ by 75% (table 12 A, figure 10 A). After thirsting, the 
animals secrete over 40% more Na+, Cl- and Ca2+ as the control animals (table 12 
B, figure 10 A).This elevated salt loss in Sorla(-/-) animals is not accompanied by 
defects in the thirst-induced reduction of urine volume (antidiuresis), as the ani-
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mals are able to reduce urine as efficient as their wild type counterparts (figure 10 
B). 
water deprivation
Na+ Cl- K+
p<0.01 p<0.01
urine
2.5
0
2.0
1.5
1.0
0.5
B volumewater ad libitum
Sorla(+/+) normal
Sorla(-/-) normal
Sorla(+/+) thirsted
Sorla(-/-) thirsted  
Figure 10: Excretion of Na+ Cl- and K+ in wild type and SORLA-deficient mice. Urinary elec-
trolyte concentrations (A) and urine volume (B) of wild type animals (Sorla(+/+)) and mice lacking 
the receptor (Sorla(-/-)) under basal conditions and after thirsting. 
Serum samples were taken under the same conditions, to assess whether the 
changes in urinary electrolytes are mirrored in the blood of Sorla(-/-) animals. In 
addition to the electrolyte measurements, I investigated hormones regulating renal 
reabsorption processes to discover a potential hormonal mis-regulation. 
Three hormones were measured. The first one, renin, is a key component of the 
renin-angiotensin cascade, converting angiotensinogen to angiotensin I. It is syn-
thesized by the renal juxtaglomerular apparatus. The renin-angiotensin system 
(RAS) is involved in blood pressure regulation and water balance. One mediator 
of its action is the adrenal steroid hormone aldosterone, which increases the reab-
sorption of Na+ and water and the secretion of K+ in the distal nephron by activat-
ing the basolateral Na+/K+-ATPase as well as different ion transporters. Another 
hormone that plays an important role in renal water retention and salt reabsorption 
is vasopressin. This peptide hormone, also known as antidiuretic hormone, is se-
creted mainly from the pituitary gland. It increases the water permeability of the 
collecting duct, e.g. by activating aquaporin-2 (AQP-2), and activates salt reab-
sorption in the thick ascending limb via NKCC2. 
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Tables 13 A and 13 B show normal Na+ and Cl- levels in blood under normal as 
well as thirsted conditions. However, it becomes apparent, that SORLA-deficient 
mice suffer from decreased K+ concentrations in serum under normal conditions 
(hypokalemia). 
Water-deprivation leads to induced vasopressin levels in both groups of animals. 
Animals lacking SORLA show a milder induction of renin upon thirsting as com-
pared to the control animals, implicating a weakened response of the RAS. More 
strikingly though is the mis-regulation of aldosterone in the receptor-deficient 
animals. Whereas the amount of aldosterone released to the bloodstream is sig-
nificantly elevated under basal conditions (table 13 A), it is actually slightly re-
duced upon thirsting (table 13 B). The situation contrasts with the physiological 
reaction of the wild type control mice, which increase aldosterone release mas-
sively upon thirsting, presumably as a downstream effect of the activated RAS. 
Table 13: Serum electrolyte concentrations. A: Serum concentrations in wild type and Sorla(-/-) 
animals with free access to drinking water. B: Serum concentrations in animals thirsted for 24 
hours. Values are shown ± standard error of the mean; p-values were calculated using Student’s t-
test. 
Sorla(+/+) Sorla(-/-)  
A: basal conditions  
Na+ (mmol/l) 152 ± 0.3 153 ± 0.3  
Cl- (mmol/l) 110 ± 0.8 109 ± 1.2  
K+ (mmol/l) 6.8 ± 0.4 5.7 ± 0.2 p < 0.05 
Renin (ng Ang-I/(ml*h)) 389 ± 81 239 ± 75  
Aldosterone (pmol/l) 347 ± 65.9 741 ± 158.1 p < 0.05 
Vasopressin (pg/ml) 35.1 ± 7.5 52.1 ± 13  
B: water deprivation  
Na+ (mmol/l) 151 ± 0.9 154 ± 0.9  
Cl- (mmol/l) 112 ± 0.7 113 ± 0.6  
K+ (mmol/l) 6.5 ± 0.2 6 ± 0.2  
Renin (ng Ang-I/(ml*h)) 2469 ± 402 1273 ± 135 p < 0.05 
Aldosterone (pmol/l) 1863 ± 385.3 578 ± 141.4 p < 0.05 
Vasopressin (pg/ml) 115.3 ± 1.7 135.7 ± 14.7  
As indicated above, the renal electrolyte and water homeostasis is intertwined 
with blood-pressure regulation. In thirsted Sorla(-/-) mice normally regulated vaso-
pressin, the presumably weakened RAS and the mis-regulated aldosterone are all 
affecting the blood pressure. Mice lacking SORLA exhibit decreased mean arterial 
pressure (MAP) during their activity phase and a lower heart rate, as measured by 
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blood pressure telemetry (table 14 A and 14 B). They are also less active than the 
wild type animals. 
Table 14: Physiological parameters. Mean arterial pressure (MAP), heart rate and activity under 
basal conditions (A) and after water deprivation (B). MAP was measured during the activity phase 
of the animals from 6 PM to 3 AM. Values are shown ± standard error of the mean; p-values were 
calculated using Student’s t-test. 
Sorla(+/+) Sorla(-/-)  
A: basal conditions  
MAP (mmHg) 130.4 ± 2.5 121.4 ± 2.5 p < 0.05 
Heart rate (beats/min) 680.7 ± 9.2 612.8 ± 5.0 p < 0.001 
Activity (counts/min) 11.6 ± 2.2 5.4 ± 0.7 p < 0.05 
B: water deprivation  
MAP (mmHg) 133.7 ± 1.1 125.1 ± 1.6 p < 0.01 
Heart rate (beats/min) 670.7 ± 9.2 611.0 ± 5.8 p < 0.001 
Activity (counts/min) 16.3 ± 3.4 9.4 ± 1.4  
 
3.3 Investigating a renal versus an adrenal phenotype in SORLA-deficient 
mice 
The electrolyte measurements revealed a dysfunction in the kidneys of mice lack-
ing SORLA. Especially the urinary K+-wasting is mirrored by a systemic hypo-
kalemia. But the complex regulation of renal function and the hormonal mis-
regulation seen in the receptor-deficient animals made it difficult to pinpoint a 
function of SORLA in this context. Especially the abnormal regulation of aldos-
terone in SORLA-deficient mice raised the question, whether the observed pheno-
type is primarily of renal origin or if the phenotypes in the kidney are secondary to 
defects at the site of aldosterone synthesis – the adrenal glands. 
Intriguingly, transcripts of the receptor have been detected in adrenal gland tissue 
by northern blot analysis (Mörwald, et al., 1997; Yamazaki, et al., 1996). Perform-
ing immunohistological staining of SORLA in murine adrenal gland cryosections, 
I could reveal that SORLA is expressed in the adrenal cortex, but not in the me-
dulla (figure 11 A-C). The receptors strongest expression can be found in the outer 
layer of the adrenal cortex (zona glomerulosa, figure 11 B), the section where al-
dosterone is produced. Specificity of the antibody in adrenal tissue was demon-
strated by absence of staining on sections from SORLA-deficient animals (figure 
11 D-F). No gross morphological abnormalities were detected in adrenal glands of 
Sorla(-/-) animals. 
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Figure 11: Sorla expression in the adrenal gland. A-C: Immunohistological staining of SORLA 
throughout the adrenal cortex – particularly in the zona glomerulosa – on cryosections. No staining 
was detectable in the adrenal medulla. D-F: Absence of SORLA-specific staining in Sorla(-/-) mice. 
Magnifications: 200x for A and D; 400x for B,C,E and F. 
To investigate, whether the observed defects result from lack of the receptor in the 
kidney or in the adrenal gland, the global gene expression patterns of both tissues 
in receptor-deficient Sorla(-/-) mice and wild types were compared. 
One group of wild type Sorla(+/+) and receptor-deficient Sorla(-/-) mice were kept 
with water ad libitum, the same number of animals was stressed by water-
deprivation for 24 hours prior to the experiment to induce the aggravated salt loss 
phenotype observed before. To reduce experimental variability, three male mice 
per group were sacrified between 10 and 11 a.m. at an exact age of 84 days. The 
kidneys and adrenal glands respectively were taken out and snap-frozen immedi-
ately after residual adipose tissue was removed. Total RNA was isolated and used 
for the synthesis of biotin-labeled cRNA. The cRNA was hybridized to Affymetrix 
GeneChips (Mouse Genome 430 2.0 Array). This DNA chip collects expression 
data of over 39.000 transcripts per sample. 
Analyses for kidney and adrenal gland were carried out in parallel. For better clar-
ity, the results of the experiments are discussed separately for each tissue. 
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3.3.1 Adrenal glands 
DNA microarray expression analysis of adrenal glands was carried out on 
SorLA18 mice and corresponding hybrid 129Balb/c wild type mice. A two-cycle 
protocol was used for synthesis of cRNA, due to the amounts of RNA obtained 
from adrenal glands. 
After normalizing the data with a variant of the RMA (robust multichip analysis) 
algorithm, the validity of the obtained data was tested by carrying out quality as-
sessments tests: Pseudoimages, box-plots of the raw/normalized intensities and 
RNA degradation plots were comparable for all samples (data not shown). Exami-
nation of M vs. A plots, which are displaying logarithmic intensity ratios M versus 
average logarithmic intensities A of the red and green channels respectively, un-
earthed an aberrance: The sample of the first wild type animal supplied with 
drinking water (Sorla(+/+) +H2O 01) did show an irregularity in the M vs. A plot 
(data not shown). Figure 12 A shows the correlation of the different adrenal gland 
data sets. Overall, the transcriptional expression is similar. Whereas the data of 
most chips show a correlation of at least 98%, wild type data set 
Sorla(+/+) +H2O 01 differs to a significant extent. Unsupervised hierarchical clus-
tering, a method automatically grouping most similar data sets, was able to cate-
gorize the data according to genotype (figure 12 B). Again, the first wild type data 
set did not cluster properly. Because of the clear divergence of this data set from 
the others, I excluded it from further statistical analyses. 
The data sets were subjected to principal component analysis. This statistical 
method transforms possibly related variables into fewer variables, so called prin-
cipal components. The first two principal components, A and B, are shown in fig-
ure 13. The first component (A) accounts for most of the variability in the adrenal 
data sets. It clearly separates the data according to the genotype. The second prin-
cipal component (B) accounts for the second highest variability, distinguishing 
between normal and thirsted mice. It can be concluded, that the genotype pro-
duces a higher divergence between the data sets than thirsting. 
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Figure 12: Correlation plot and unsupervised hierarchical clustering of the adrenal data sets. 
A: Correlation plot showing complete identity of the data sets in bright red and divergence of 5% 
identity in black; B: Hierarchical trees obtained after performing an unsupervised clustering using 
the data sets for normal condition (left) and water-deprivation (right). 
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Figure 13: Principal component plot for adrenal gland Affymetrix data. Principal component 
A (abscissa) separates the data set effectively according to genotypes; component B (ordinate) 
distinguishes between experimental conditions. 
To compare the expression levels of individual genes, two values were calculated. 
The so called fold-change represents the factor by which the average expression in 
receptor-deficient mice is changed as compared to wild types. To facilitate com-
prehension and calculation, factors between one and zero (representing downregu-
lation) are shown as negative reciprocals (e.g. -4 instead of 0.25). The second im-
portant value is the p-value, representing the likelihood that the observed change 
occurred by chance. It was calculated using Student’s t-test. With data sets this 
large (>45.000 probe sets) it is likely to observe false positives just by chance. To 
correct the p-values according to the size of the data sets, the Benjamini-Hochberg 
correction was used. This very stringent method lowers the t-test p-values. 
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Figure 14: Volcano plots representing the adrenal Affymetrix data. Differentially regulated 
probe sets of normal (A, B) and thirsted (C, D) mice; p-values used for the plots were either uncor-
rected (A, C) or corrected by the Benjamini-Hochberg method (B, D) to reduce false positives; 
probe sets underlying a pronounced differential regulation are encircled and listed in table 15. 
To look at individual genes strongly affected by the deficiency of SORLA, the 
negative logarithm of the p-value to the base of ten is plotted against the negative 
logarithm of the fold-change to the base of two. Dots in the so called volcano plot 
represent one probe set each (figure 14). Most probe sets, which are neither highly 
nor significantly regulated, cluster at the lower part of the chart towards the center 
of the abscissa. However, probe sets with a high fold-change appear towards the 
outer left and right, significantly regulated probe sets are displayed in the upper 
part of the plot. Thus, dots appearing in the upper corners represent the most in-
teresting candidate genes. 
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Table 15: Highly differential probe sets in the adrenal gland. List of probe sets marked in fig-
ure 14. The p-values listed here are not corrected with the Benjamini-Hochberg algorithm. 
  probe set ID gene symbol fold-change p-value 
A/B 
normal 
a 1431591_s_at Isg15 
LOC100038882 
LOC100044225 
LOC677168 
1.474 6.19E-06 
1420618_at Cpeb4 1.863 9.44E-06 
1440624_at not annotated in NetAffx 
 
(chromosome 4 
genomic contig) 
8.556 9.70E-06 
1419179_at Txnl4a 2.264 1.36E-05 
b 1445214_at not annotated in NetAffx 
 
(chromosome 4 
genomic contig) 
-2.165 4.70E-06 
c 1424454_at Tmem87a -191.133 2.23E-03 
C/D 
thirsted 
a 1425113_x_at TranscriptID BI105961 -51.423 4.11E-06 
1438852_x_at Mcm6 -6.690 4.27E-06 
1419620_at Pttg1 -27.805 1.71E-05 
1439483_at AI506816 -61.615 2.14E-05 
1447894_x_at H2afb3 -45.610 3.90E-05 
b 1418499_a_at Kcne3 3.971 5.05E-07 
1452677_at LOC100044383 
Pnpt1 
7.973 7.15E-07 
c 1457666_s_at 
1421551_s_at 
Ifi202b 240.195 
51.633 
1.30E-04 
5.20E-04 
1415824_at Scd2 38.905 1.83E-04 
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To investigate which adrenal functions may be affected by SORLA-deficiency, it 
is not only important to take single highly differential genes into account but also 
to consider trends in the overall changes to the transcriptome. 
Looking at the non-adjusted p-values, more than 700 genes are significantly 
changed more than 1.5-fold between the SORLA-deficient and control animals 
under normal conditions. After thirsting, the number of 1.5-fold changed probe 
sets increases to more than 1100. With slightly more than 450 probe sets signifi-
cantly changed more than 1.5-fold while comparing normal and water-deprived 
animals of the genotype, thirsting as such affects both mice stains to a similar ex-
tent. At a transcriptional level, the adrenal glands are affected by the lack of 
SORLA, with the genotypic effect being more pronounced than the stress effect. 
The numbers in table 16 confirm the observation, that more genes are changed 
due to the lack of SORLA as to the thirsting, a trend already visible in the princi-
pal component analysis in figure 13. To get an idea of which functions may be 
fulfilled by the differentially expressed gene products, all genes with an expres-
sion level significantly differing by a factor higher than 1.5 were explored using 
the web-based database tool DAVID (http://david.abcc.ncifcrf.gov/). The data for 
adrenal glands and kidneys (see chapter 3.3.2) are displayed in figure 15. 
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Table 16: Number of probe sets being significantly changed in adrenal glands, sorted by fold 
change and p-value. A and B show the number of significant probe sets after Benjamini-
Hochberg false discovery rate correction in brackets. 
A Sorla(-/-) +H2O vs. Sorla(+/+) +H2O 
  all p < 0.05 p < 0.02 p < 0.01 p < 0.005 p < 0.001 
all 45101 2275 (0) 1059 (0) 597 (0) 338 (0) 92 (0) 
FC > 1.1 14775 1938 (0) 891 (0) 482 (0) 261 (0) 66 (0) 
FC > 1.5 2412 729 (0) 406 (0) 238 (0) 142 (0) 38 (0) 
FC > 2.0 764 304 (0) 197 (0) 125 (0) 84 (0) 24 (0) 
FC > 3.0 248 122 (0) 85 (0) 57 (0) 43 (0) 15 (0) 
expected by chance 2255 902 451 225 45 
B Sorla(-/-) -H2O vs. Sorla(+/+) -H2O 
  all p < 0.05 p < 0.02 p < 0.01 p < 0.005 p < 0.001 
All 45101 2856 (4) 1418 (2) 823 (0) 452 (0) 109 (0) 
FC > 1.1 13551 2737 (4) 1370 (2) 804 (0) 448 (0) 108 (0) 
FC > 1.5 2218 1153 (4) 708 (2) 456 (0) 274 (0) 79 (0) 
FC > 2.0 785 483 (4) 342 (2) 241 (0) 156 (0) 57 (0) 
FC > 3.0 239 164 (4) 127 (2) 95 (0) 72 (0) 34 (0) 
expected by chance 2255 902 451 225 45 
A and B: Welch's t-test, unpaired, unequal variance 
asymptotic p-value computation 
no multiple testing correction (in brackets: Benjamini-Hochberg correction) 
C Sorla(+/+) +H2O vs. Sorla(+/+) -H2O 
  all p < 0.05 p < 0.02 p < 0.01 p < 0.005 p < 0.001 
all 45101 1813   741   370   184   33   
FC > 1.1 14581 1631 694 350 173 30 
FC > 1.5 1922 472 219 113 71 13 
FC > 2.0 473 129 65 34 22 5 
FC > 3.0 125 32   19   10   6   1   
expected by chance 2255 902 451 225 45 
D Sorla(-/-) +H2O vs. Sorla(-/-) -H2O 
  all p < 0.05 p < 0.02 p < 0.01 p < 0.005 p < 0.001 
all 45101 1990   829   406   197   45   
FC > 1.1 12038 1787 769 383 191 45 
FC > 1.5 1206 457 230 123 73 19 
FC > 2.0 257 110 62 36 21 6 
FC > 3.0 44 17   4   2   1   0   
expected by chance 2255 902 451 225 45 
C and D: Welch's t-test, unpaired, unequal variance 
asymptotic p-value computation 
no multiple testing correction 
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The numbers in table 16 confirm the observation, that more genes are changed 
due to the lack of SORLA as to the thirsting, a trend already visible in the princi-
pal component analysis in figure 13. To get an idea of which functions may be 
fulfilled by the differentially expressed gene products, all genes with an expres-
sion level significantly differing by a factor higher than 1.5 were explored using 
the web-based database tool DAVID (http://david.abcc.ncifcrf.gov/). The data for 
adrenal glands and kidneys (see chapter 3.3.2) are displayed in figure 15. 
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Figure 15: GO-term categories found for significantly changed probe sets in adrenal gland 
and kidney. All probe sets differentially regulated with fold change > 1.5 and p-value < 0.05; each 
probe set is usually annotated with more than one Gene Ontology (GO) term and hence partially 
represented in more than one group. Categories a through v represent GO terms, w represents a 
Swiss-Prot/Protein Information Resource keyword category. It has to be mentioned that each probe 
set is usually annotated with more than one gene ontology term. Therefore, the probe sets can be 
represented in more than one bar. 
Clustering all probe sets meeting the abovementioned cutoff criteria (fold-change 
> 1.5; p < 0.05; irrespective of the condition) by Gene Ontology (GO) annotation 
results in quite different distributions in the two organs. In total, much more path-
ways seem to be affected in the kidney. Interestingly, the total numbers of genes 
involved in “cellular physiological processes” (figure 15 c), “catalytic activity” 
(l), “biopolymer metabolism” (t), “alternative splicing” (u), nucleotide binding (v) 
and “phosphorylation” (w) correlate between the organs. 
With my focus on identification of metabolic pathways, I analyzed the rather 
vaguely GO-terms shown in figure 15 and the corresponding gene lists. While 
investigating the data using the PANTHER classification System 
(http://www.pantherdb.org/), one specific pathway became apparent: the cate-
cholamine-synthesis pathway. Table 17 shows probe sets corresponding to genes 
that have been reported to be involved in the catecholamine metabolism. While 
some of these genes are specific for the nervous system (dopamine acts as a neu-
rotransmitter and -modulator in the central nervous system, norepinephrine act as 
neuromodulator in the sympathetic nervous system), most genes are also ex-
pressed in chromaffin cells of the adrenal medulla. 
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The adrenal synthesis of catecholamines is depicted in figure 35 (chapter 4.2.2). 
Starting from the amino acid tyrosine, the enzymes tyrosine hydroxylase (Th) and 
DOPA decarboxylase (Ddc) synthesize dopamine. The vesicular monoamine 
transporter (Slc18a1) transports the dopamine into vesicles, where it is converted 
to norepinephrine by dopamine beta-hydroxylase (Dbh). Due to its hydrophobic-
ity, norepinephrine (as the other catecholamines) passively leaks out of its synthe-
sis and storage vesicles, requiring constant sequestration by Slc18a1. However, 
cytosolic norepinephrine is substrate to phenylethanolamine N-methyltransferase 
(Pnmt) which synthesizes epinephrine. As the other catecholamines, epinephrine 
is also subject to Slc18a1 transport, whereby it is stored in vesicles until released. 
The degradation of catecholamines is carried out by monoamine oxidase A (Mao 
a) and catechol-o-methyltransferase (Comt). 
In SORLA-deficient mice, the genes of all biosynthetic enzymes are transcription-
ally downregulated with a fold-change between -1.2 and -2.0. The differential 
expression becomes more pronounced with thirsting (cf. table 17 and figure 35 in 
chapter 4.2.2). 
To study whether downregulation has an effect on the catecholamine-synthesis, I 
measured catecholamine levels in isolated adrenal glands. Mice were sacrificed 
and adrenal glands quickly taken out. After removal of remaining adipose tissue, 
the organs were immediately homogenized in 0.2 M perchloric acid and cate-
cholamines were measured via reverse-phase HPLC and subsequent electro-
chemical detection. 
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Figure 16 shows reduced levels of the catecholamine epinephrine, the end-product 
of the down-regulated synthesis pathway. The other catecholamines dopamine and 
norepinephrine are not significantly changed. 
The catecholamine synthesis and degradation pathways share one enzyme each 
with the serotonin pathway. The final step in the synthesis of serotonin is carried 
out by DOPA decarboxylase (Ddc). Since one probe set representing the gene for 
this enzyme is downregulated, the question arises whether this effect extends to 
(and plays a role in) serotonin-synthesizing organs. This idea could be refuted by 
measuring serotonine levels in different tissues, as shown in figure 17. No change 
between SORLA-deficient animals and wild types was obvious. 
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Figure 17: Amount of serotonine in adrenal gland, brain, intestine kidney and lung of wild 
type and SORLA-deficient mice under normal conditions and after thirsting. Amount of sero-
tonin per mg organ weight. Errorbars represent standard deviation. 
By comparing the adrenal gene expression pattern of Sorla(-/-) mice with wild 
types, I could reveal a mis-regulation of genes of the catecholamine pathway. This 
observation was supported by lower levels of epinephrine in adrenal glands. Epi-
nephrine could play a role in kidney metabolism, as it activates the basolateral 
Na+/K+-exchangers, which are present along the renal nephron. However, the site 
of adrenal catecholamine synthesis is the medulla, a region in which Sorla expres-
sion could not be detected (cf. figure 11). 
The differential transcriptome in the adrenal glands of mice lacking SORLA does 
not offer an explanation for mis-regulated aldosterone synthesis or secretion. Nor 
does it provide any evidence for defects in angiotensin II or K+ -sensing mecha-
nisms, both required for proper regulation of aldosterone secretion. Therefore, I 
focused on investigating the renal expression pattern to find an evidence for the 
primary electrolyte phenotype in the kidney. 
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3.3.2 Kidney 
To develop an idea which renal defects may lead to the observed phenotype in 
renal ion homeostasis, the kidney was also subjected to comparative gene expres-
sion analysis. RNA from whole kidney preparations was used to generate labeled 
cRNA for hybridization on Affymetrix Mouse Genome 430 2.0 Arrays. 
DNA chip expression analysis of kidneys was carried out on SorLA27 mice and 
corresponding hybrid 129Bl/6 wild type mice. Labeled cRNA was synthesized 
using a one-cycle protocol. 
After normalizing the data with a variant of the RMA algorithm, the obtained data 
was examined by carrying out quality assessments tests, according to the treat-
ment of the adrenal gland data. Pseudoimages, box-plots of the raw/normalized 
intensities and RNA degradation plots were comparable for all samples (data not 
shown). The sample of one SORLA-deficient animal supplied with drinking water 
(Sorla(-/-) +H2O 01) did show a divergent M vs. A plot. 
Results 
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Figure 18 shows that transcriptional difference between the genotypes diverges 
with thirsting. The data set of the untreated SORLA-deficient sample 
Sorla(-/-) +H2O 01 differs strongly from the others. Together with the irregular M 
vs. A plot this was reason to exclude the data set from further statistical analyses. 
While unsupervised hierarchical clustering is unable to clearly separate two 
groups under normal conditions, a clear classification is possible in the thirsted 
subset of animals (figure 18 B). 
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Figure 18: Correlation plot and unsupervised hierarchical clustering of the adrenal data sets. 
A: Correlation plot showing complete identity of the data sets in bright red and divergence of 5% 
identity in black; B: Hierarchical trees obtained after performing an unsupervised clustering using 
the data sets for normal condition (left) and water-deprivation (right). 
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Figure 19: Principal component plot for kidney Affymetrix data. Principal component A 
clearly separates the data sets according to the condition; component B distinguishes the geno-
types; the marginal difference between the mice held with water contrasts with the clear difference 
between thirsted animals. 
 
That the difference between wild types and SORLA-deficient mice markedly in-
creases after thirsting becomes visible in a principal component analysis (figure 
19). Principle component B is hardly able to distinguish the unthirsted groups, 
whereas thirsting clearly increases the distance between the data sets of both 
genotypes. The antidiuretic stress triggers differential transcriptional responses in 
wild types and Sorla(-/-) mice. 
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Figure 20: Volcano plots representing the renal Affymetrix data. Differentially regulated probe 
sets of normal (A, B) and thirsted (C, D) mice; p-values used for the plots were either uncorrected 
(A, C) or corrected by the Benjamini-Hochberg method (B, D) to reduce false positives. Interest-
ing probe sets are encircled and listed in table 18. 
 
 
Single highly differentially expressed genes become obvious in the volcano plot 
(figure 20). In the non-thirsted state, very few genes fulfill the significance criteria 
after applying the Benjamini-Hochberg correction. This situation is completely 
different in thirsted mice. 
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Table 18: Highly differential probe sets in the kidney. List of probe sets marked in figure 20. 
The p-values listed here are not adjusted with the Benjamini-Hochberg correction. 
  probe set ID gene symbol fold-change p-value 
A/B 
normal 
a 1447396_at not annotated in NetAffx 
 
(chromosome 18 
genomic contig) 
-7.346 5.25E-06 
C/D 
thirsted 
a 1457678_at male epididymis cDNA 
 
RIKEN clone 
9230105B05 
-2.303 4.78E-07 
1437923_at male hippocampus cDNA 
 
RIKEN clone 
C630001M21 
-2.199 1.70E-06 
1441404_at not annotated in NetAffx 
 
(chromosome 11 
genomic contig) 
-1.963 3.39E-06 
1417547_at Sart3 -1.476 1.67E-06 
b 1443696_s_at Habp2 2.457 2.87E-06 
c 1417462_at 
1417461_at 
Cap1 60.825 
24.790 
2.66E-06 
1.91E-05 
d 1422603_at Rnase4 -17.098 1.10E-05 
e 1421144_at Rpgrip1 74.821 9.50E-04 
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Table 19: Number of probe sets being significantly changed in kidneys, sorted by fold change 
and p-value. A and B show the number of significant probe sets after Benjamini-Hochberg false 
discovery rate correction in brackets. 
A Sorla(-/-) +H2O vs. Sorla(+/+) +H2O 
  all p < 0.05 p < 0.02 p < 0.01 p < 0.005 p < 0.001 
all 45101 1156 (0) 445 (0) 228 (0) 109 (0) 31 (0) 
FC > 1.1 11788 972 (0) 381 (0) 203 (0) 97 (0) 29 (0) 
FC > 1.5 869 310 (0) 161 (0) 95 (0) 58 (0) 16 (0) 
FC > 2.0 246 131 (0) 79 (0) 54 (0) 33 (0) 10 (0) 
FC > 3.0 70 50 (0) 32 (0) 21 (0) 13 (0) 4 (0) 
expected by chance 2255 902 451 225 45 
B Sorla(-/-) -H2O vs. Sorla(+/+) -H2O 
  all p < 0.05 p < 0.02 p < 0.01 p < 0.005 p < 0.001 
all 45101 7453 (6) 2851 (0) 1566 (0) 910 (0) 237 (0) 
FC > 1.1 20644 4861 (6) 2444 (0) 1459 (0) 872 (0) 227 (0) 
FC > 1.5 2773 1547 (5) 969 (0) 650 (0) 428 (0) 132 (0) 
FC > 2.0 721 542 (4) 382 (0) 289 (0) 203 (0) 81 (0) 
FC > 3.0 170 138 (1) 103 (0) 91 (0) 72 (0) 33 (0) 
expected by chance 2255 902 451 225 45 
A and B: Welch's t-test, unpaired, unequal variance 
asymptotic p-value computation 
no multiple testing correction (in brackets: Benjamini-Hochberg correction) 
C Sorla(+/+) +H2O vs. Sorla(+/+) -H2O 
  all p < 0.05 p < 0.02 p < 0.01 p < 0.005 p < 0.001 
all 45101 3720   1823   1019   562   150   
FC > 1.1 15735 3412 1744 984 546 147 
FC > 1.5 2118 1048 632 399 243 82 
FC > 2.0 405 227 144 94 58 15 
FC > 3.0 77 42   35   19   13   4   
expected by chance 2255 902 451 225 45 
D Sorla(-/-) +H2O vs. Sorla(-/-) -H2O 
  all p < 0.05 p < 0.02 p < 0.01 p < 0.005 p < 0.001 
all 45101 7217   2669   1344   672   134   
FC > 1.1 20887 5328 2302 1190 593 109 
FC > 1.5 2941 1299 756 443 248 50 
FC > 2.0 625 353 226 163 106 17 
FC > 3.0 89 57   42   36   23   6   
expected by chance 2255 902 451 225 45 
B and C: Welch's t-test, unpaired, unequal variance 
asymptotic p-value computation 
no multiple testing correction 
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In contrast to the adrenal gland, the kidney seems to be less effected by the tar-
geted disruption of the Sorla gene (table 19). Under basal conditions, 1156 probe 
sets differ significantly (p<0.05) between the two genotypes (cf. 2275 probe sets 
in adrenal glands, table 16 A, chapter 3.3.1). This situation changes dramatically 
during water-deprivation. In total, more than 7400 probe sets are significantly 
changed in the kidney, of these more than 1500 with a fold-change higher than 1.5 
(table 19 B). The numbers in table 19 C and D also demonstrate, that thirsting 
exacerbates the renal transcriptional differences between wild types and Sorla(-/-) 
animals, an effect not seen in adrenal glands. 
Whereas the lack of the receptor alone has a rather mild effect, the combination of 
SORLA-deficiency with thirsting leads to a differential activation of a broad vari-
ety of genes in the murine kidney. The functional range of affected genes was al-
ready shown in figure 15 (chapter 3.3.1). In contrast to the adrenal gland data, the 
kidney data did not reveal groups of genes involved in specific pathways. 
3.3.3 Confirmation of Affymetrix results via TaqMan analysis 
The transcriptional changes in the catecholamine pathway in the adrenal gland 
could already indirectly be validated by measuring the metabolites. In order to 
validate the other results obtained from the DNA chip data, the transcriptional 
expression level of some probe sets was determined via quantitative real-time 
PCR (TaqMan). 
TaqMan primers and probes were selected for genes highly differentially ex-
pressed in Affymetrix-Assays under at least one condition (normal/thirsted) in at 
least three different tissues. Tissues analyzed were: adrenal gland, kidney, brain 
stem (not shown) and primary hippocampal neurons (not shown). For Affymetrix-
Analysis, kidney tissue was taken from SorLA27 and 129Bl/6 animals, all other 
tissues were taken from SorLA18 and 129Balb/c animals. 
Most of the differential regulation seen in the gene chip data could be reproduced 
in TaqMan assays (table 20, brain stem and primary neurons not shown). The se-
lected assays turned out to be not suitable for validation of the kidney Affymetrix 
data. This can be explained by the different genetic and transcriptional back-
ground of the animals used for the DNA chips and the real-time PCR (129Bl/6 
and 129Balb/c respectively). Noteworthy is the gene Ifi202b, which is expressed 
in 129Balb/c mice but whose transcription is not detectable by microarray or 
TaqMan assays in all analyzed SorLA18 tissues. In contrast to that, it does not 
seem to be expressed in the tissue of SorLA27 or 129Bl/6 animals at significant 
levels (table 20, left), therefore resembling an artifact in the hybrid 129Balb/c 
mice used. 
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Due to the high variability between individual Affimetrix analyses, a validation of 
such an experiment is usually done by real-time PCR using the same samples that 
have been used for the microarrays. I could confirm the validity of the chip data 
by using independent samples. Even though the microarrays were processed in 
parallel and all steps in the process (such as isolation of RNA and synthesis of 
cDNA and cRNA) were carefully monitored, the kidney microarray data could not 
be confirmed by real-time PCR. The divergence of their data resulted most likely 
from the different hybrid background of the mice used. Due to identical setup and 
positive examination of all parameters during the Affymetrix analyses, I consider 
the kidney data as valid. 
The analysis of renal gene expression in mice deficient for SORLA shows a dif-
ferential transcription that strongly aggravates with thirsting, suggesting a role of 
the receptor in this organ. Still, the data did not reveal any specific transcription-
ally mis-regulated pathways. To identify renal mechanisms which may cause the 
observed electrolyte phenotype in the Sorla(-/-) mice, I challenged the kidney with 
specific pharmacological interventions. 
3.4 Pharmacological Experiments 
Mice lacking SORLA display a distinct salt loss – indicating defects in renal ion 
handling in these animals. Renal mechanisms in sodium transport involve the ac-
tivation of the sodium-chloride-cotransporter NCC, responsible for regulated 
Na+/Cl- transport in the distal convoluted tubule, or the activation of sodium-
potassium-chloride-cotransporter NKCC2, the major salt-reabsorption pathway in 
the thick ascending limb of Henle’s loop. Both transporters can be blocked by 
pharmacological intervention. The supposed mis-regulation of aldosterone levels 
observed in Sorla(-/-) mice could be a balancing mechanism as well, as aldosterone 
increases the reabsorption of sodium. Its effects can be suppressed by pharmaco-
logically blocking the aldosterone-receptor. 
By blocking the abovementioned pathways, I intended to separate counterbalanc-
ing mechanisms from negative effects that may be produced by the lack of 
SORLA, and therefore stress the renal system in favor of a more pronounced and 
less cryptic phenotype. 
3.4.1 Blockage of NCC activity with thiazide 
Thiazide diuretics (e.g. hydrochlorothiazide) block the thiazide-sensitive sodium-
chloride-cotransporter NCC, the major regulated uptake pathway for Na+ and Cl- 
in the distal convoluted tubule. This intervention results in elevated salt excretion 
combined with a higher urine volume. 
SORLA-deficient mice and wild type control animals were injected with hydro-
chlorothiazide and urine was collected in metabolic cages. After five hours, the 
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injections were repeated and urine collected for another five hours. Control urine 
was collected for five hours prior to the experiment under the same conditions 
without injection of thiazide. 
Sorla(+/+) thiazide 5-10h
Sorla(+/+) thiazide 0-5h
Sorla(+/+) untreated
untreatedSorla(-/-)
thiazide 0-5hSorla(-/-)
thiazide 5-10hSorla(-/-)
25
0
20
15
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5
Na+ Cl- K+
p<0.05
p<0.05
p<0.05
p<0.001
 
Figure 21: Secreted hourly amount of Na+, Cl- and K+ (in µmol per hour) before and after 
administration sodium-hydrochlorothiazide. The blue bars represent wild type mice (Sorla(+/+)), 
the red bars show data from SORLA-deficient animals (Sorla(-/-)). Urine samples were collected 
for 5 hours each. After collecting control urine samples (untreated), the animals were injected with 
sodium-hydrochlorothiazide and urine was collected for five hours (thiazide 0-5h). Injections and 
collection were repeated subsequently (thiazide 5-10h). Error bars represent standard deviation, 
n ≥ 16 for each bar. 
As anticipated, Na+ and Cl- excretion increases after thiazide administration. In 
SORLA-deficient mice, this effect is less pronounced (figure 21). The fact that 
thiazide-induced loss of these ions is lower in the receptor-deficient mice suggests 
a lower basal activity of the thiazide-sensitive NCC in these animals. 
Even though thiazide is blocking NCC, a receptor only transporting Na+ and Cl-, 
some K+ loss appears. This effect seems to be lower in the knockout mice, though 
it is not statistically significant. 
There are three explanations for elevated K+ excretion upon thiazide treatment. 
First, due to reduced NCC activity, a higher Na+ delivery to the downstream col-
lecting duct occurs. There, increased activity of Na+/K+-exchangers compensates 
this loss at the expense of potassium ions. Second, the nephric flow-rate is in-
creased under diuresis. This effectively decreases the tubular concentration of K+. 
As a result, more K+ enters the lumen via passive channels such as ROMK. 
The last explanation for thiazide-induced potassium-wasting is that the diuresis 
leads to a systemic decrease in the volume of blood serum (hypovolemia), which 
results in activation of the renin-angiotensin-aldosterone-system. Aldosterone in 
turn activates the Na+/K+-exchangers, consequently leading in further loss of K+. 
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This would be in line with the mis-regulated release of aldosterone in Sorla(-/-) 
mice. 
3.4.2 Blockage of aldosterone-induced action with eplerenone 
Aldosterone increases the reabsorption of Na+ and water and the secretion of K+ in 
the aldosterone-sensitive distal nephron, which includes the late distal convoluted 
tubule (DCT2), connecting tubule (CNT), and cortical collecting duct (CD). This 
happens mainly by activating the basolateral Na+/K+-ATPase and by translocating 
the Na+ channel ENaC to the apical surface. To prevent a critical depletion, the 
kidney could counterbalance this mechanism by induction of more proximal elec-
trolyte transport processes, such as NKCC2 in the thick ascending limb. 
To separate any effects caused by the elevated basal level of aldosterone from the 
phenotype, Sorla(-/-) mice and wild type animals were treated with the aldosterone 
antagonist eplerenone. The potassium-sparing diuretic eplerenone specifically 
blocks the mineralocorticoid receptor, preventing it from binding aldosterone. 
Blockage of this receptor – and therefore inhibition of aldosterone action – would 
reverse the reabsorption of Na+ and the secretion of K+ and should consequently 
result in a higher urinary Na+/K+ ratio. 
The hydrophobic substance eplerenone is only slightly soluble in water. I tested 
several ways of administering the drug to mice. No effects were seen after mixing 
the substance into the dietary mash of the animals (not shown). The low solubility 
of eplerenone impeded the approaches to dissolve it in the drinking water or to 
inject it directly. Finally, the mice were force fed with an aqueous eplerenone-
suspension by gavage twice a day (200 mg eplrerenone per kg body weight per 
day in two gavages à 200 µl each, control animals received water) for 13 consecu-
tive days (Keidar, et al., 2005). Urine was collected in metabolic cages overnight. 
The diuretic eplerenone increased the average urine volume collected per hour by 
12% in wild types (1621.31 ± 283.97 ml before treatment, 1810.40 ± 303.13 ml 
after treatment) and by 10% (1081.14 ± 192.00 ml before treatment, 1191.34 ± 
275.23 ml after treatment) in receptor-deficient mice respectively. As exemplarily 
visualized in figure 22, the mice did not respond as expected. Even though Sorla(-
/-) animals show a higher ratio of excreted urinary Na+ to K+ after treatment with 
eplerenone (0.573 ± 0.065 before treatment, 0.853 ± 0.124 after treatment), 
Sorla(+/+) mice did not react with an increase in that quotient (1.156 ± 0.085 before 
treatment, 1.174 ± 0.203 after treatment). 
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Figure 22: Ratio of urinary Na+ and K+ concentrations before and after administration of 
eplerenone. While wildtypes are not reacting to the administration of aldosterone, knockouts are 
showing a slight increase of the urinary Na+/K+-ratio. 
The eplerenone treatment was not distinctly blocking the action of aldosterone. It 
is interesting, that the wild type animals reacted differently from the SORLA-
deficient mice, eventually responding differently to eplerenone. But most likely, 
the administration of the drug did not work in the chosen form. 
To circumvent problems with the directed application of drugs, a different ap-
proach was chosen for testing the activity of NKCC2. 
3.4.3 Bumetanide-sensitive NKCC2-mediated K+-transport in isolated TAL 
The diuretic bumetanide acts through blockade of NKCC2, preventing the trans-
porter to conserve Na+ and K+ in the thick ascending limb of Henle’s loop. Hence 
it falls into the group of loop-diuretics. As the unsuccessful administration of 
eplerenone has shown, the readout of systemic pharmacologic intervention in 
mice in vivo can be difficult. To reduce obfuscating interferences by systemic bal-
ancing mechanisms and to facilitate the targeted application of the pharmacologic 
agents, bumetanide-administration was approached from a different ex vivo angle. 
Bumetanide acts only in the thick ascending limb. This tissue is characterized by a 
comparably high resistance to collagenase. Hence digestion with this cocktail of 
degrading enzymatic allows gentle isolation of tubular fragments of this segment 
from the inner stripe of the outer medulla (ISOM) of the kidney. After the ISOM 
was excised from the kidney, it was minced and digested with collagenase (de-
picted in FIGURE 21 A). In this way isolated tubules were separated from con-
taminating cells (mainly colleting duct cells, also thin ascending limb cells) using 
their different sedimentation rate. Thick ascending limb tubules were isolated to a 
purity of more than 85% (exemplified in figure 24). 
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Figure 23: Isolation of TAL fragments (A) and major K+ transport mechanisms in TAL (B). 
A: Schematic illustration of the TAL isolation process. The inner stripe of the outer medulla 
(ISOM) is excised from kidney sections, minced and treated with collagenase. The resulting mix-
ture of TAL fragments and contaminating cells is separated by centrifugation. B: Major transcellu-
lar pathways accountable for the transmembrane transport of K+ in TAL cells. Transporting ele-
ments are labelled in blue, their inhibitors are in red. 
The NKCC2 activty in intact isolated tubules was determined by measuring up-
take of radioactive rubidium (86Rb+), a substitute for potassium. To differentiate 
between NKCC2 activity and alternative transport mechanism for K+/Rb+, only 
bumetanide-sensitive uptake was considered. The Na+/K+-ATPase was inhibited 
by the arrow poison ouabain, potassium channels (ROMK) were blocked by bar-
ium ions (Ba2+), as shown in figure 23 B. 
 
Figure 24: Isolated thick ascending limb tubules. TAL tubules were purified from the ISOM to a 
purity of more than 85% by sequential collagenase treatment and sedimentation (vide figure 23). 
The inset shows an intact tubule. Magnification: 100x, 400x for the inset. 
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Figure 25. Bumetanide-sensitive 86Rb+ uptake in isolated thick ascending limb tubules. A: box 
plot. B: bar graph with bars representing the average and the median of each group. Upper error 
bars in B show standard deviation, lower error bars represent standard error of the mean. The p-
value was calculated using Student’s t-test for paired samples. 
For the uptake assay, each batch of isolated tubules was split into two and treated 
with and without bumetanide. The difference between 86Rb+-uptake with and 
without bumetanide was considered as bumetanide-sensitive fraction and ex-
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pressed as percentage of the uptake without bumetanide (uptake without bumet-
anide was set to 100%). 
Interestingly, SORLA-deficiency led to a higher bumetanide-sensitive 86Rb+-
uptake in isolated thick ascending limb tubules (figure 25), as compared to age- 
and sex-matched wild type samples. 
Sorla(-/-) mice exhibit a higher NKCC2 activity in isolated TAL tubules. To check 
whether this is due to changed protein levels of the transporter and if other spe-
cific transport processes are also affected in the kidney of these animals, I carried 
out Western blot analyses of different renal tranporters. 
3.5 Electrolyte transporters in the distal nephron 
NKCC2 has been reported to be phosphorylated upon activation (Gimenez and 
Forbush, 2005). I detected the transporter with an anti-NKCC2 antibody that rec-
ognizes all transporter variants, and with an anti-pNKCC2 antibody specific for 
the variant phosphorylated at two of its three known phosphorylation sites (T100 
and T105 in human NKCC2, T96 and T101 in murine NKCC2). 
SORLA
pNKCC2
NKCC2 (total)
Na+/K+-ATPase
A
-AVP +AVP
SORLA
pNKCC2
NKCC2 (total)
Na+/K+-ATPase
B
pNKCC2
NKCC2 (total)
Na+/K+-ATPase
C
 
Figure 26: NKCC2 in the thick ascending limb. Western blots exemplifying protein levels of 
total and phosphorylated NKCC2 in isolated thick ascending limb tubules untreated or treated with 
AVP (A, B) and whole kidney membrane preparations (C) of the same animals. A: SORLA, 
NKCC2, pNKCC2 and Na+/K+-ATPase in a membrane fraction enriching intracellular vesicles. B: 
SORLA, NKCC2, pNKCC2 and Na+/K+-ATPase in a membrane fraction enriching cell membrane 
fragments. C: NKCC2, pNKCC2 ad Na+/K+-ATPase in a membrane fraction enriching cell mem-
brane fragments. 
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In order to test for NKCC2 levels, isolated tubules of the thick ascending limb 
were purified (one kidney per animal), split into two portions and treated in pres-
ence or absence of arginine vasopressin (+/-AVP). Two different membrane prepa-
rations of each aliquot of tubules were compared to test for protein levels in intra-
cellular vesicles (smaller vesicular membrane fragments are enriched in the 
100,000 × g fraction, figure 26 A) and at the cell surface (cell membrane frag-
ments are enriched in the 20,000 × g fraction, figure 26 B). The trans-membrane 
Na+/K+-ATPase was used as a loading control as its expression level does not 
change between Sorla(+/+) and Sorla(-/-) animals (demonstrated in figure 27). 
In all Sorla(-/-) fractions, NKCC2 phosphorylation is markedly reduced, whereas 
the total protein levels are unchanged, a trend also visible in whole kidney mem-
brane preparations from the same animals (figure 26 C). 
Because Sorla is expressed in all distal nephron segments, the chances are that 
NKCC2 is not the only electrolyte transporter affected in SORLA-deficient mice. 
Expression levels of other proteins involved in electrolyte transport processes in 
nephron areas that express Sorla were analyzed. In particular I was interested in: 
barttin, the accessory -subunit of the renal chloride channels ClC-Ka and ClC-
Kb; the epithelial sodium channel ENaC; the potassium chloride cotransporter 
KCC4; the sodium hydrogen exchanger NHE3; and the renal outer medulla potas-
sium channel ROMK. 
Na+/K+-ATPase
KCC4
barttin
Sorla(+/+) Sorla(-/-)
ENaC
NHE3
actin
ROMK
Sorla(+/+) Sorla(-/-)
 
Figure 27: Western blots of barttin, the -subunit of ENaC, KCC4, Na+/K+-ATPase, NHE3 
and ROMK in wild types and mice lacking SORLA. Western Blots shown here were carried out 
on whole kidney lysates. SORLA-deficient animals show increased expression of ENaC , and 
NHE3 and slightly reduced expression of ROMK. 
As nephron segments other than TAL cannot be isolated specifically, proteins 
from those segments were quantified in whole kidney lysates. Western blot analy-
sis shows comparable protein levels of barttin, KCC4 and Na+/K+-ATPase; 
ROMK levels are slightly decreased (figure 27). In contrast, expression of the 
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alpha subunit of ENaC and of NHE3 are more pronounced in mice lacking 
SORLA. 
As SORLA-deficiency in mice led to differential excretion of Na+ and Cl- in re-
sponse to treatment with thiazide, the expression of NCC was also investigated 
via Western blot. As NKCC2, NCC has been reported to be phosphorylated upon 
activation. For this reason, phospho-specific antibodies (pNCC T55, T60 and S91) 
as well as a phospho-unspecific NCC (total) antibody were used. The NCC West-
ern blots were carried out in collaboration with the laboratory of Dario R. Alessi 
in Dundee, Scotland. As expected from the pharmacological experiment, figure 28 
shows differential NCC expression in total kidney lysates of mice lacking 
SORLA. Interestingly, total NCC protein levels are elevated and the transporter is 
hyperphosphorylated as compared to control animals. This effect, which is inde-
pendent of thirsting, is in contrast with the observation that thiazide has a milder 
effect on SORLA-deficient mice. If NCC is hyperphosphorylated and thus more 
active, e.g. as counterbalancing response to a defect elsewhere, blocking the 
transporters (higher) activity should have a larger impact in Sorla(-/-) mice. 
pNCC T60
pNCC T55
NCC (total)
pNCC S91
GAPDH
Sorla(+/+)
-H2O
Sorla(+/+)
+H2O
Sorla(-/-)
-H2O
Sorla(-/-)
+H2O
 
Figure 28: Western blots of NCC in wild types and in mice lacking SORLA. Mice were 
thirsted for 24h (-H2O) or treated normally (+H2O). NCC and GAPDH western were performed 
on whole kidney lysates. Westerns shown here were carried out by the group of Dario Alessi. 
In conclusion, I demonstrated that the electrolyte homeostasis phenotype in 
SORLA-deficient mice coincides with an abnormal expression and phosphoryla-
tion of several electrolyte transporters, first and foremost NCC and NKCC2. 
3.6 Signaling in distal renal ion-homeostasis 
The lower effectiveness of thiazide and the increased bumetanide-sensitive 86Rb+-
flux as well as the different phosphorylation patterns of the transporters NCC and 
NKCC2 in the tissue of SORLA-deficient mice points towards a defective regula-
tion of distal electrolyte reabsorption. 
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NCC and NKCC2 are members of the same gene family. The Slc12a family con-
sists of the sodium-chloride-cotransporter NCC, the two sodium-potassium-
chloride cotransporters NKCC1 and NKCC2 as well as the four potassium-
chloride cotransporters KCC1-4. A group of kinases have recently been identified 
as key-players regulating these pathways (Gamba, 2005). These include members 
of the WNK (with no lysine) kinase family and SPAK (STE20-related, proline-
alanine-rich kinase). They have been reported to be involved in the phosphoryla-
tion of members of the Slc12a family of chloride-cation cotransporters. 
To test for defects in regulatory kinases, I investigated the phosphorylation pattern 
the abovementioned signaling proteins. In cooperation with the lab of Dario R. 
Alessi, I analyzed the kinases WNK1, 3 and 4 and SPAK by immunoprecipitation 
and Western blot analysis using phospho-specific antibodies. Unfortunately, the 
antibodies against the WNK proteins were unable to precipitate enough material 
to detect the kinases in any of the two labs (not shown). However, the immuno-
precipitation of SPAK (figure 29) revealed a stronger phosphorylation of the 
kinase in Sorla(-/-) mice, in line with the hyperphosphorylation of NCC. 
ERK1/2
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SPAK S373-p
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+H2O
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Figure 29: Western blots of immunoprecipitated SPAK in wild types and in mice lacking 
SORLA. Mice were thirsted for 24h (-H2O) or treated normally (+H2O). NCC, ERK1/2 and 
GAPDH western were performed on whole kidney lysates, SPAK was immunoprecipitated from 
the same lysates. Westerns shown here were carried out by the group of Dario Alessi. 
SPAK has been reported to phosphorylate both NCC and NKCC2 (Moriguchi, et 
al., 2005). The lower phosphorylation of NKCC2 in SORLA-deficient mice con-
tradicts the observed hyperphosphorylation of NCC and SPAK, suggesting 
mechanisms for both transporters that are independent from each other. The ex-
pression patterns of NCC and NKCC2 are confined to separate segments of the 
nephron. NKCC2 is exclusively expressed in the TAL, NCC is only expressed in 
the more distal DCT. 
Immunohistological staining of kidney sections shows a significant difference 
between Sorla(-/-) and wild type mice in the TAL (figure 30).While SPAK is local-
ized in vesicles close to the apical membrane of the TAL cells in wild types, 
where it partially localizes with NKCC2, it mis-localizes in SORLA-deficient 
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animals. White arrow heads in figure 30 mark SPAK expression in areas distant to 
the apical cell membrane and SPAK’s target NKCC2. 
Sorla(+/+)
Sorla(-/-)
SPAK / NKCC2 pSPAK / NKCC2
 
Figure 30: Localization of SPAK and NKCC2 in the thick ascending limb. Immunohistologi-
cal detection of total SPAK (red, left panel) or its phosphorylated form (pSPAK) (red, right panel) 
and NKCC2 (green) in kidneys of the indicated genotypes. Co-localization of both proteins is 
indicated by yellow color. The insets represent magnifications of apical cell regions. Arrow heads 
highlight the different vesicular localization of SPAK/pSPAK in the sub-apical space in TAL cells 
of Sorla(-/-) mice. Magnifications: 1000x, 4000x for insets. 
The mis-localization of SPAK in TAL cells may be a reason for the massively 
reduced phosphorylation of NKCC2 in mice lacking SORLA. Since this was ob-
served only in TAL sections and not in the DCT, a different mechanism may be 
involved in the localization of SPAK to NCC, resulting in an efficient phosphory-
lation of the latter. 
3.7 Identification of interaction partners 
SORLA has been reported to influence the localization of the transmembrane-
protein APP in the brain by binding to adaptor proteins (Schmidt, et al., 2007). A 
similar function could be possible for SPAK. But as the kinase is a cytosolic pro-
tein, a putative interaction with SORLA, direct or indirect, is likely to occur with 
the cytosolic domain of the receptor. 
To discover physiological interactions of the cytosolic portion of SORLA in a 
renal context, I followed two parallel approaches: yeast two-hybrid screening and 
peptide pull-down. 
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3.7.1 Yeast Two-Hybrid 
The first approach to identify interaction partners was a yeast two-hybrid analysis 
using the intracellular domain of SORLA. This screening method’s concept is 
based on the property of some transcription factors in yeast, which require two 
functional subunits: A DNA-interacting domain binds to the specific upstream 
activating sequence of the DNA and thereby positions a second activating domain, 
which starts the transcription. In the two-hybrid system, the two subunits are 
physically separated as each is fused to a different recombinant protein. Both pro-
teins are unable to start transcription on their own. If the protein fused to the 
DNA-interacting domain (bait) interacts with the fusion-proteins containing the 
activation domain (prey), both domains come into close vicinity and start tran-
scription. 
In a yeast two-hybrid system, separate yeast clones contain bait and prey vectors. 
Transcription starts only after mating two clones with interacting bait/prey pro-
teins. The separation of the prey proteins in distinct yeast clones is a great advan-
tage of this system. Each clone harbors the cDNA coding for the prey protein, 
allowing easy identification by DNA-sequencing. 
A cDNA encoding the cytosolic portion (amino acids 2163-2214) of the human 
SORLA was cloned into the bait vector pBTM117c, fusing it to the DNA-binding 
LexA repressor. In parallel, the cDNA was cloned into the prey vector pACT4-1b, 
fusing the cytosolic SORLA domain with the activation domain of the transcrip-
tion activator GAL4 (Ralser, et al., 2006). The automated screening was carried 
out in collaboration with the group of Prof. Dr. Erich Wanker (Max-Delbrück-
Centrum Berlin-Buch) using a custom cDNA library, also based on the pACT4-1b 
(Erich Wanker, not published). 
Transcriptional activation was detected by reporter genes, which were turned on 
upon positive bait-prey interactions. All yeast strains used require medium sup-
plemented with histidine and uracil (SD2) to grow normally. The reporter genes 
HIS3 and URA3 allow growth on SD4 minimal medium (without amino acids), 
the lacZ gene allows detection via -galactosidase activity. 
The fusion protein of the SORLA cytosolic domain and LexA turned out to be 
autoactivating in a preliminary test. The yeast clone was able to grow on the nutri-
ent-deficient medium SD4 and induces blue staining in medium containing X-gal 
(figure 31). SorCS3 constructs cloned in parallel into the same vector backbone 
were not autoactivating. Hence the SORLA screening could not be carried out as 
planned. 
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Figure 31: Auto-activation test of the bait constructs for SORLA and SORCS3. pBTM117c 
bait constructs encoding the protein segment specified in brackets were grown on SD2 and SD4 
media without and with IPTG and X-gal (lacZ-SD2 and lacZ-SD4). Growth on SD4 medium or 
blue staining indicate auto-activation. 
3.7.2 Peptide pull-down 
An alternative strategy for screening interaction partners of SORLA was pursued 
by performing a pull-down with peptides of the receptors cytosolic domain. 
In contrast to the yeast two-hybrid approach, this method does not require a cDNA 
library of interaction partners. Instead, the immobilized peptides interact with en-
dogenous proteins from tissue lysates. Binding proteins are enriched by washing 
away unspecific interaction partners. Conditions and therefore stringency can be 
adjusted by changing the buffers used for binding and washing. 
This way, it is more difficult to identify individual binding partners, since putative 
interaction partners are not individually present within the screen (as yeast clones 
are in a yeast two-hybrid screen), but as a mixture that has to be separated first. I 
approached this problem by gradient gel electrophoresis. Putative interacting pro-
teins were identified by mass spectrometry. 
In this approach, five peptides covering the human cytosolic domain in an over-
lapping manner (figure 33 B) were coupled to sepharose beads and incubated with 
whole kidney lysate. After washing, the bound proteins were separated by SDS 
polyacrylamide gel electrophoresis and stained with Coomassie Blue. Prominent 
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bands were cut out and sent to Bent Honoré (University of Aarhus, Denmark) for 
mass spectrometry. 
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Figure 32: SORLA peptide pull-down optimization whole kidney lysate. A: Exemplary 
Coomassie-stained polyacylamide gels showing pull-downs using immobilized peptides covering 
the intracellular tail of SORLA. Pull-downs were performed using RIPA (left site) or DOC (right 
site) buffer for kidney lysis and washing of the immobilized peptides. B: Comparison of pull-down 
experiments with wild-type (Sorla(+/+))and SORLA-deficient (Sorla(-/-)) kidneys using RIPA buffer. 
RIPA buffer and DOC buffer were tested for whole kidney protein preparations 
and washing of the immobilized peptides (figure 32 A). RIPA buffer was chosen 
for the following experiments, as more distinct protein bands could be reproduci-
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bly isolated from the eluates. No differences in the band pattern were seen in ex-
periments performed with lysates from wild-type or Sorla gene-disrupted kidneys 
(figure 32 B). 
The most prominent bands appeared in the lanes of peptide 1 and 2. They were 
identified as two heat shock proteins: heast shock 70 kDa protein 9 (alternative 
name: mortalin, figure 33 A 1) and heat shock 70 kDa protein 8 (figure 33 A 2). It 
is not uncommon for short, synthesized peptides to bind heat shock proteins, as 
this class of proteins is binding to un- or misfolded peptides in vivo, fulfilling a 
chaperone-like role. 
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Figure 33: Pull-down of interaction partners from whole kidney lysate. A: Representative 
Coomassie-stained polyacylamide gradient gel showing the pull-down using immobilized peptides 
covering the intracellular tail of SORLA. Arrows are marking interaction partners identified by 
mass spectrometry in several independent screens. B: Amino-acid sequence of the intracellular 
portion of human SORLA and peptides used for the pull-down. 
The transmembrane-receptor megalin was pulled out with peptide 4 (figure 33 A 
3). The endocytotic receptor, which is capable of binding various ligands, is 
highly abundant in the kidney, but its expression in the proximal tubule does not 
overlap with the distal expression of Sorla. This lead to the conclusion, that the 
observed interaction in whole-kidney lysate does not reflect a physiological situa-
tion. 
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Peptide 5, covering the sequence closest to the transmembrane domain of 
SORLA, bound most different proteins, as seen in figure 33 A. Identified proteins 
are the µ1 subunit of the adaptor-related protein complex 2 (AP-2), the vacuolar 
protein sorting 26 homolog A (VPS26A), a subunit of the retromer complex, and 
the ADP-ribosylation factor 4 (ARF4). These proteins are involved in vesicular 
trafficking. The alpha subunits of Na+/K+-ATPase and mitochondrial ATPase were 
also pulled down from whole kidney lysate, proteins playing a role in facilitated 
solute transport. 
An interaction of SORLA with the abovementioned proteins implicates the recep-
tor with intracellular trafficking processes. Especially interactions with retromer 
and the AP-2 complex fit the role of the receptor suggested in neuronal transport 
processes. 
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4 Discussion 
In my thesis, I analyzed the function of the VPS10p receptor SORLA in the kid-
ney. The expression of Sorla has been characterized by quantitative realtime-PCR 
in the developing and adult kidney in mice. Using immunohistochemistry, the 
expression of the receptor was confined to the thick ascending limb (TAL), the 
distal convoluted tubule (DCT), the connecting tubule (CNT) and the collecting 
duct (CD) of the adult murine nephron. Extrarenal expression of SORLA was 
shown in the adrenal gland cortex, particularly in the zona glomerulosa. 
In a mouse model lacking SORLA, a defect in renal solute reabsorption was 
shown. This phenotype includes defects in handling of electrolytes, especially 
Na+, Cl-, K+, and Ca2+. The salt loss phenotype is accompanied by mis-regulated 
aldosterone-secretion and decreased mean arterial pressure (MAP) and heart rate. 
While investigating the cause of the renal phenotype, the comparison of the renal 
and adrenal transcriptomes of wild type animals and mice lacking SORLA re-
vealed an adrenal defect in the catecholamine synthesis pathway, resulting in 
lower levels of epinephrine in the adrenal gland. 
A more detailed investigation of the kidney uncovered that the electrolyte trans-
porters NKCC2, NCC and NHE3 (and ROMK) are differentially expressed or 
abnormally phosphorylated. 
A signalling kinase regulating the activity of NKCC2 and NCC, SPAK, is abnor-
mally distributed in the TAL epithelium of mice lacking SORLA, suggesting a 
role of the VPS10p receptor in cellular trafficking of the enzyme. This hypothesis 
was further substantiated by the identification of putative SORLA-interacting pro-
teins involved in trafficking using peptide pull-down assays. 
4.1 SORLA in the murine kidney 
Expression of the Sorla gene locus in adult human (Mörwald, et al., 1997) and 
murine (Hermans-Borgmeyer, et al., 1998) kidney was first described together 
with the discovery of the VPS10p-domain containing receptor itself. A more pre-
cise study reported expression of the receptor in E14 embryos and adults (Riedel, 
et al., 2002). I confirmed the embryonic expression by detecting Sorla transcripts 
at the onset of kidney development at E12.5 and stable expression in the kidneys 
of E14.5 embryos (figures 7 and 8, chapter 3.1). 
Conerning the adult kidney, Riedel et al. previously confined the expression of 
SORLA to the collecting duct epithelium (Riedel, et al., 2002). My findings con-
trast with this published observation. The expression of the receptor is stretching 
from thick ascending limb (TAL) of Henle’s loop through distal convoluted tubule 
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(DCT) and connecting tubule (CNT) to the collecting duct system (CD). Epithelial 
cells in these nephron segments express SORLA mainly in intracellular vesicular 
structures along their apical side and in perinuclear regions (figure 9, chapter 3.1). 
This localization of SORLA is in line with earlier studies, which described 
SORLA expression in brain and cell culture (Jacobsen, et al., 2002; Motoi, et al., 
1999). SORLA-positive subcellular compartments in the kidney resemble most 
likely early endosomal vesicles and TGN, as the receptor is capable of shuttling 
between these structures (Jacobsen, et al., 2002; Nielsen, et al., 2007; Schmidt, et 
al., 2007; Seaman, 2004). This route is depicted in figure 2, chapter 1.1.6.1. 
Expression of the SORLA-expressing nephron segments allows drawing conclu-
sions concerning the physiological processes the receptor may be involved in. 
In contrast to the quantitative (but mostly uncontrolled and passive) transport 
mechanisms for water and electrolytes in the proximal tubule, the SORLA ex-
pressing segments from TAL to CD are essential for active and highly regulated 
reabsorption of essential electrolytes and water. The most proximal expression of 
SORLA can be found in the TAL of Henle’s loop. Overall, the function of the loop 
of Henle can be described as uncoupling of water and salt reabsorption. While 
isoosmotic transport processes are dominant in the proximal tubule, the thin de-
scending limb reabsorbs around 10% of the water filtered at the glomerulus. The 
high water permeability of this nephron segment combined with the inability to 
reabsorb Na+ results in concentrated tubular fluid entering the following segment. 
This creates a favorable gradient for Na+ reabsorbtion in the thin ascending limb, 
whose epithelium permits this gradient to drive passive paracellular reabsorption. 
As the tubular fluid enter the virtually water impermeable TAL, active ion trans-
port mechanisms become dominant. 25% of the filtered Na+ are reabsorbed in this 
segment, making the net salt reabsorption of Henle’s loop larger than the water 
reabsorption. As a result, hypo-osmotic tubular fluid (as compared to plasma) is 
leaving the loop. 
The main luminal entry step for Na+ and Cl- in TAL is via the kidney specific api-
cal form of the Na+/K+/Cl--symporter NKCC2 (Haas and Forbush, 1998; Molony, 
et al., 1987). The cotransporter requires equal amounts of K+ and Na+ to be trans-
ported, even though there is far less K+ available in the lumen than Na+. To pre-
vent tubular depletion of K+ long before much Na+ is reabsorbed, the luminal 
membrane has a large number of K+-channels (ROMK) (Xu, et al., 1997), allow-
ing much of the intracellular potassium to leak back into the tubular fluid (see also 
figure 23 B, chapter 3.4.3). Thus under normal conditions, the limited amount of 
potassium does not restrict sodium and chloride transport through the cotrans-
porter. A permanent activity of the basolateral Na+/K+-ATPase is creating an in-
creasing Na+-gradient towards the interstitium to facilitate the required transport. 
In addition to the transcellular reabsorption of sodium via NKCC2, a considerable 
portion of total reabsorption in the thick ascending limb occurs by paracellular 
diffusion. A high paracellular conductance for sodium and a positive luminal po-
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tential in this segment form a significant driving force for cations, also maintained 
by Na+/K+-ATPase activity. 
The next tubular segment, the DCT, is responsible for the reabsorption of 5% of 
the filtered Na+ and Cl- from tubular fluid leaving the loop of Henle in an already 
hypo-osmotic state, while – similar to the TAL – this segment remains imperme-
able for water. Accordingly, the DCT also acts as a diluting segment. The major 
entry step for active reabsorption of Na+ by this segment is via the sodium-
chloride symporter (NCC). Besides sodium and chloride reabsorption, epithelial 
cells in the distal convoluted tubule have apical Ca2+-channels that are regulated 
by parathyroid hormone, rendering this segment the major site for the control of 
Ca2+ homeostasis. 
In the CD, several different cell types act in concert to maintain electrolyte bal-
ance. Reabsorption of Na+ and water is accomplished by the aldosterone-sensitive 
principal cells that make up approximately 70% of the epithelium. The luminal 
entry of Na+ into these cells functions via epithelial Na+ channels. Reabsorption of 
Cl- occurs partially via paracellular routes but is also actively carried out by an-
other class of cells, the type B intercalated cells. 
The reabsorption and the permeability of most of the CD system can vary between 
very low or very high. In the absence of hormonal stimuli, the hypo-osmotic tubu-
lar fluid entering this system remains hypo-osmotic. When it reaches the me-
dullary portion of the CD, an enormous osmotic gradient induces medullary reab-
sorption to some extent, even though there is vanishingly low cortical water 
reabsorption without hormonal stimulation. However, because of the high tubular 
volume at this point – due to no reabsorption in earlier collecting duct portions – 
most of the water entering the medullary collecting duct flows through to the 
ureter. 
4.1.1 Sorla(-/-) animals are wasting Na+ and K+ respectively 
Judging from its distal expression pattern, SORLA may influence the regulated 
electrolyte and water reabsorption. To test this hypothesis, I investigated the renal 
salt and water handling in a SORLA-deficient mouse model, previously generated 
by targeted disruption of the Sorla-gene (Andersen, et al., 2005). 
Reabsorption in DCT, CNT and CD is crucial for fine-tuning electrolyte levels in 
the blood. Compared to plasma, tubular fluid leaves the loop of Henle in a hypo-
osmotic state, making active processes compulsory for further reabsorption of 
electrolytes. Many of these processes are governed by the interplay of two hormo-
nal regulators. One important player in the distal nephron is the peptide hormone 
vasopressin, which controls the adjustment of blood pressure (Brenner, 2007). 
Vasopressin-induced action includes the activation of apical water channels (aq-
uaporins) in the CD, allowing reabsorption of water. Additionally it activates 
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NKCC2 in the TAL segment, therewith enhancing the hypo-osmolarity of the tu-
bular fluid entering the CD to facilitate passive uptake of water. However, vaso-
pressin levels are not significantly altered by SORLA-deficiency (table 13, chap-
ter 3.2). This goes in line with the ability of Sorla(-/-) mice to concentrate urine 
normally (figure 10 B, chapter 3.2). 
The second important hormone regulating the function of the distal tubule is al-
dosterone. It promotes both kaliuretic as well as NaCl-retaining function (Mene-
ton, et al., 2004), which is already reflected by how the hormone’s release is trig-
gered: Aldosterone is released upon low NaCl levels (mediated by angiotensin II) 
as well as high K+-levels in serum (detected directly by aldosterone secreting cells 
in the adrenal cortex). 
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Figure 34: Induction of aldosterone and its effects. The release of the mineralcorticoid hormone 
is triggered by three main stimuli. Renin secreted in the renal juxtaglomerular apparatus (JGA) 
induces angiotensin I release in the liver, which in turn triggers angiotensin II release (predomi-
nantly in lung). High levels of plasma angiotensin II, K+ or the adrenocorticotropic hormone 
(ACTH, produced in the anterior pituitary gland) induce aldosterone secretion in the adrenal cor-
tex. Circulating aldosterone promotes reabsorption of Na+ and secretion of K+ in distal nephrons of 
the kidney. Except for the pituitary gland, Sorla is expressed in all organs mentioned above (cf. 
chapter 1.1.6). 
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Judging from the urinary Na+ and K+ levels, it becomes obvious that Sorla(-/-) mice 
are able to retain Na+ but at the same time are wasting K+ under normal condi-
tions. However, after thirsting, the mice excrete more Na+ and less K+ than wild 
type controls. Explaining this observation with differential aldosterone-induced 
mechanisms would imply higher aldosterone-action under basal conditions and a 
lower action in the thirsted state. This was confirmed after measuring serum levels 
of the mineralcorticoid: The receptor-deficient mice have significantly higher 
basal aldosterone levels but fail to increase those levels upon thirsting, a physio-
logical response shown by the wild type controls (table 13, chapter 3.2), providing 
a physiological explanation for the altered Na+/K+ levels. 
High aldosterone does also explain elevated expression levels of ENaC and 
NHE3 (figure 27, chapter 3.5), as both proteins are reported to be induced by the 
hormone (Alvarez de la Rosa, et al., 2002; Drumm, et al., 2006). 
4.2 SORLA and aldosterone 
One explanation for the inability of the gene-targeted mice to increase the release 
of aldosterone is the basal loss of K+ (accompanied by hypokalemia), that the 
animals suffer from (table 13, chapter 3.2). Even higher aldosterone levels would 
lead to critical loss of K+, eventually inducing a lethal hypokalemic state. But the 
mice show high blood levels of aldosterone – eliciting increased K+-secretion – 
under basal conditions in the first place, long before any safeguard mechanism 
would be necessary in wild type animals. 
The mineralcorticoid aldosterone is synthesized in and secreted from cells of the 
outer layer of the adrenal cortex (zona glomerulosa) in response to increased K+ 
levels or upon activation by the renin-angiotensin system (Bravo, 1977; Vecsei, et 
al., 1978). 
4.2.1 SORLA is expressed in the adrenal gland 
An expression of Sorla in adrenal glands of rabbit (Yamazaki, et al., 1996) and 
chicken (Mörwald, et al., 1997) has been shown by Northern Blot analysis. Here, 
expression of SORLA was confined to the cortex of murine adrenal glands by 
immunohistology (figure 11, chapter 3.3). The pronounced expression of the re-
ceptor in this most superficial cortical layer (figure 11 A and B) suggests a role of 
the receptor in aldosterone release. 
To get an idea of whether the renal phenotype seen in Sorla(-/-) mice is a result of 
SORLA-deficiency in the kidney or is rather caused by a defect in the adrenal 
gland, I performed comparative transcriptome analysis in both tissues of wild type 
and receptor-deficient mice. 
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4.2.2 SORLA-deficiency influences adrenal gland function 
Alongside with the potential involvement of the receptor in the release of aldos-
terone in the zona glomerulosa (as discussed above), gene expression analyses in 
wild type and Sorla(-/-) mice suggests that receptor-deficiency may interfere with 
more processes: More than 700 probesets were differentially regulated between 
animals with and without SORLA in this screen, dividing the resulting expression 
data clearly into two groups according to the genotype (figure 13, chapter 3.1). 
One striking finding that caught one’s eye was an alteration in transcripts for en-
zymes involved in the synthesis of the catecholamine epinephrine (also referred to 
as adrenaline). All genes involved in its synthesis pathway are expressed at lower 
levels in mice lacking Sorla (summarized in figure 35). The consequence of this 
transcriptional down-regulation could be measured directly in form of lower epi-
nephrine levels in adrenal glands of these mice (figure 16, chapter 3.3.1). 
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Figure 35: Adrenal catecholamine synthesis pathway. The synthesis of catecholamines – start-
ing at the amino acid tyrosine – is characterized by several enzymatic steps (arrows labelled with 
white ellipses), that are taking place both in the cytosol as well as in vesicular structures; enzymes 
down-regulated in Sorla(-/-) animals are marked by green arrows. See also table 17, chapter 3.3.1. 
In short-term stress situations, the “fight-or-flight” hormone’s function sets in. 
One of its various actions is to prepare the body for sustained muscle activity. In-
termittent exercise (e.g. during sprints) can greatly increase the extracellular K+ 
concentration, due to the excessive release of this electrolyte upon muscle cell 
depolarisation. Epinephrine counteracts by activating plasma-membrane Na+/K+-
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ATPases, a function without which the suddenly high levels of K+ could become 
dangerous for sensitive tissues such as the heart. Plasma-membrane Na+/K+-
ATPases are also the driving force for most active reabsorption processes along 
the renal nephron, suggesting an influence of epinephrine release on kidney func-
tion. 
The catecholamine epinephrine is released from chromaffin cells of the adrenal 
medulla. These cells closely resemble postganglionic neurons and are innervated 
by preganglionic fibers of the autonomous sympathetic nervous system. The sym-
pathetic nervous system is coordinated by superior centers such as the hypothala-
mus, which itself is tightly linked with the central nervous system. SORLA is not 
only expressed in the central nervous system (Motoi, et al., 1999), it has been de-
tected in cell bodies and proximal axons of sympathetic neurons as well (Posse De 
Chaves, et al., 2000). However, SORLA expression was not detectable in the ad-
renal medulla by immunohistological stainings (figure 11 C, chapter 3.3). This 
observation makes a direct influence of SORLA on epinephrine release in chro-
maffin cells very unlikely, but does not rule out an upstream effect on the sympa-
thetic nervous system. 
4.3 Effect of Sorla-deficiency on the renal transcriptome 
Gene expression analysis in kidney of gene-disrupted and wild type mice revealed 
that absence of the receptor has only modest effects on the renal transcriptome 
under basal conditions. Slightly more than 300 genes are significantly changed by 
a factor higher than 1.5. However, stressing the organ by depriving the animals of 
water increases the total number of differentially expressed genes massively. More 
than 1,500 genes are differentially regulated in the thirsted state. 
This effect illustrates the importance of SORLA for renal stress function. Under 
normal conditions, absence of SORLA results in salt loss. Yet, the organism can 
cope with the receptor deficiency. The salt loss phenotype of the Sorla(-/-) mice 
does not suggest a more severe phenotype after thirsting, as the animals lose large 
quantities of salt under basal conditions already. However, looking at the tran-
scriptional data, the underlying primary phenotype seems to deteriorate with 
thirsting, as SORLA-deficient kidneys require activation of regulative processes at 
a transcriptional level – a process unnecessary under basal conditions. 
Transcriptional gene expression analysis in kidney tissues did not reveal any ob-
viously affected pathways. Regulatory effects on solute transport activity inde-
pendent of gene transcription might be an explanation for this phenomenon. 
Therefore, my focus shifted towards specific reabsorptive processes that could 
explain the urine electrolyte phenotype. 
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4.4 Electrolyte transporters in the kidney 
Based on the salt loss phenotype in receptor-deficient animals, possible defects in 
cotransporters NCC and NKCC2 were considered. Together with the ubiquitous 
basolateral Na+/K+/Cl--cotransporter NKCC1, the transporters NCC and NKCC2 
form the sodium driven branch of the electroneutral cation/Cl--cotransporter fam-
ily (Slc12a family) (Gamba, 2005; Gimenez, 2006). Activity of the latter two 
transporters can only be found on the apical epithelium of the renal nephron (fig-
ure 36) where both contribute significantly to tubular salt reabsorption (Molony, et 
al., 1987; Obermüller, et al., 1995). 
4.4.1 Pharmacological intervention 
To stress the reabsorptive processes depending on these transporters, their func-
tions were blocked either with an NCC-specific thiazide diuretic or the NKCC2-
specific drug bumetanide. 
TAL
CD
DCT2
CNT
DCT1
NKCC2 activity
(bumetanide-sensitive)
NCC activity
(thiazide-sensitive)
aldosterone-sensitive distal nephron
(ASDN, eplerenone-sensitive)  
Figure 36: Nephron segments targeted by pharmacological intervention. NCC activity (in red) 
was inhibited by treatment with thiazide. NKCC2 activity (in blue) was targeted with bumetanide 
in TAL tubules isolated from the inner stripe of the outer medulla (ISOM), as marked by dashed 
lines. Eplerenone was administered to inhibit aldosterone-mediated processes in the aldosterone-
sensitive distal nephron (ASDN). TAL: thick ascending limb of Henle’s loop; DCT1/2: first and 
second segment of the distal convoluted tubule; CNT: connecting tubule; CD: collecting duct sys-
tem. Cf. FIGURE 9 in chapter 3.1. 
Compared to wild types, NCC-specific uptake of Na+ and Cl- seems to be de-
creased in Sorla(-/-) mice (figure 21, chapter 3.4.1). The animals lose less salt upon 
thiazide-treatment. This observation contradicts with the findings that NCC is 
hyperphosphorylated in these animals (figure 28 in chapter 3.5, see also next 
chapter), as phosphorylation of the transporter was suggested to be required for its 
full activation (Moriguchi, et al., 2005). 
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To explain the effects of thiazide treatment, secondary physiological events – pas-
sive effects as well as active balancing mechanisms – have to be taken into con-
sideration. An inactivity of NCC results in a substantial decrease of salt reabsorp-
tion in the DCT. Subsequently, tubular segments following the DCT have to 
handle tubular fluid with a higher osmolality as compared to the normal situation. 
This impairs normal water reabsorption in the CD, which could lead to the release 
of the antidiuretic hormone vasopressin. A subsequent increase of NKCC2 activity 
in TAL (see 4.1.1), would attenuate the salt loss. As vasopressin levels could not 
be measured, the results obtained allow only the limited conclusion whether mice 
lacking SORLA handle thiazide-induced stress differently to wild types. 
To circumvent compensatory mechanisms in the process of blocking NKCC2 ac-
tivity with bumetanide, I took advantage of the TALs resistance to collagenase 
and isolated tubules of this segment. In this context, fewer factors are blurring the 
effects of the pharmacological treatment. 
NKCC2 activity, measured as bumetanide-sensitive 86Rb+-uptake appears to be 
higher in isolated tubules of mice lacking SORLA (figure 25, chapter 3.4.3). This 
contrasts with the hypophosphorylation of the cotransporter in these animals (fig-
ure 26 in chapter 3.5, see next chapter). As for NCC, NKCC2 has been reported to 
be phosphorylated upon activation (Gimenez and Forbush, 2003), thus a de-
creased phosphorylation suggests a lower NKCC2 activity in Sorla(-/-) mice. 
Since only TAL fragments were treated, no other tubular segments could interfere 
with the measurements. But even in isolated TAL, uptake of K+/Rb+ may occur 
via different routes (depicted in figure 23, chapter 3.4.3). Na+/K+-ATPases (total 
expression not changed, figures 26 and 27, chapter 3.5), physiologically building 
up a driving Na+ gradient across the basolateral membrane, were inhibited by the 
arrow poison ouabain. The K+ channel ROMK was blocked with Ba2+ ions. Pro-
tein levels of the channel were slightly reduced in whole kidney lysates of 
Sorla(-/-) mice (figure 27, chapter 3.5). Assuming an incomplete blockage of the 
channels, this difference on protein level could be mirrored by a slightly different 
residual outward flux rate of Rb+, resulting in an accumulation of Rb+ inside the 
cells. 
The third pharmacological approach, the blockage of the mineralcorticoid receptor 
with the antagonist eplerenone, and therewith impeding aldosterone action, failed 
due to technical difficulties in properly administering this poorly soluble drug to 
animals. 
Taken together, the pharmacological intervention in the kidney did show differen-
tial NCC and NKCC2 specific salt uptake in Sorla gene-targeted mice, but it did 
not clearly answer the question, which pathways may primarily be affected by 
SORLA deficiency. 
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4.4.2 Evidence for a misregulation of NCC: Sorla(-/-) mice suffer from 
calciuria 
Another evidence for mis-regulated NCC activity is the increased urinary excre-
tion of calcium (calciuria), which was observed in Sorla gene-targeted animals. 
Around 60% of the urinary Ca2+ are reabsorbed in the proximal tubule. Most of 
the remaining portion is taken up in the distal nephron, where it mainly undergoes 
transcellular transport via luminal calcium channels and basolateral Ca2+-ATPases 
and Na/Ca-antiporters. In the DCT, the Na/Ca-antiport activity leads to a negative 
correlation of Ca2+ uptake with the uptake of Na+. Consequently, thiazide diuret-
ics, blocking the Na+/Cl--cotransporter NCC in DCT, boost the reabsorption of 
Ca2+ in that segment (Costanzo, 1985; Suki, 1979). 
Activity of NCC is regulated by phosphorylation via the WNK-SPAK pathway 
(Pacheco-Alvarez, et al., 2006; Reinhard, et al., 2005; Richardson, et al., 2008), 
comparable to the related NKCCs (vide infra). The calciuria observed in Sorla(-/-) 
mice (table 12, chapter 3.2) points towards a hyperactivity of the thiazide-
sensitive cotransporter. In line with this observation, NCC is hyperphosphorylated 
in these animals (figure 28, chapter 3.5). 
Aldosterone has been reported to increase phosphorylation of the cotransporter 
(Chiga, et al., 2008). This does not fit with the data from thirsted mice (cf. table 
13 in chapter 3.2, and figure 28 in chapter 3.5): aldosterone levels are lower in 
thirsted Sorla(-/-) mice as compared to equally treated wild types. Further investi-
gation is required to test, whether this hyper-phosphorylation of NCC is deter-
mined by mechanisms overruling the aldosterone signalling, or if SORLA is re-
quired for its proper regulation. 
4.4.3 Evidence for a misregulation of NKCC2: The renal Sorla(-/-) phenotype 
shares elements with the Bartter syndrome 
The uncoupling of reabsorptive processes for salt and water in the thin descending 
and thick ascending limb renders Henle’s loop a critical player in the regulated 
salt uptake in the distal nephron. 
Na+ transport in the TAL is a multi-component system (figure 37). The basolateral 
Na+/K+-ATPase transports Na+ from TAL-cells into the interstitium, creating a 
Na+-gradient across the epithelium. This gradient is used by the Na+/K+/Cl--
cotransporter NKCC2 to drive not only Na+ but also K+ and Cl- transport into the 
cells. Accordingly, K+ is transported into the TAL cells from the basolateral side 
(Na+/K+-ATPase) and the apical side (NKCC2). To balance intracellular concen-
trations of this electrolyte, it is recycled by the K+-channel ROMK, mainly into 
the tubular lumen. Following the electrochemical gradient created by the Na+/K+-
ATPase, Cl- exits towards the interstitium mainly via the Cl--channels ClCNKB 
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and, to a lesser degree, ClCNKA. Both Cl--channels require the subunit Barttin for 
proper function. 
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Figure 37: Na+-transporting components in TAL. Arrows mark the physiological transport di-
rection of the indicated ions; transporting components are labeled in blue. This cartoon does not 
show stoichiometric transport ratios. 
In humans, mutations in the genes encoding NKCC2, ROMK, CLCNKB or Bart-
tin cause Bartter-syndrome type I, II, III or IV, respectively (Birkenhager, et al., 
2001; Scheinman, et al., 1999). Patients suffering from autosomal-recessive Bart-
ter-syndromes exhibit disturbances in renal salt and volume handling. Lower than 
normal reabsorption of Na+ in the TAL results in hyperreninemic hyperaldostero-
nism (high blood levels of renin and aldosterone), accompanied by polyuria, en-
hanced excretion of K+ (hyperkaliuria) and Ca2+ (hypercalciuria), as well as low 
K+ levels in blood (hypokalemia). In some patients, a low blood pressure can be 
observed, even though renin and aldosterone are high. 
Taken together, the observations made in Sorla(-/-) mice resemble some of the de-
fects seen in Bartter syndrome: Under basal conditions, the animals suffer from 
hypercalciuria, hyperkaliuria with hypokalemia and high aldosterone (tables 12 
and 13, figure 10, in chapter 3.2). The MAP of mice lacking SORLA is reduced 
during their activity phase (table 14, chapter 3.2). As SORLA is expressed in TAL 
these findings hint towards a possible function for the receptor in salt reabsorption 
processes in this nephron segment. 
Even though NKCC2 levels are normal in Sorla(-/-) mice, the animals fail to phos-
phorylate the transporter at Thr 96 and Thr 101 (figure 26, chapter 3.5). Together 
with a third threonine (Thr 114 in mice), these phospho-acceptor residues com-
prise a regulatory domain for the activation of the cotransporter. Initially identi-
fied in Squalus acanthias NKCC1, the three sites are highly conserved in the so-
dium-driven branch of cation-coupled cotransporter protein family and their 
phosphorylation has been reported to mediate activation of NKCC1/2 upon stimu-
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lation (Darman and Forbush, 2002; Gimenez and Forbush, 2003). In the case of 
NKCC2 however, Giménez and Forbush could show in Xenopus laevis oocytes, 
that the transporter still retains 50% of its activity in the absence of phosphoryla-
tion at these sites (Gimenez and Forbush, 2005). 
4.4.4 Sorla(-/-) mice are hypotonic 
A clinical symptom of hypokalemia is high blood pressure (Krishna, et al., 1989). 
However, mice deficient for SORLA show a reduced mean arterial pressure 
(MAP) during their activity phase as well as a reduced heart rate (table 14, chapter 
3.2). 
In general, changes in Na+ levels and blood pressure have greater effects on the 
aldosterone secretion than do equivalent changes in K+ balance. In SORLA-
deficient mice, however, it is unlikely that the high aldosterone levels are conse-
quence of the low blood pressure because blood pressure-driven aldosterone acti-
vation is mediated by the renin-angiotensin-system (RAS), requiring high renin 
levels. In fact, the low levels of circulating renin in Sorla(-/-) mice suggest a low 
activation of the RAS (table 13, chapter 3.2). 
Renin is released from granular cells of the juxtaglomerular apparatus, which lies 
between the macula densa (MD) and the renal corpuscle of a nephron. Renin re-
lease is triggered by several stimuli, including decreased blood pressure, sympa-
thetic nervous activity and decreases in tubular sodium chloride levels. SORLA is 
expressed in the MD (not shown), together with NKCC2 (Lapointe, et al., 1990; 
Lorenz, et al., 1991). 
Concerning juxtaglomerular renin secretion, MD cells act as sensing elements for 
tubular NaCl concentrations (Skøtt and Briggs, 1987). In contrast to TAL, MD 
cells do not possess basolateral Na+/K+-ATPase activity. It was proposed that Na+-
extrusion in these cells is regulated via an ouabain-sensitive apical form of H+/K+-
ATPase (Peti-Peterdi and Bell, 1999). Because of the low effectivity of this Na+-
efflux system and the absence of other alternatives, the intracellular Na+ concen-
tration should reflect the luminal NaCl delivery to MD cells. 
NKCC2 activity is responsible for 80 % of the NaCl-influx into MD cells, thus 
being an important element in the NaCl-sensing mechanism. Absence of SORLA, 
which leads to a nearly complete lack of phosphorylation of NKCC2, has no or 
little impact on this mechanism in the MD, as renin-release is downregulated upon 
increased NaCl levels in urine: Renin levels are only partly down-regulated under 
basal conditions, under which Na+-levels are only slightly increased, and mas-
sively down after thirsting, when receptor-deficient mice waste Na+ (viz. tables 12 
and 13, chapter 3.2). 
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An inactivity of NKCC2 in Sorla-deficient mice would lead to low intracellular 
levels of NaCl and subsequent release of renin. In mice lacking SORLA, levels of 
circulating renin are lower as in control animals, providing evidence for an in-
creased activity of NKCC2 in this tissue. 
 
4.4.5 SORLA influences SPAK activity 
Mechanisms responsible for the activating phosphorylation of NKCC2 are still not 
fully understood. Using a yeast two-hybrid approach, the kinases SPAK and 
OSR1 were recently identified as interaction partners of NKCC1’s NH2-terminus 
through a RFQV-motif (Piechotta, et al., 2002), which is also conserved in 
NKCC2. The NH2-terminus NCC harbours a RFTI motif, which could act as a 
SPAK/OSR1 consensus sequence, and it has been demonstrated, that both NKCC2 
and NCC can be phosphorylated by SPAK (Moriguchi, et al., 2005). NKCC2 acti-
vation by SPAK is governed by kinases of the WNK family (Ponce-Coria, et al., 
2008; Richardson and Alessi, 2008). 
In whole kidney lysates of mice lacking SORLA, SPAK is hyperphosphorylated 
(figure 29, chapter 3.6). Suprisingly, increased activity of SPAK does not translate 
into an increased phosphorylation rate of its downstream target NKCC2. Rather 
NKCC2 is not phosphorylated at all. Mislocalization of SPAK in the TAL of 
SORLA-deficient mice may provide an explanation for the apparant paradox, as 
for successful phosphorylation, the kinase needs to interact with its target. 
The antibody used in this study only detects murine NKCC2 residues T96 and 
T101 if both are phosphorylated (Gimenez and Forbush, 2005). No statements can 
be made concerning phosphorylation at T114, and other modulating phosphoryla-
tion sites in NKCC2 cannot be ruled out either (Darman and Forbush, 2002). Un-
der these circumstances, NKCC2 can be assumed to bear residual activity. This 
partial reduction of NKCC2-activity in Sorla gene disrupted mice could explain 
the observation of some – but not all – hallmarks of the human Bartter syndrome. 
Interestingly, some aspects of the observed phenotype differ from the human Bart-
ter syndrome: The hypokalemic state is milder after thirsting; the animals are not 
hyperkaliuric (as compared to control animals under the same conditions). The 
animals also do not suffer from hyperreninemia. While deprived from water, the 
mice actually react with a milder increase of blood renin-levels as wild type con-
trols. These observations are indicating a role of SORLA in other mechanisms as 
well. 
Discussion 
 128 
Cl-
Na+
Cl-K+( )
PP
P
SPAK
OSR1
P
WNK1
WNK4
WNK3
PPs
P
P
P
P
Cl-
Cl-
Cl-
Inactivation
NKCC2 / NCC
cytosol
extracellular space
COOH
SORLA
COOH
COOHNH2 NH2
P phosphate group
inhibition
proposed
activation
activation
proposed
interaction
 
Figure 38: Mechaninsms responsible for the activation of NKCC2 and NCC. NKCC2 and 
NCC are both activated upon WNK signalling via phosphorylation by SPAK/OSR1. SPAK/OSR1 
can phosphorylate the cotransporters at three conserved threonines in its N-terminal region. While 
NCC is hyperphosphorylated in Sorla(-/-) mice, phosphorylation of NKCC2 in the same animals is 
dramatically decreased. The abnormal localization of SPAK in TAL, suggests a role of SORLA in 
establishing proper localization of the kinase towards NKCC2-containing vesicles. On the con-
trary, lack of SORLA in DCT does not negatively influence phosphorylation of NCC. Due to the 
high homology of the three transporters, some of the depicted interactions were published for 
NKCC1 but are proposed for NKCC2 and NCC as well (Gimenez, 2006). 
 
4.5 Conclusion: Sorla-deficiency has an impact on regulated salt 
homeostasis 
In this work, I provided evidence for an involvement of SORLA in regulated salt 
reabsorption pathways. As a result, Na+ and K+ homeostasis is disturbed in mice 
deficient for the Sorla gene. This finding can be explained with mis-regulation of 
aldosterone release in the adrenal glands of these animals. SORLA is expressed in 
the zona glomerulosa, the site of aldosterone synthesis. Future work has to deter-
mine at which point the receptor is involved in the synthesis or release of aldos-
terone. The approach presented in this work – comparative analysis of adrenal 
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transcriptomes of mice with and deficient for Sorla – did not reveal the molecular 
mechanisms how the receptor influences aldosterone release. 
A complicating fact is that not only adrenal glands influence kidney function by 
the release of hormones such as aldosterone. Kidneys do also affect adrenal gland 
function, for example by activating the renin-angiotensin-aldosterone system. A 
possible concept to separate the action of SORLA in both organs could be a bilat-
eral adrenalectomy in wild type and receptor-deficient mice. Kidney functions of 
animals treated in such a way could be investigated without being influenced by 
differential adrenal functions. However, this concept is unidirectional: While adult 
mice can survive several weeks without adrenal glands (Hoffman-Goetz, et al., 
2004) a bilateral nephrectomy would be lethal. Mice with a tissue-specific disrup-
tion of the Sorla gene in the distal nephron, e.g. using the using the CLCNKB 
promoter (Kobayashi, et al., 2002), could enable investigation of adrenal gland 
function depending on presence or absence of the receptor in the kidney. 
The adrenal hormone aldosterone governs two functions in kidney: Secretion of 
K+ and retention of NaCl (Halperin, et al., 2006). In some situations however, the 
kidney only needs to fulfill one of these two tasks. A recently discovered group of 
kinases does play an important role in deciding which way to go: the WNK 
kinases (Gamba, 2005; Kahle, et al., 2003; Subramanya, et al., 2006). Members of 
this protein family have been shown to regulate downstream targets through the 
proline-alanine-rich STE20-related kinase SPAK (Vitari, et al., 2005). 
SPAK is hyperphosphorylated in Sorla(-/-) mice. Recently, this kinase has been 
reported to be responsible for mediating phosphorylation in order to activate 
members of the sodium-driven branch of the chloride-coupled cotransporters 
(coded by the Slc12a gene family) (Moriguchi, et al., 2005; Ponce-Coria, et al., 
2008). Two members of this family, the bumetanide-sensitive apical Na+/K+/Cl--
cotransporter NKCC2 and the thiazide-sensitive Na+/Cl--cotransporter NCC are 
expressed within the same nephron segments as SORLA. And indeed, both 
NKCC2 and NCC are mis-phosphorylated in mice lacking SORLA. Additionally, 
both transporters show altered activity in these animals, finally resulting in urinary 
salt wasting and hypokalemia. 
This work presents evidence that SORLA is involved in the WNK-SPAK-Slc12a 
pathway, regulating Na+ and K+ homeostasis. Future research needs to address at 
which point SORLA influences this signaling cascade. 
A cue is given by the proposed function of the receptor. Due to its homology to 
the yeast sorting receptor VPS10p, its intracellular localization and trafficking 
motifs within its cytosolic domain, the receptor could be involved in transporting 
cargo proteins (such as NKCC2 or NCC) to its proper location. SORLA fulfils a 
similar function in the CNS, where it reroutes the amyloid precursor APP and af-
fects plaque-formation in Alzheimer’s disease (Andersen, et al., 2006; Schmidt, et 
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al., 2007). This idea is strengthened by the identification of putative interaction 
partners (ARF4, AP2 and the retromer complex, see figure 33, chapter 3.7.2), 
which are involved in intracellular transport (Chang, et al., 1993; Collins, 2008; 
Deretic, 2006). Due to its features, it could also act as a scaffold, bringing kinases 
in close vicinity to its target, as suggested by the mis-localization of SPAK in TAL 
cells lacking SORLA. 
The different phosphorylation state of NKCC2 and NCC can be explained by 
SORLA being involved in bringing together SPAK and NKCC2, while SPAK and 
NCC meet in a SORLA-independent manner (figure 38). However, without di-
rectly measuring the phosphorylation state and activity of both transporters from 
wild type and Sorla(-/-) mice, it is difficult to prove that statement. Activity meas-
urements under defined conditions could be achieved by microperfusion experi-
ments either in intact kidneys or in isolated tubule segments, as decribed for rats 
(Bank, et al., 1974). 
The discovered extra-renal phenotype of mice lacking SORLA – the receptor’s 
influence on the catecholamine metabolism – could also have an implication for 
kidney function: Catecholamines influence renin release through -adrenergic 
receptors. This defect could be the reason for the hypotension in the activity phase 
of Sorla(-/-) mice. Additionally, epinephrine has a modulating effect on Na+/K+-
ATPases, which are the driving force of active electroclyte reabsorption along the 
nephron (Brenner, 2007; Churchill, 1988). An influence of the adrenal lack of 
SORLA on kidney function can clearly be hypothesized in this context. However, 
future studies have to substantiate the receptor’s role in the adrenal and its sys-
temic impact. 
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